{"alternate_symbols":[],"name":"Phocomelia","medgen_id":"C0031575","type":"Disease","id":"27813","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002994\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009829\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0009829\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Uterine Carcinosarcoma","medgen_id":"C0280630","type":"Disease","id":"37020","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"213610\"}"]}
{"alternate_symbols":[],"name":"Myosclerosis","medgen_id":"C1611706","type":"Disease","id":"36658","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"624040\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Short Rib Polydactyly Syndrome","medgen_id":"C0036996","type":"Disease","id":"36665","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"1505\"}","{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"693090\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Restrictive cardiomyopathy","medgen_id":"C0007196","type":"Disease","id":"10605","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001723\",\"type\":\"primary\"}","{\"db\":\"MeSH\",\"id\":\"D002313\"}","{\"db\":\"Orphanet\",\"id\":\"217632\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001723\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"atypical cerebral palsy","medgen_id":"CN479605","type":"Disease","id":"37979","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"TIDEX, University of British Columbia\",\"id\":\"ACP27_PALM_v1\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Pulmonary arteriovenous malformation","medgen_id":"C1857690","type":"Disease","id":"25670","attribute_content":[],"symbol":"PAVM","keywords":[],"alternate_names":["Pulmonary av malformation"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002114\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006537\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006548\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006548\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pulmonary av malformation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006548\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9777\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9777\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["PPPP"],"name":"Porokeratosis punctata palmaris et plantaris","medgen_id":"C1867982","type":"Disease","id":"1888","attribute_content":[],"symbol":"PPKP2","keywords":[],"alternate_names":["PALMOPLANTAR KERATODERMA, PUNCTATE TYPE II"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"175860\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"175860\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PALMOPLANTAR KERATODERMA, PUNCTATE TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"175860\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PPPP\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8180\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PPPP\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Porokeratosis+Punctata+Palmaris+et+Plantaris/5876\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8180\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"175860\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Epidermolysis bullosa simplex, generalized, with scarring and hair loss","medgen_id":"C4310631","type":"Disease","id":"36796","attribute_content":[],"symbol":"EBSSH","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"617294\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"508529\"}","{\"db\":\"OMIM\",\"id\":\"617294\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"OROFACIODIGITAL SYNDROME XVIII","medgen_id":"C4693651","type":"Disease","id":"39750","attribute_content":[],"symbol":"OFD18","keywords":[],"alternate_names":["OFDS XVIII","ORAL-FACIAL-DIGITAL SYNDROME, TYPE XVIII"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"508501\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OFDS XVIII\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ORAL-FACIAL-DIGITAL SYNDROME, TYPE XVIII\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617927\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Phosphoglycerate dehydrogenase deficiency","medgen_id":"C1866174","type":"Disease","id":"3293","attribute_content":[],"symbol":"PHGDHD","keywords":[],"alternate_names":["PHGDH DEFICIENCY"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"601815\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79351\"}","{\"db\":\"OMIM\",\"id\":\"601815\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PHGDH DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Phosphoglycerate+dehydrogenase+deficiency/9103\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601815\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Neurofibromas","medgen_id":"C0162678","type":"Finding","id":"22147","attribute_content":[],"keywords":[],"alternate_names":["Neurofibromata","Neurofibromatosis","multiple neurofibromas"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001067\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006746\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007386\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007612\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001067\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neurofibromata\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001067\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Neurofibromatosis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001067\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"multiple neurofibromas\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001067\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Mental retardation, X-linked 99, syndromic, female-restricted","medgen_id":"C4225416","type":"Disease","id":"34767","attribute_content":[],"symbol":"MRXS99F","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"300968\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"480880\"}","{\"db\":\"OMIM\",\"id\":\"300968\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Breast carcinoma","medgen_id":"C0678222","type":"Finding","id":"23475","attribute_content":[],"keywords":[],"alternate_names":["Breast cancer"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003002\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"180257\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003002\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Breast cancer\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003002\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":["AUNX1"],"name":"Deafness, X-linked 5","medgen_id":"C1845095","type":"Disease","id":"4933","attribute_content":[],"symbol":"DFNX5","keywords":[],"alternate_names":["AUDITORY NEUROPATHY, X-LINKED, 1, WITH PERIPHERAL SENSORY NEUROPATHY"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"300614\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139583\"}","{\"db\":\"OMIM\",\"id\":\"300614\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AUDITORY NEUROPATHY, X-LINKED, 1, WITH PERIPHERAL SENSORY NEUROPATHY\"}","{\"db\":\"OMIM\",\"id\":\"300614\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AUNX1\"}","{\"db\":\"OMIM\",\"id\":\"300614\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Chromosome 16p13.3 duplication syndrome","medgen_id":"C3150708","type":"Disease","id":"6679","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"613458\",\"type\":\"MIM\"}"]}
{"alternate_symbols":[],"name":"Anonychia","medgen_id":"C3277900","type":"Disease","id":"411","attribute_content":[],"symbol":"NDNC4","keywords":[],"alternate_names":["ANONYCHIA TOTALIS","ANONYCHIA/HYPONYCHIA CONGENITA","Absent nails","Aplastic nails","NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007593\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008384\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79143\"}","{\"db\":\"Orphanet\",\"id\":\"94150\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANONYCHIA TOTALIS\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ANONYCHIA/HYPONYCHIA CONGENITA\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Absent nails\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Aplastic nails\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"OMIM\",\"id\":\"610573.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NAIL DISORDER, NONSYNDROMIC CONGENITAL, 4\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Anonychia+Congenita/488\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001798\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10048\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"23610003\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"206800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["PPKE","TYLOSIS"],"name":"Localized epidermolytic hyperkeratosis","medgen_id":"C1721006","type":"Disease","id":"5722","attribute_content":[],"symbol":"EPPK","keywords":[],"alternate_names":["Epidermolytic palmoplantar keratoderma"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007559\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"144200\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"144200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PPKE\"}","{\"db\":\"OMIM\",\"id\":\"144200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TYLOSIS\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007559\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"144200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2156\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Atopic dermatitis","medgen_id":"C1847528","type":"Disease","id":"22129","attribute_content":[],"keywords":[],"alternate_names":["Atopic dermatitis, chronic","Baby eczema"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001047\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007533\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007564\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001047\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Atopic dermatitis, chronic\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001047\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Baby eczema\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001047\",\"ref_field\":\"name\"}","{\"db\":\"Undiagnosed Diseases Network,NIH\",\"id\":\"d9f9da08-cabf-403f-9797-eaeb0e628e2e_1\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":["SVAS"],"name":"Subvalvular aortic stenosis","medgen_id":"C0340375","type":"Disease","id":"32689","attribute_content":[],"keywords":[],"alternate_names":["Subaortic stenosis"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001682\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001682\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Subaortic stenosis\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5052\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SVAS\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001682\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5052\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"public_definition":"Multiple endocrine neoplasia is a group of disorders that affect the body's network of hormone-producing glands called the endocrine system. Hormones are chemical messengers that travel through the bloodstream and regulate the function of cells and tissues throughout the body. Multiple endocrine neoplasia typically involves tumors (neoplasia) in at least two endocrine glands; tumors can also develop in other organs and tissues. These growths can be noncancerous (benign) or cancerous (malignant). If the tumors become cancerous, the condition can be life-threatening.The major forms of multiple endocrine neoplasia are called type 1, type 2, and type 4. These types are distinguished by the genes involved, the types of hormones made, and the characteristic signs and symptoms.Many different types of tumors are associated with multiple endocrine neoplasia. Type 1 frequently involves tumors of the parathyroid glands, the pituitary gland, and the pancreas. Tumors in these glands can lead to the overproduction of hormones. The most common sign of multiple endocrine neoplasia type 1 is overactivity of the parathyroid glands (hyperparathyroidism). Hyperparathyroidism disrupts the normal balance of calcium in the blood, which can lead to kidney stones, thinning of bones, nausea and vomiting, high blood pressure (hypertension), weakness, and fatigue.The most common sign of multiple endocrine neoplasia type 2 is a form of thyroid cancer called medullary thyroid carcinoma. Some people with this disorder also develop a pheochromocytoma, which is an adrenal gland tumor that can cause dangerously high blood pressure. Multiple endocrine neoplasia type 2 is divided into three subtypes: type 2A, type 2B (formerly called type 3), and familial medullary thyroid carcinoma (FMTC). These subtypes differ in their characteristic signs and symptoms and risk of specific tumors; for example, hyperparathyroidism occurs only in type 2A, and medullary thyroid carcinoma is the only feature of FMTC. The signs and symptoms of multiple endocrine neoplasia type 2 are relatively consistent within any one family.Multiple endocrine neoplasia type 4 appears to have signs and symptoms similar to those of type 1, although it is caused by mutations in a different gene. Hyperparathyroidism is the most common feature, followed by tumors of the pituitary gland, additional endocrine glands, and other organs.","name":"Multiple endocrine neoplasia, type 4","medgen_id":"C1970712","type":"Disease","id":"3045","attribute_content":[],"symbol":"MEN4","keywords":["Hereditary cancer syndrome","Neoplasm"],"alternate_names":["MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"610755\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"600778.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV\"}","{\"db\":\"OMIM\",\"id\":\"600778.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV\"}","{\"db\":\"OMIM\",\"id\":\"600778.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV\"}","{\"db\":\"OMIM\",\"id\":\"600778.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV\"}","{\"db\":\"OMIM\",\"id\":\"600778.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV\"}","{\"db\":\"OMIM\",\"id\":\"600778.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV\"}","{\"db\":\"OMIM\",\"id\":\"610755\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IV\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Multiple+endocrine+neoplasia%2C+type+4/8918\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"multiple-endocrine-neoplasia\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610755\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["EL4"],"name":"Ovalocytosis, southeast Asian","medgen_id":"C1833690","type":"Disease","id":"3251","attribute_content":[],"symbol":"SAO","keywords":[],"alternate_names":["ELLIPTOCYTOSIS 4","HE, STOMATOCYTIC","Ovalocytosis, Malaysian-Melanesian-Filipino type","Stomatocytic elliptocytosis, hereditary"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"166900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98868\"}","{\"db\":\"OMIM\",\"id\":\"166900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ELLIPTOCYTOSIS 4\"}","{\"db\":\"OMIM\",\"id\":\"166900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HE, STOMATOCYTIC\"}","{\"db\":\"OMIM\",\"id\":\"166900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EL4\"}","{\"db\":\"OMIM\",\"id\":\"166900\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["MRD","PUJO","UPJO"],"name":"Multicystic renal dysplasia, bilateral","medgen_id":"C1840451","type":"Disease","id":"2975","attribute_content":[],"symbol":"CAKUT2","keywords":["Neoplasm"],"alternate_names":["URETEROPELVIC JUNCTION OBSTRUCTION"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"143400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2190\"}","{\"db\":\"Orphanet\",\"id\":\"97364\"}","{\"db\":\"OMIM\",\"id\":\"143400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"URETEROPELVIC JUNCTION OBSTRUCTION\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9517\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRD\"}","{\"db\":\"OMIM\",\"id\":\"143400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PUJO\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9517\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PUJO\"}","{\"db\":\"OMIM\",\"id\":\"143400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"UPJO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Multicystic+renal+dysplasia%2C+bilateral/4939\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9517\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"143400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Left ventricular noncompaction cardiomyopathy","medgen_id":"C4021133","type":"Disease","id":"29561","attribute_content":[],"keywords":[],"alternate_names":["Left ventricular non-compaction cardiomyopathy"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011664\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011664\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Left ventricular non-compaction cardiomyopathy\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011664\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Klatskin tumor","medgen_id":"C0206702","type":"Disease","id":"40443","attribute_content":[],"keywords":[],"alternate_names":["Hilar Cholangiocarcinoma"],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"99978\"}","{\"db\":\"NCBI for submitter\",\"id\":\"23368\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hilar Cholangiocarcinoma\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10175\",\"ref_field\":\"name\"}","{\"db\":\"Orphanet\",\"id\":\"99978\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"253017000\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"IL21R immunodeficiency","medgen_id":"C3554687","type":"Disease","id":"17779","attribute_content":[],"symbol":"IMD56","keywords":[],"alternate_names":["IMMUNODEFICIENCY 56"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"615207\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"357329\"}","{\"db\":\"OMIM\",\"id\":\"605383.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 56\"}","{\"db\":\"OMIM\",\"id\":\"605383.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 56\"}","{\"db\":\"OMIM\",\"id\":\"605383.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 56\"}","{\"db\":\"OMIM\",\"id\":\"615207\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 56\"}","{\"db\":\"OMIM\",\"id\":\"615207\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"B-cell expansion with NFKB and T-cell anergy","medgen_id":"C4551967","type":"Disease","id":"33577","attribute_content":[],"symbol":"BENTA","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"616452\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"464336\"}","{\"db\":\"OMIM\",\"id\":\"616452\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Paroxysmal dyskinesia","medgen_id":"C0752210","type":"Finding","id":"26028","attribute_content":[],"keywords":[],"alternate_names":["Involuntary dystonic or choreiform movements"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007166\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007166\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Involuntary dystonic or choreiform movements\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007166\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":["LMPH1C"],"name":"Lymphatic malformation 3","medgen_id":"C4747646","type":"Disease","id":"6786","attribute_content":[],"symbol":"LMPHM3","keywords":[],"alternate_names":["Lymphedema, hereditary, IC"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"613480\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"79452\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lymphedema%2C+hereditary%2C+ic/8770\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lymphedema, hereditary, IC\"}","{\"db\":\"OMIM\",\"id\":\"613480\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LMPH1C\"}","{\"db\":\"OMIM\",\"id\":\"613480\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Hemimegalencephaly","medgen_id":"C0431391","type":"Disease","id":"26044","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007206\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"99802\"}","{\"db\":\"GeneTests\",\"id\":\"320345\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007206\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2637\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":["LCAPD2"],"name":"MASP2 deficiency","medgen_id":"C3151085","type":"Disease","id":"10145","attribute_content":[],"keywords":[],"alternate_names":["LECTIN COMPLEMENT ACTIVATION PATHWAY, DEFECT IN, 2"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"613791\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"613791\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LECTIN COMPLEMENT ACTIVATION PATHWAY, DEFECT IN, 2\"}","{\"db\":\"OMIM\",\"id\":\"613791\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LCAPD2\"}"]}
{"alternate_symbols":[],"name":"Atypical teratoid rhabdoid tumor","medgen_id":"CN207484","type":"Disease","id":"41532","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":[]}
{"alternate_symbols":[],"name":"Emery-Dreifuss muscular dystrophy 4, autosomal dominant","medgen_id":"C2751807","type":"Disease","id":"6693","attribute_content":[],"symbol":"EDMD4","keywords":[],"alternate_names":["EMERY-DREIFUSS MUSCULAR DYSTROPHY 4 WITH VARIABLE FEATURES"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"612998\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"261\"}","{\"db\":\"OMIM\",\"id\":\"608441.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 4 WITH VARIABLE FEATURES\"}","{\"db\":\"OMIM\",\"id\":\"608441.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 4 WITH VARIABLE FEATURES\"}","{\"db\":\"OMIM\",\"id\":\"612998\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EMERY-DREIFUSS MUSCULAR DYSTROPHY 4 WITH VARIABLE FEATURES\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Emery-dreifuss+muscular+dystrophy+4%2C+autosomal+dominant/8305\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612998\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Spastic paraplegia 23","medgen_id":"C0796019","type":"Disease","id":"4408","attribute_content":[],"symbol":"SPG23","keywords":[],"alternate_names":["SPASTIC PARAPARESIS, VITILIGO, PREMATURE GRAYING, CHARACTERISTIC FACIES","SPASTIC PARAPLEGIA WITH PIGMENTARY ABNORMALITIES"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"270750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101003\"}","{\"db\":\"OMIM\",\"id\":\"270750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPARESIS, VITILIGO, PREMATURE GRAYING, CHARACTERISTIC FACIES\"}","{\"db\":\"OMIM\",\"id\":\"270750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPASTIC PARAPLEGIA WITH PIGMENTARY ABNORMALITIES\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spastic+paraplegia+23/6688\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"336\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"270750\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Robin sequence","medgen_id":"C0031900","type":"Disease","id":"5760","attribute_content":[],"symbol":"PRBNS","keywords":[],"alternate_names":["Pierre Robin Syndrome","Pierre-Robin sequence","Pierre-robin anomaly","Pierre-robin deformity","Pierre-robin malformation"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000201\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"261800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"138044\"}","{\"db\":\"Orphanet\",\"id\":\"718\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000201\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pierre-Robin sequence\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000201\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pierre-robin anomaly\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000201\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pierre-robin deformity\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000201\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pierre-robin malformation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000201\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"4602007\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"261800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Achalasia","medgen_id":"C0014848","type":"Finding","id":"23159","attribute_content":[],"keywords":[],"alternate_names":["Achalasia of the esophagus"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002571\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002571\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Achalasia of the esophagus\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002571\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5708\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Spastic paraparesis","medgen_id":"C0037771","type":"Disease","id":"23002","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002313\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007191\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002313\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4912\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"public_definition":"Atopic dermatitis (also known as atopic eczema) is a disorder characterized by inflammation of the skin (dermatitis). The condition usually begins in early infancy, and it often disappears before adolescence. However, in some affected individuals the condition continues into adulthood; in others, it does not begin until adulthood. Hallmarks of atopic dermatitis include dry, itchy skin and red rashes that come and go. The rashes can occur on any part of the body, although the pattern tends to be different at different ages. In affected infants, the rashes commonly occur on the face, scalp, hands, and feet. In children, the rashes are usually found in the bend of the elbows and knees and on the front of the neck. In adolescents and adults, the rashes typically occur on the wrists, ankles, and eyelids in addition to the bend of the elbows and knees. Scratching the itchy skin can lead to oozing and crusting of the rashes and thickening and hardening (lichenification) of the skin. The itchiness can be so severe as to disturb sleep and impair a person's quality of life.The word \"atopic\" indicates an association with allergies. While atopic dermatitis is not always due to an allergic reaction, it is commonly associated with other allergic disorders: up to 60 percent of people with atopic dermatitis develop asthma or hay fever (allergic rhinitis) later in life, and up to 30 percent have food allergies. Atopic dermatitis is often the beginning of a series of allergic disorders, referred to as the \"atopic march.\" Development of these disorders typically follows a pattern, beginning with atopic dermatitis, followed by food allergies, then hay fever, and finally asthma. However, not all individuals with atopic dermatitis will progress through the atopic march, and not all individuals with one allergic disease will develop others.Individuals with atopic dermatitis have an increased risk of developing other conditions related to inflammation, such as inflammatory bowel disease, rheumatoid arthritis, and hair loss caused by a malfunctioning immune reaction (alopecia areata). They also have an increased risk of having a behavioral or psychiatric disorder, such as attention-deficit/hyperactivity disorder (ADHD) or depression.In a particular subset of individuals with atopic dermatitis, the immune system is unable to protect the body from foreign invaders such as bacteria and fungi (which is known as immunodeficiency). These individuals are prone to recurrent infections. Most also have other allergic disorders, such as asthma, hay fever, and food allergies.Atopic dermatitis can also be a feature of separate disorders that have a number of signs and symptoms, which can include skin abnormalities and immunodeficiency. Some such disorders are Netherton syndrome; immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome; and severe dermatitis, multiple allergies, metabolic wasting (SAM) syndrome.","name":"Dermatitis, atopic, 2","medgen_id":"C1853965","type":"Disease","id":"1084","attribute_content":[],"symbol":"ATOD2","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"605803\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dermatitis%2C+atopic%2C+2/8210\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"atopic-dermatitis\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"605803\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["COFS"],"name":"Cerebro-oculo-facio-skeletal syndrome","medgen_id":"C0220722","type":"Disease","id":"1348","attribute_content":[],"symbol":"COFS1","keywords":[],"alternate_names":["CEREBROOCULOFACIOSKELETAL SYNDROME 1","XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"214150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1466\"}","{\"db\":\"OMIM\",\"id\":\"214150\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBROOCULOFACIOSKELETAL SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"609413.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBROOCULOFACIOSKELETAL SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"609413.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBROOCULOFACIOSKELETAL SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"609413.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBROOCULOFACIOSKELETAL SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"609413.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBROOCULOFACIOSKELETAL SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"609413.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CEREBROOCULOFACIOSKELETAL SYNDROME 1\"}","{\"db\":\"OMIM\",\"id\":\"126340.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP D\"}","{\"db\":\"OMIM\",\"id\":\"214150\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"COFS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cerebro-Oculo-Facio-Skeletal+Syndrome/1246\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6027\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"41283003\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"214150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"DEND syndrome","medgen_id":"C4303593","type":"Disease","id":"39923","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"79134\"}"]}
{"alternate_symbols":["LCCS"],"name":"Lethal congenital contracture syndrome 1","medgen_id":"C1854664","type":"Disease","id":"2551","attribute_content":[],"symbol":"LCCS1","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"253310\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1486\"}","{\"db\":\"Orphanet\",\"id\":\"294965\"}","{\"db\":\"OMIM\",\"id\":\"253310\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LCCS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3227\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LCCS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lethal+congenital+contracture+syndrome+1/4185\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3227\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"253310\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Autosomal recessive myogenic arthrogryposis multiplex congenita","medgen_id":"C4707155","type":"Disease","id":"41911","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"319332\"}"]}
{"alternate_symbols":[],"public_definition":"Nearsightedness, also known as myopia, is an eye condition that causes blurry distance vision. People who are nearsighted have more trouble seeing things that are far away (such as when driving) than things that are close up (such as when reading or using a computer). If it is not treated with corrective lenses or surgery, nearsightedness can lead to squinting, eyestrain, headaches, and significant visual impairment.Nearsightedness usually begins in childhood or adolescence. It tends to worsen with age until adulthood, when it may stop getting worse (stabilize). In some people, nearsightedness improves in later adulthood.For normal vision, light passes through the clear cornea at the front of the eye and is focused by the lens onto the surface of the retina, which is the lining of the back of the eye that contains light-sensing cells. People who are nearsighted typically have eyeballs that are too long from front to back. As a result, light entering the eye is focused too far forward, in front of the retina instead of on its surface. It is this change that causes distant objects to appear blurry. The longer the eyeball is, the farther forward light rays will be focused and the more severely nearsighted a person will be.Nearsightedness is measured by how powerful a lens must be to correct it. The standard unit of lens power is called a diopter. Negative (minus) powered lenses are used to correct nearsightedness. The more severe a person's nearsightedness, the larger the number of diopters required for correction. In an individual with nearsightedness, one eye may be more nearsighted than the other.Eye doctors often refer to nearsightedness less than -5 or -6 diopters as \"common myopia.\" Nearsightedness of -6 diopters or more is commonly called \"high myopia.\" This distinction is important because high myopia increases a person's risk of developing other eye problems that can lead to permanent vision loss or blindness. These problems include tearing and detachment of the retina, clouding of the lens (cataract), and an eye disease called glaucoma that is usually related to increased pressure within the eye. The risk of these other eye problems increases with the severity of the nearsightedness. The term \"pathological myopia\" is used to describe cases in which high myopia leads to tissue damage within the eye.","name":"Myopia","medgen_id":"C0027092","type":"Disease","id":"18121","attribute_content":[],"keywords":[],"alternate_names":["Close sighted","Near sighted","Near sightedness","Nearsightedness"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000545\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001110\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007847\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"PS160700\",\"type\":\"Phenotypic series\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000545\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Close sighted\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000545\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Near sighted\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000545\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Near sightedness\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000545\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Nearsightedness\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000545\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"nearsightedness\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"name":"Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-positive, NK cell-positive","medgen_id":"C1837028","type":"Disease","id":"3721","attribute_content":[],"keywords":[],"alternate_names":["SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE","Severe Combined Immune Deficiency, Autosomal Recessive, TCell -Negative, B Cell-Positive, NK Cell-Positive, IL7R-Related"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"608971\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"169154\"}","{\"db\":\"Orphanet\",\"id\":\"169157\"}","{\"db\":\"OMIM\",\"id\":\"608971\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SCID, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-POSITIVE, NK CELL-POSITIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Severe+combined+immunodeficiency%2C+autosomal+recessive%2C+t+cell-negative%2C+b+cell-positive%2C+nk+cell-positive/9288\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"KHAN-KHAN-KATSANIS SYNDROME","type":"Disease","id":"41789","attribute_content":[],"symbol":"3KS","keywords":[],"alternate_names":["3K SYNDROME"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"618460\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618460\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"3K SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"608532.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608532.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608532.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618460\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618460\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["DCS","NLSDI"],"public_definition":"Chanarin-Dorfman syndrome is a condition in which fats (lipids) are stored abnormally in the body. Affected individuals cannot break down certain fats called triglycerides, and these fats accumulate in organs and tissues, including skin, liver, muscles, intestine, eyes, and ears. People with this condition also have dry, scaly skin (ichthyosis), which is usually present at birth. Additional features of this condition include an enlarged liver (hepatomegaly), clouding of the lens of the eyes (cataracts), difficulty with coordinating movements (ataxia), hearing loss, short stature, muscle weakness (myopathy), involuntary movement of the eyes (nystagmus), and mild intellectual disability.The signs and symptoms vary greatly among individuals with Chanarin-Dorfman syndrome. Some people may have ichthyosis only, while others may have problems affecting many areas of the body.","name":"Triglyceride storage disease with ichthyosis","medgen_id":"C0268238","type":"Disease","id":"1412","attribute_content":[],"symbol":"CDS","keywords":[],"alternate_names":["Chanarin-Dorfman Syndrome"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"275630\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"165\"}","{\"db\":\"Orphanet\",\"id\":\"98907\"}","{\"db\":\"OMIM\",\"id\":\"275630\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DCS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3979\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DCS\"}","{\"db\":\"OMIM\",\"id\":\"275630\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NLSDI\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3979\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NLSDI\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chanarin-Dorfman+Syndrome/1269\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"19604005\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"chanarin-dorfman-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"275630\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3979\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Carney complex variant","medgen_id":"C1837245","type":"Disease","id":"725","attribute_content":[],"keywords":["Neoplasm"],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"608837\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Carney+complex+variant/7901\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Cone/cone-rod dystrophy","medgen_id":"C0730290","type":"Disease","id":"21734","attribute_content":[],"keywords":[],"alternate_names":["Cone dystrophy","Cone rod dystrophy","Cone-rod retinal dystrophy"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000548\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008157\",\"type\":\"secondary\"}","{\"db\":\"Orphanet\",\"id\":\"1871\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000548\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cone dystrophy\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000548\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cone rod dystrophy\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000548\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cone-rod retinal dystrophy\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000548\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Sialidosis","medgen_id":"C0268226","type":"Disease","id":"38022","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"309294\"}","{\"db\":\"Orphanet\",\"id\":\"309294 \",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Hyperphenylalaninemia, mild, non-bh4-deficient","medgen_id":"C4479270","type":"Disease","id":"37047","attribute_content":[],"symbol":"HPANBH4","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"617384\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"617384\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["PWLS"],"name":"Schaaf-yang syndrome","medgen_id":"C3809877","type":"Disease","id":"18442","attribute_content":[],"symbol":"SHFYNG","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"615547\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"398073\"}","{\"db\":\"OMIM\",\"id\":\"615547\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PWLS\"}","{\"db\":\"OMIM\",\"id\":\"615547\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Goldmann-Favre syndrome","medgen_id":"C0339541","type":"Disease","id":"8965","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"53540\"}"]}
{"alternate_symbols":[],"public_definition":"Xia-Gibbs syndrome is a neurological disorder characterized by weak muscle tone (hypotonia), mild to severe intellectual disability and delayed development. Expressive language skills (vocabulary and the production of speech) are particularly affected; children with this condition usually do not speak their first word, a milestone typically achieved within the first year, until age two or later, and some never learn to talk. Development of motor skills, such as crawling and walking, can also be delayed.Other signs and symptoms of Xia-Gibbs syndrome vary among affected individuals. Additional neurological features include poor coordination and balance (ataxia) and seizures. Feeding problems and sleep abnormalities can also occur in people with the condition, and many affected individuals experience short pauses in breathing while they sleep (obstructive sleep apnea). In some people with Xia-Gibbs syndrome, imaging tests of the brain show abnormalities in the brain's structure. For example, the tissue connecting the left and right halves of the brain (the corpus callosum) can be abnormally thin.Xia-Gibbs syndrome can also affect physical development. Growth is usually impaired, and many affected individuals are shorter than their peers. Side-to-side curvature of the spine (scoliosis) is also a common feature. Some people with Xia-Gibbs syndrome have unusual facial features, such as a broad forehead, low-set ears or ears that stick out, widely space eyes (hypertelorism), eye openings that slant up or down (upslanting palpebral fissures or downslanting palpebral fissures), a flat bridge of the nose, or a thin upper lip. Other, less-common abnormalities involving the bones and skin include premature fusion of certain skull bones (craniosynostosis), unusually loose (lax) joints, and loose skin.Behavior problems can also occur in Xia-Gibbs syndrome. Some affected individuals have features of autism spectrum disorder, which is characterized by impaired communication and social interactions, or of attention-deficit/hyperactivity disorder (ADHD). Other problems can include aggression, anxiety, poor impulse control, and self-injury.","name":"Xia-Gibbs syndrome","medgen_id":"C4014419","type":"Disease","id":"18781","attribute_content":[],"symbol":"MRD25","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"615829\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"412069\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"xia-gibbs-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"xia-gibbs-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615829\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["ISSX2"],"name":"Early infantile epileptic encephalopathy 2","medgen_id":"C1839333","type":"Disease","id":"2108","attribute_content":[],"symbol":"EIEE2","keywords":[],"alternate_names":["INFANTILE SPASM SYNDROME, X-LINKED 2"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1934\"}","{\"db\":\"Orphanet\",\"id\":\"3451\"}","{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INFANTILE SPASM SYNDROME, X-LINKED 2\"}","{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ISSX2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+2/8342\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300672\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Colpocephaly","medgen_id":"C0431384","type":"Disease","id":"31999","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0030048\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0030048\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10008\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Rasopathy","medgen_id":"CN166718","type":"Disease","id":"17678","attribute_content":[],"keywords":[],"alternate_names":["Noonan spectrum disorder","Noonan syndrome and Noonan-related syndrome","rasopathies"],"xrefs":["{\"db\":\"GenomeConnect, ClinGen\",\"id\":\"genomeconnect_15815_622\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Noonan spectrum disorder\"}"]}
{"alternate_symbols":[],"public_definition":"The chromosome 13q14 deletion syndrome is characterized by retinoblastoma (180200), variable degrees of mental impairment, and characteristic facial features, including high forehead, prominent philtrum, and anteverted earlobes (summary by Caselli et al., 2007).","name":"13q partial monosomy syndrome","medgen_id":"C3151302","type":"Disease","id":"16053","attribute_content":[],"keywords":[],"alternate_names":["CHROMOSOME 13q DELETION SYNDROME","Chromosome 13q14 deletion syndrome"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"613884\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"613884\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHROMOSOME 13q DELETION SYNDROME\"}","{\"db\":\"SNOMED CT\",\"id\":\"29257000\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613884\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"name":"Skeletal myopathy","medgen_id":"C1533847","type":"Finding","id":"23970","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003756\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003756\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":["MRD27"],"name":"Mental retardation, autosomal dominant 27","medgen_id":"C4014528","type":"Disease","id":"21236","attribute_content":[],"symbol":"CSS9","keywords":[],"alternate_names":["COFFIN-SIRIS SYNDROME 9"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"615866\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1465\"}","{\"db\":\"OMIM\",\"id\":\"600898.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COFFIN-SIRIS SYNDROME 9\"}","{\"db\":\"OMIM\",\"id\":\"600898.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COFFIN-SIRIS SYNDROME 9\"}","{\"db\":\"OMIM\",\"id\":\"615866\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COFFIN-SIRIS SYNDROME 9\"}","{\"db\":\"OMIM\",\"id\":\"615866\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRD27\"}","{\"db\":\"OMIM\",\"id\":\"615866\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["ACUG","EOS"],"name":"Blau syndrome","medgen_id":"C1861303","type":"Disease","id":"4676","attribute_content":[],"symbol":"BLAUS","keywords":[],"alternate_names":["SARCOIDOSIS, EARLY-ONSET"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3274\"}","{\"db\":\"Orphanet\",\"id\":\"90340\"}","{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SARCOIDOSIS, EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ACUG\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"304\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ACUG\"}","{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EOS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Synovitis+granulomatous+with+uveitis+and+cranial+neuropathies/6974\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"blau-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"304\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"186580\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"The nephrotic syndrome refers to a genetically heterogeneous group of disorders characterized by proteinuria, hypoalbuminemia, and edema, resulting in end-stage kidney disease if untreated. Inherited defects in podocyte structure and function have been observed in some children with the steroid-resistant subtype of nephrotic syndrome (summary by Ozaltin et al., 2011).\r\nFor a general phenotypic description and a discussion of genetic heterogeneity of nephrotic syndrome, see NPHS1 (256300).","name":"Nephrotic syndrome, type 6","medgen_id":"C3280100","type":"Disease","id":"16539","attribute_content":[],"symbol":"NPHS6","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"614196\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"656\"}","{\"db\":\"Orphanet\",\"id\":\"93214\"}","{\"db\":\"Orphanet\",\"id\":\"93216\"}","{\"db\":\"Orphanet\",\"id\":\"93217\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephrotic+syndrome%2C+type+6/8990\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614196\",\"type\":\"MIM\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614196\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Myelodysplasia","medgen_id":"C0026985","type":"Disease","id":"16782","attribute_content":[],"keywords":[],"alternate_names":["Hypoplastic myelodysplasia"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002863\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004832\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006730\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002863\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hypoplastic myelodysplasia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002863\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Multiple mitochondrial dysfunctions syndrome","medgen_id":"C3502075","type":"Disease","id":"34497","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"PS605711\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"289573\"}","{\"db\":\"OMIM\",\"id\":\"PS605711\",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Multiple endocrine neoplasia","medgen_id":"C0027662","type":"Disease","id":"33367","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"PS131100\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"276161\"}","{\"db\":\"SNOMED CT\",\"id\":\"46724008\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":["LGMD1G"],"name":"Limb-girdle muscular dystrophy, type 1G","medgen_id":"C1836765","type":"Disease","id":"5407","attribute_content":[],"symbol":"LGMDD3","keywords":[],"alternate_names":["MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 3"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"609115\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"55596\"}","{\"db\":\"OMIM\",\"id\":\"607137.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 3\"}","{\"db\":\"OMIM\",\"id\":\"607137.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 3\"}","{\"db\":\"OMIM\",\"id\":\"609115\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL DOMINANT 3\"}","{\"db\":\"OMIM\",\"id\":\"609115\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LGMD1G\"}","{\"db\":\"OMIM\",\"id\":\"609115\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Cryptophthalmos","medgen_id":"C0311249","type":"Disease","id":"22192","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001126\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008032\",\"type\":\"secondary\"}","{\"db\":\"Orphanet\",\"id\":\"98562\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001126\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10505\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Short-rib polydactyly syndrome type III","medgen_id":"C0432197","type":"Disease","id":"38405","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"93271\"}"]}
{"alternate_symbols":["CMT6","CMT6A","HMSN6","HSMN6"],"name":"Hereditary motor and sensory neuropathy with optic atrophy","medgen_id":"C0393807","type":"Disease","id":"2032","attribute_content":[],"symbol":"HMSN6A","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, TYPE 6","CHARCOT-MARIE-TOOTH DISEASE, TYPE 6A","HMSN VIA","NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA","NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA, WITH OPTIC ATROPHY","PERIPHERAL NEUROPATHY AND OPTIC ATROPHY"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90120\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, TYPE 6\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, TYPE 6A\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"608507.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIA, WITH OPTIC ATROPHY\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PERIPHERAL NEUROPATHY AND OPTIC ATROPHY\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT6\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT6A\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN6\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+motor+and+sensory+neuropathy+with+optic+atrophy/8523\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"128203003\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601152\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["SRPS4"],"name":"Type IV short rib polydactyly syndrome","medgen_id":"C0432198","type":"Disease","id":"3724","attribute_content":[],"symbol":"SRTD12","keywords":[],"alternate_names":["SHORT RIB SYNDROME, BEEMER TYPE","SRPS IV"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"269860\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93268\"}","{\"db\":\"OMIM\",\"id\":\"269860\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SHORT RIB SYNDROME, BEEMER TYPE\"}","{\"db\":\"OMIM\",\"id\":\"269860\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SRPS IV\"}","{\"db\":\"OMIM\",\"id\":\"269860\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SRPS4\"}","{\"db\":\"SNOMED CT\",\"id\":\"254052001\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"269860\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Diabetes mellitus","medgen_id":"C0011849","type":"Disease","id":"35564","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000819\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004908\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008217\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008234\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008260\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000819\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"73211009\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Papillary renal cell carcinoma","medgen_id":"C1306837","type":"Disease","id":"25826","attribute_content":[],"symbol":"RCCP","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006766\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006776\",\"type\":\"secondary\"}","{\"db\":\"Orphanet\",\"id\":\"319298\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006766\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9572\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9572\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Craniofacial-skeletal-dermatologic dysplasia","medgen_id":"C0220658","type":"Disease","id":"8596","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"710\"}","{\"db\":\"Orphanet\",\"id\":\"93258\"}","{\"db\":\"Orphanet\",\"id\":\"93259\"}","{\"db\":\"Orphanet\",\"id\":\"93260\"}"]}
{"alternate_symbols":[],"name":"Intrahepatic cholangiocarcinoma","medgen_id":"C0345905","type":"Disease","id":"40444","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Office of Rare Diseases\",\"id\":\"6042\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Cortical visual impairment","medgen_id":"C4048268","type":"Finding","id":"17247","attribute_content":[],"keywords":[],"alternate_names":["CVI","Cerebral visual impairment","Cortical blindness","Cortical/cerebral visual impairment"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000595\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"447788\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CVI\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cerebral visual impairment\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cortical blindness\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cortical/cerebral visual impairment\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100704\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"public_definition":"Attention-deficit/hyperactivity disorder (ADHD) is a behavioral disorder that typically begins in childhood and is characterized by a short attention span (inattention), an inability to be calm and stay still (hyperactivity), and poor impulse control (impulsivity). Some people with ADHD have problems with only inattention or with hyperactivity and impulsivity, but most have problems related to all three features.In people with ADHD, the characteristic behaviors are frequent and severe enough to interfere with the activities of daily living such as school, work, and relationships with others. Because of an inability to stay focused on tasks, people with inattention may be easily distracted, forgetful, avoid tasks that require sustained attention, have difficulty organizing tasks, or frequently lose items.Hyperactivity is usually shown by frequent movement. Individuals with this feature often fidget or tap their foot when seated, leave their seat when it is inappropriate to do so (such as in the classroom), or talk a lot and interrupt others.Impulsivity can result in hasty actions without thought for the consequences. Individuals with poor impulse control may have difficulty waiting for their turn, deferring to others, or considering their actions before acting.More than two-thirds of all individuals with ADHD have additional conditions, including insomnia, mood or anxiety disorders, learning disorders, or substance use disorders. Affected individuals may also have autism spectrum disorder, which is characterized by impaired communication and social interaction, or Tourette syndrome, which is a disorder characterized by repetitive and involuntary movements or noises called tics.In most affected individuals, ADHD continues throughout life, but in about one-third of individuals, signs and symptoms of ADHD go away by adulthood.","name":"Attention deficit hyperactivity disorder","medgen_id":"C1263846","type":"Disease","id":"33114","attribute_content":[],"symbol":"ADHD","keywords":[],"ghr_links":"attention-deficit/hyperactivity disorder","alternate_names":["Attention deficit","Attention deficit disorder","Attention deficits","Childhood attention deficit/hyperactivity disorder","HYPERACTIVITY OF CHILDHOOD"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001576\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001577\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006973\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007018\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"143465\",\"type\":\"MIM\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007018\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Attention deficit\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007018\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Attention deficit disorder\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007018\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Attention deficits\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007018\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Childhood attention deficit/hyperactivity disorder\"}","{\"db\":\"OMIM\",\"id\":\"143465\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERACTIVITY OF CHILDHOOD\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"attention-deficit-hyperactivity-disorder\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007018\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"406506008\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"attention-deficit-hyperactivity-disorder\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"143465\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Jacobsen syndrome is a condition caused by a loss of genetic material from chromosome 11. Because this deletion occurs at the end (terminus) of the long (q) arm of chromosome 11, Jacobsen syndrome is also known as 11q terminal deletion disorder.The signs and symptoms of Jacobsen syndrome vary considerably. Most affected individuals have delayed development, including the development of speech and motor skills (such as sitting, standing, and walking). Most also have cognitive impairment and learning difficulties. Behavioral problems have been reported, including compulsive behavior (such as shredding paper), a short attention span, and easy distractibility. Many people with Jacobsen syndrome have been diagnosed with attention-deficit/hyperactivity disorder (ADHD). Jacobsen syndrome is also associated with an increased likelihood of autism spectrum disorders, which are characterized by impaired communication and socialization skills.Jacobsen syndrome is also characterized by distinctive facial features. These include small and low-set ears, widely set eyes (hypertelorism) with droopy eyelids (ptosis), skin folds covering the inner corner of the eyes (epicanthal folds), a broad nasal bridge, downturned corners of the mouth, a thin upper lip, and a small lower jaw. Affected individuals often have a large head size (macrocephaly) and a skull abnormality called trigonocephaly, which gives the forehead a pointed appearance.More than 90 percent of people with Jacobsen syndrome have a bleeding disorder called Paris-Trousseau syndrome. This condition causes a lifelong risk of abnormal bleeding and easy bruising. Paris-Trousseau syndrome is a disorder of platelets, which are blood cell fragments that are necessary for blood clotting.Other features of Jacobsen syndrome can include heart defects, feeding difficulties in infancy, short stature, frequent ear and sinus infections, and skeletal abnormalities. The disorder can also affect the digestive system, kidneys, and genitalia. The life expectancy of people with Jacobsen syndrome is unknown, although affected individuals have lived into adulthood.","name":"11q partial monosomy syndrome","medgen_id":"C0795841","type":"Disease","id":"2431","attribute_content":[],"symbol":"JBS","keywords":[],"alternate_names":["Jacobsen Distal 11q Deletion Syndrome"],"xrefs":["{\"db\":\"Gene\",\"id\":\"3719\"}","{\"db\":\"OMIM\",\"id\":\"147791\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2308\"}","{\"db\":\"SNOMED CT\",\"id\":\"4325000\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"jacobsen-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"147791\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"307\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["EDS5","XMVD"],"name":"Cardiac valvular dysplasia, X-linked","medgen_id":"C0262436","type":"Disease","id":"711","attribute_content":[],"symbol":"CVD1","keywords":[],"alternate_names":["EHLERS-DANLOS SYNDROME, TYPE V"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"314400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1864\"}","{\"db\":\"OMIM\",\"id\":\"314400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EHLERS-DANLOS SYNDROME, TYPE V\"}","{\"db\":\"OMIM\",\"id\":\"314400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EDS5\"}","{\"db\":\"OMIM\",\"id\":\"314400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XMVD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1096\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"XMVD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cardiac+Valvular+Dysplasia%2C+X-Linked/1082\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1096\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"314400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1096\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["TTDP"],"name":"Trichothiodystrophy 1, photosensitive","medgen_id":"C1866504","type":"Disease","id":"4296","attribute_content":[],"symbol":"TTD1","keywords":[],"alternate_names":["ICHTHYOSIFORM ERYTHRODERMA WITH HAIR ABNORMALITY AND MENTAL AND GROWTH RETARDATION","TAY SYNDROME","TRICHOTHIODYSTROPHY 3, PHOTOSENSITIVE","TRICHOTHIODYSTROPHY WITH CONGENITAL ICHTHYOSIS","Trichothiodystrophy, complementation group A"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"601675\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"33364\"}","{\"db\":\"Orphanet\",\"id\":\"670\"}","{\"db\":\"OMIM\",\"id\":\"601675\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ICHTHYOSIFORM ERYTHRODERMA WITH HAIR ABNORMALITY AND MENTAL AND GROWTH RETARDATION\"}","{\"db\":\"OMIM\",\"id\":\"601675\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TAY SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"608780.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY 3, PHOTOSENSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"608780.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY 3, PHOTOSENSITIVE\"}","{\"db\":\"OMIM\",\"id\":\"601675\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TRICHOTHIODYSTROPHY WITH CONGENITAL ICHTHYOSIS\"}","{\"db\":\"OMIM\",\"id\":\"601675\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TTDP\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5270\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"TTDP\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5270\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601675\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["AOVD","BAV"],"name":"Bicuspid aortic valve","medgen_id":"C0149630","type":"Disease","id":"33346","attribute_content":[],"keywords":[],"alternate_names":["Aortic valve disease"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001647\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"PS109730\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"402075\"}","{\"db\":\"OMIM\",\"id\":\"PS109730\",\"type\":\"Phenotypic series\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Aortic valve disease\"}","{\"db\":\"OMIM\",\"id\":\"109730\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AOVD\"}","{\"db\":\"OMIM\",\"id\":\"109730\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BAV\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001647\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"72352009\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"D-2-hydroxyglutaric aciduria","medgen_id":"C1833429","type":"Disease","id":"30204","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012321\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"79315\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012321\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"public_definition":"Blau syndrome is an inflammatory disorder that primarily affects the skin, joints, and eyes. Signs and symptoms begin in childhood, usually before age 4.A form of skin inflammation called granulomatous dermatitis is typically the earliest sign of Blau syndrome. This skin condition causes a persistent rash that can be scaly or involve hard lumps (nodules) that can be felt under the skin. The rash is usually found on the torso, arms, and legs.Arthritis is another common feature of Blau syndrome. In affected individuals, arthritis is characterized by inflammation of the lining of joints (the synovium). This inflammation, known as synovitis, is associated with swelling and joint pain. Synovitis usually begins in the joints of the hands, feet, wrists, and ankles. As the condition worsens, it can involve additional joints and restrict movement by decreasing the range of motion in many joints.Most people with Blau syndrome also develop uveitis, which is swelling and inflammation of the middle layer of the eye (the uvea). The uvea includes the colored portion of the eye (the iris) and related tissues that underlie the white part of the eye (the sclera). Uveitis can cause eye irritation and pain, increased sensitivity to bright light (photophobia), and blurred vision. Other structures in the eye can also become inflamed, including the outermost protective layer of the eye (the conjunctiva), the tear glands, the specialized light-sensitive tissue that lines the back of the eye (the retina), and the nerve that carries information from the eye to the brain (the optic nerve). Inflammation of any of these structures can lead to severe vision impairment or blindness.Some individuals with Blau syndrome develop kidney disease (nephritis) due to inflammation. They may also have deposits of calcium in the kidneys (nephrocalcinosis) and often develop chronic kidney failure. Inflammation of blood vessels (vasculitis) can cause scarring and tissue death in the vessels and impedes blood flow to tissues and organs.Less commonly, Blau syndrome can affect other parts of the body, including the liver, spleen, salivary gland, brain, blood vessels, lungs, and heart. Inflammation involving these organs and tissues can impair their function and cause life-threatening complications. Rarely, affected individuals have episodes of fever or high blood pressure in the blood vessels that carry blood from the heart to the lungs (pulmonary hypertension).","name":"Sarcoidosis, early-onset","medgen_id":"C1836122","type":"Disease","id":"4368","attribute_content":[],"symbol":"EOS","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"609464\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90341\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Sarcoidosis%2C+early-onset/9263\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"blau-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609464\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Caf-au-lait macules with pulmonary stenosis","medgen_id":"C0553586","type":"Disease","id":"15928","attribute_content":[],"symbol":"WTSN","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"193520\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3444\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cafe-Au-Lait+Macules+with+Pulmonary/9637\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"403820003\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"193520\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Sialidosis is a severe inherited disorder that affects many organs and tissues, including the nervous system. This disorder is divided into two types, which are distinguished by the age at which symptoms appear and the severity of features.Sialidosis type I, also referred to as cherry-red spot myoclonus syndrome, is the less severe form of this condition. People with type I develop signs and symptoms of sialidosis in their teens or twenties. Initially, affected individuals experience problems walking (gait disturbance) and/or a loss of sharp vision (reduced visual acuity). Individuals with sialidosis type I also experience muscle twitches (myoclonus), difficulty coordinating movements (ataxia), leg tremors, and seizures. The myoclonus worsens over time, causing difficulty sitting, standing, or walking. People with sialidosis type I eventually require wheelchair assistance. Affected individuals have progressive vision problems, including impaired color vision or night blindness. An eye abnormality called a cherry-red spot, which can be identified with an eye examination, is characteristic of this disorder. Sialidosis type I does not affect intelligence or life expectancy.Sialidosis type II, the more severe type of the disorder, is further divided into congenital, infantile, and juvenile forms. The features of congenital sialidosis type II can develop before birth. This form of sialidosis is associated with an abnormal buildup of fluid in the abdominal cavity (ascites) or widespread swelling before birth caused by fluid accumulation (hydrops fetalis). Affected infants may also have an enlarged liver and spleen (hepatosplenomegaly), abnormal bone development (dysostosis multiplex), and distinctive facial features that are often described as \"coarse.\" As a result of these serious health problems, individuals with congenital sialidosis type II usually are stillborn or die soon after birth.Infantile sialidosis type II shares some features with the congenital form, although the signs and symptoms are slightly less severe and begin within the first year of life. Features of the infantile form include hepatosplenomegaly, dysostosis multiplex, \"coarse\" facial features, short stature, and intellectual disability. As children with infantile sialidosis type II get older, they may develop myoclonus and cherry-red spots. Other signs and symptoms include hearing loss, overgrowth of the gums (gingival hyperplasia), and widely spaced teeth. Affected individuals may survive into childhood or adolescence.The juvenile form has the least severe signs and symptoms of the different forms of sialidosis type II. Features of this condition usually appear in late childhood and may include mildly \"coarse\" facial features, mild bone abnormalities, cherry-red spots, myoclonus, intellectual disability, and dark red spots on the skin (angiokeratomas). The life expectancy of individuals with juvenile sialidosis type II varies depending on the severity of symptoms.","name":"Sialidosis type I","medgen_id":"C0023806","type":"Disease","id":"9310","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"812\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7639\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"sialidosis\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"name":"Acute monoblastic leukemia","medgen_id":"C0457334","type":"Disease","id":"41533","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Office of Rare Diseases\",\"id\":\"525\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Apolipoprotein C2 deficiency","medgen_id":"C1720779","type":"Disease","id":"323","attribute_content":[],"keywords":[],"alternate_names":["APOC2 DEFICIENCY","C-II ANAPOLIPOPROTEINEMIA","HYPERLIPOPROTEINEMIA, TYPE IB"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"207750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"444490\"}","{\"db\":\"OMIM\",\"id\":\"207750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"APOC2 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"207750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"C-II ANAPOLIPOPROTEINEMIA\"}","{\"db\":\"OMIM\",\"id\":\"207750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"OMIM\",\"id\":\"608083.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERLIPOPROTEINEMIA, TYPE IB\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Apolipoprotein+C2+deficiency/7704\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Ganglioglioma","medgen_id":"C0206716","type":"Disease","id":"41521","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"251949\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2430\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Intestinal pseudo-obstruction","medgen_id":"C0021847","type":"Disease","id":"17848","attribute_content":[],"symbol":"CSBS","keywords":[],"alternate_names":["Congenital short bowel syndrome","Intestinal pseudoobstruction"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004389\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"615237\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2301\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004389\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Intestinal pseudoobstruction\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004389\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6789\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"615237\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Lissencephaly","medgen_id":"C0266463","type":"Disease","id":"16724","attribute_content":[],"keywords":[],"alternate_names":["Agyria"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001339\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002537\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0031882\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"PS607432\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"48471\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001339\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Agyria\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001339\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"204036008\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":["SCAE"],"public_definition":"Myoclonic epilepsy myopathy sensory ataxia, commonly called MEMSA, is part of a group of conditions called the POLG-related disorders. The conditions in this group feature a range of similar signs and symptoms involving muscle-, nerve-, and brain-related functions. The signs and symptoms of MEMSA typically appear during young adulthood. This condition had previously been known as spinocerebellar ataxia with epilepsy (SCAE).The first symptom of MEMSA is usually cerebellar ataxia, which refers to problems with coordination and balance due to defects in the part of the brain that is involved in coordinating movement (cerebellum). Recurrent seizures (epilepsy) usually develop later, often in combination with uncontrollable muscle jerks (myoclonus). The seizures usually begin in the right arm and spread to become generalized throughout the body. Additionally, affected individuals may have severe brain dysfunction (encephalopathy) or muscle weakness (myopathy). The myopathy can affect muscles close to the center of the body (proximal), such as the muscles of the hips, thighs, upper arms, or neck, or muscles farther away from the center of the body (distal), such as the muscles of the hands or feet. The myopathy may be especially noticeable during exercise (exercise intolerance).","name":"Myoclonic epilepsy myopathy sensory ataxia","medgen_id":"C1843852","type":"Disease","id":"9412","attribute_content":[],"symbol":"MEMSA","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"254881\"}","{\"db\":\"OMIM\",\"id\":\"607459\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SCAE\"}","{\"db\":\"GeneTests\",\"id\":\"319098\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"myoclonic-epilepsy-myopathy-sensory-ataxia\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":["KHM"],"public_definition":"Vohwinkel syndrome is a disorder with classic and variant forms, both of which affect the skin.In the classic form of Vohwinkel syndrome, affected individuals have thick, honeycomb-like calluses on the palms of the hands and soles of the feet (palmoplantar keratoses) beginning in infancy or early childhood. Affected children also typically have distinctive starfish-shaped patches of thickened skin on the tops of the fingers and toes or on the knees. Within a few years they develop tight bands of abnormal fibrous tissue around their fingers and toes (pseudoainhum); the bands may cut off the circulation to the digits and result in spontaneous amputation. People with the classic form of the disorder also have hearing loss.The variant form of Vohwinkel syndrome does not involve hearing loss, and the skin features also include widespread dry, scaly skin (ichthyosis), especially on the limbs. The ichthyosis is usually mild, and there may also be mild reddening of the skin (erythroderma). Some affected infants are born with a tight, clear sheath covering their skin called a collodion membrane. This membrane is usually shed during the first few weeks of life.","name":"Mutilating keratoderma","medgen_id":"C0265964","type":"Disease","id":"1723","attribute_content":[],"symbol":"VOWNKL","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"124500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"494\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3092\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"KHM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Vohwinkel+syndrome/7413\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3092\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"24559001\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"vohwinkel-syndrome\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"124500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Pulmonary arterial hypertension","medgen_id":"C2973725","type":"Finding","id":"17082","attribute_content":[],"keywords":[],"alternate_names":["Primary pulmonary hypertension","Pulmonary artery hypertension","Pulmonary hypertension"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002092\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006546\",\"type\":\"secondary\"}","{\"db\":\"Orphanet\",\"id\":\"182090\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002092\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Primary pulmonary hypertension\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002092\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pulmonary artery hypertension\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Pulmonary+Hypertension/6088\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pulmonary hypertension\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002092\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Glioblastoma multiforme","medgen_id":"C1621958","type":"Disease","id":"30059","attribute_content":[],"symbol":"GBM","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012174\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0100843\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012174\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2491\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"137800\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["MPS III"],"public_definition":"Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects the brain and spinal cord (central nervous system). Other body systems can also be involved.People with MPS III generally do not display any features of the condition at birth, but they begin to show signs and symptoms of the disorder during early childhood. Affected children often initially have delayed speech and behavior problems. They may become restless, destructive, anxious, or aggressive, and some display features of autism spectrum disorder, which is a condition characterized by difficulty with social interactions and communication. Sleep disturbances are also very common in children with MPS III. This condition causes progressive intellectual disability and the loss of previously acquired skills (developmental regression). In later stages of the disorder, people with MPS III may develop seizures and movement disorders.The physical features of MPS III are less pronounced than those of other types of mucopolysaccharidosis. Individuals with MPS III typically have mildly \"coarse\" facial features, a large head (macrocephaly), a slightly enlarged liver (mild hepatomegaly), and a soft out-pouching around the belly-button (umbilical hernia) or lower abdomen (inguinal hernia). Some people with MPS III have short stature, joint stiffness, or mild dysostosis multiplex, which refers to multiple skeletal abnormalities seen on x-ray. Affected individuals often experience chronic diarrhea and recurrent upper respiratory and ear infections. People with MPS III may also have hearing loss and vision problems.MPS III is divided into types IIIA, IIIB, IIIC, and IIID, which are distinguished by their genetic cause. The different types of MPS III have similar signs and symptoms, although the features of MPS IIIA typically appear earlier in life and progress more rapidly. People with MPS III usually live into adolescence or early adulthood.","name":"Sanfilippo syndrome","medgen_id":"C0026706","type":"Disease","id":"6283","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"581\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3807\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"88393000\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"mucopolysaccharidosis-type-iii\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"name":"Leukocyte adhesion deficiency","medgen_id":"C0272187","type":"Disease","id":"10543","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"2968\"}"]}
{"alternate_symbols":[],"name":"Infantile liver failure syndrome 2","medgen_id":"C3809651","type":"Disease","id":"33970","attribute_content":[],"symbol":"ILFS2","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"616483\",\"type\":\"MIM\"}"]}
{"alternate_symbols":["EDM","MED"],"name":"Multiple epiphyseal dysplasia","medgen_id":"C0026760","type":"Disease","id":"23227","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002654\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"251\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10756\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EDM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10756\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MED\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002654\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10756\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"MYH9-related disorder","medgen_id":"C1854520","type":"Disease","id":"36485","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"807\"}","{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"30835\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"IMMUNODEFICIENCY 55","medgen_id":"C4693356","type":"Disease","id":"38495","attribute_content":[],"symbol":"IMD55","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"617827\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"505227\"}","{\"db\":\"OMIM\",\"id\":\"610608.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610608.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610608.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610608.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617827\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617827\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Centronuclear myopathy is a condition characterized by muscle weakness (myopathy) and wasting (atrophy) in the skeletal muscles, which are the muscles used for movement. The severity of centronuclear myopathy varies among affected individuals, even among members of the same family.People with centronuclear myopathy begin experiencing muscle weakness at any time from birth to early adulthood. The muscle weakness slowly worsens over time and can lead to delayed development of motor skills, such as crawling or walking; muscle pain during exercise; and difficulty walking. Some affected individuals may need wheelchair assistance as the muscles atrophy and weakness becomes more severe. In rare instances, the muscle weakness improves over time.Some people with centronuclear myopathy experience mild to severe breathing problems related to the weakness of muscles needed for breathing. People with centronuclear myopathy may have droopy eyelids (ptosis) and weakness in other facial muscles, including the muscles that control eye movement. People with this condition may also have foot abnormalities, a high arch in the roof of the mouth (high-arched palate), and abnormal side-to-side curvature of the spine (scoliosis). Rarely, individuals with centronuclear myopathy have a weakened heart muscle (cardiomyopathy), disturbances in nerve function (neuropathy), or intellectual disability.A key feature of centronuclear myopathy is the displacement of the nucleus in muscle cells, which can be viewed under a microscope. Normally the nucleus is found at the edges of the rod-shaped muscle cells, but in people with centronuclear myopathy the nucleus is located in the center of these cells. How the change in location of the nucleus affects muscle cell function is unknown.","name":"Myopathy, centronuclear, 4","medgen_id":"C3553709","type":"Disease","id":"17362","attribute_content":[],"symbol":"CNM4","keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"OMIM\",\"id\":\"614807\",\"type\":\"MIM\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"centronuclear-myopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614807\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CMT6B"],"name":"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB, WITH OPTIC ATROPHY","medgen_id":"C4225302","type":"Disease","id":"33965","attribute_content":[],"symbol":"HMSN6B","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, TYPE 6B","HMSN VIB","NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"616505\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"616505\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, TYPE 6B\"}","{\"db\":\"OMIM\",\"id\":\"616505\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"610826.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE VIB\"}","{\"db\":\"OMIM\",\"id\":\"616505\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT6B\"}","{\"db\":\"OMIM\",\"id\":\"616505\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"616505\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Tobacco use disorder","medgen_id":"C0040336","type":"Disease","id":"18583","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"SNOMED CT\",\"id\":\"89765005\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Immunodeficiency 26 with or without neurologic abnormalities","medgen_id":"C4014833","type":"Disease","id":"31835","attribute_content":[],"symbol":"IMD26","keywords":[],"alternate_names":["IMMUNODEFICIENCY 26 WITH NEUROLOGIC ABNORMALITIES"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"615966\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"600899.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 26 WITH NEUROLOGIC ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"600899.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 26 WITH NEUROLOGIC ABNORMALITIES\"}","{\"db\":\"OMIM\",\"id\":\"615966\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CMT2I","CMT2J","DI-CMTD"],"public_definition":"Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors). Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.","name":"Charcot-Marie-Tooth disease dominant intermediate 3","medgen_id":"C1843075","type":"Disease","id":"1419","attribute_content":[],"symbol":"CMTDID","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D","CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE D"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"607791\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"159440.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D\"}","{\"db\":\"OMIM\",\"id\":\"607791\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE D\"}","{\"db\":\"OMIM\",\"id\":\"607791\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE D\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000247963\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT2I\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000247963\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT2J\"}","{\"db\":\"OMIM\",\"id\":\"607791\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DI-CMTD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Dominant+Intermediate+3/1280\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9207\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"charcot-marie-tooth-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607791\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Renal dysplasia","medgen_id":"C0266313","type":"Disease","id":"21426","attribute_content":[],"symbol":"RTD","keywords":[],"alternate_names":["Dysplastic kidneys","Renal adysplasia","Renal tubular dysgenesis","Renotubular dysgenesis"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000110\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000116\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004721\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008660\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"267430\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3033\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000110\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Dysplastic kidneys\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000110\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Renal adysplasia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008660\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Renal tubular dysgenesis\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008660\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Renotubular dysgenesis\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Renal+dysplasia/9216\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000110\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"204949001\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"267430\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"379\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Ateleiotic dwarfism","medgen_id":"C0342573","type":"Disease","id":"2425","attribute_content":[],"symbol":"IGHD1A","keywords":[],"alternate_names":["IGHD IA","PITUITARY DWARFISM I"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"262400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"631\"}","{\"db\":\"OMIM\",\"id\":\"262400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IGHD IA\"}","{\"db\":\"OMIM\",\"id\":\"262400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PITUITARY DWARFISM I\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ateleiotic+dwarfism/7728\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"71003000\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"262400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7399\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["COI"],"name":"Congenital ocular coloboma","medgen_id":"C0009363","type":"Disease","id":"9897","attribute_content":[],"keywords":[],"alternate_names":["COLOBOMA OF IRIS, CHOROID, AND RETINA","COLOBOMA, OCULAR, AUTOSOMAL DOMINANT","COLOBOMA, UVEORETINAL","Coloboma","Coloboma of eye","Notched pupil","Ocular coloboma","Ocular colobomas"],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000589\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007767\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007995\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"120200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"194\"}","{\"db\":\"OMIM\",\"id\":\"120200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COLOBOMA OF IRIS, CHOROID, AND RETINA\"}","{\"db\":\"OMIM\",\"id\":\"120200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COLOBOMA, OCULAR, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"120200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"COLOBOMA, UVEORETINAL\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000589\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Coloboma\"}","{\"db\":\"SNOMED CT\",\"id\":\"92828000\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Coloboma of eye\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000589\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Notched pupil\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000589\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ocular coloboma\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000589\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ocular colobomas\"}","{\"db\":\"OMIM\",\"id\":\"120200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"COI\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Microphthalmia%2C+isolated%2C+with+coloboma+7/8883\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"93390002\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Intrahepatic Cholestasis","medgen_id":"C0008372","type":"Disease","id":"22363","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001406\",\"type\":\"primary\"}"]}
{"alternate_symbols":[],"name":"D-Glyceric aciduria","medgen_id":"C0342765","type":"Disease","id":"39924","attribute_content":[],"keywords":[],"alternate_names":[],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"941\"}"]}
{"alternate_symbols":["LQT2/9, DIGENIC"],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 9","medgen_id":"C2678485","type":"Disease","id":"2567","attribute_content":[],"symbol":"LQT9","keywords":[],"alternate_names":["LONG QT SYNDROME 2/9, DIGENIC","LONG QT SYNDROME 9, ACQUIRED, SUSCEPTIBILITY TO"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301559\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1385\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"611818\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"OMIM\",\"id\":\"611818\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LONG QT SYNDROME 2/9, DIGENIC\"}","{\"db\":\"OMIM\",\"id\":\"611818\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LONG QT SYNDROME 9, ACQUIRED, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"611818\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"LQT2/9, DIGENIC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+9/4306\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10435\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611818\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10435\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Timothy syndrome is a multisystem disorder characterized by cardiac, hand/foot, facial, and neurodevelopmental features. Typical cardiac findings include a rate-corrected QT interval \u003e480 ms, functional 2:1 AV block with bradycardia, tachyarrhythmias, and congenital heart defects (patent ductus arteriosus, patent foramen ovale, ventricular septal defect, tetralogy of Fallot, hypertrophic cardiomyopathy). The diagnosis of Timothy syndrome is generally made within the first few days of life although it may be suspected prenatally due to 2:1 AV block or bradycardia in the fetus. Hand/foot findings are unilateral or bilateral cutaneous syndactyly variably involving fingers two (index), three (middle), four (ring), and five (little) and bilateral cutaneous syndactyly of toes two and three. Facial findings include depressed nasal bridge, low-set ears, thin vermilion border of the upper lip, and round face. Neuropsychiatric involvement includes global developmental delays and autism spectrum disorders. Ventricular tachyarrhythmia is the leading cause of death, followed by infection and complications of intractable hypoglycemia. Average age of death is 2.5 years.","name":"Timothy syndrome","medgen_id":"C1832916","type":"Disease","id":"4276","attribute_content":[],"symbol":"TS","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301577\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1403\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"601005\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"65283\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+8/4305\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"timothy-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9294\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1403\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601005\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Charcot-Marie-Tooth neuropathy type 2E/1F (CMT2E/1F) is characterized by a progressive peripheral motor and sensory neuropathy with variable clinical and electrophysiologic expression. Disease onset ranges from the first to the fifth decade of life; in some cases disease onset can be in infancy. Affected individuals have difficulty walking and running because of progressive distal weakness and wasting of the muscles of the lower limbs. Paresis in the distal part of the lower limbs varies from mild weakness to a complete paralysis of the distal muscle groups. Tendon reflexes are diminished or absent. Sensory signs are not prominent but are present in all affected individuals. Pes cavus, hammer toes, and claw hands are frequently observed. Ambulation is generally preserved.","name":"Charcot-Marie-Tooth disease, demyelinating, type 1f","medgen_id":"C1843164","type":"Disease","id":"881","attribute_content":[],"symbol":"CMT1F","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1F","Charcot-Marie-Tooth disease, type 1F"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301366\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1187\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301384\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1205\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"607734\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101085\"}","{\"db\":\"OMIM\",\"id\":\"607734\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1F\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+1F/1289\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth disease, type 1F\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1187\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607734\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["cblD"],"public_definition":"Disorders of intracellular cobalamin metabolism have a variable phenotype and age of onset that are influenced by the severity and location within the pathway of the defect. The prototype and best understood phenotype is cblC; it is also the most common of these disorders. The age of initial presentation of cblC spans a wide range: In utero with fetal presentation of nonimmune hydrops, cardiomyopathy, and intrauterine growth restriction. Newborns, who can have microcephaly, poor feeding, and encephalopathy. Infants, who can have poor feeding and slow growth, neurologic abnormality, and, rarely, hemolytic uremic syndrome (HUS). Toddlers, who can have poor growth, progressive microcephaly, cytopenias (including megaloblastic anemia), global developmental delay, encephalopathy, and neurologic signs such as hypotonia and seizures. Adolescents and adults, who can have neuropsychiatric symptoms, progressive cognitive decline, thromboembolic compications, and/or subacute combined degeneration of the spinal cord.","name":"Methylmalonic acidemia with homocystinuria cblD","medgen_id":"C1848552","type":"Disease","id":"2914","attribute_content":[],"symbol":"MAHCD","keywords":[],"alternate_names":["METHYLMALONIC ACIDEMIA, cblH TYPE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE","cblD (variant 1)","cblD (variant 2)"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301409\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1231\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301503\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1328\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"277410\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"308380\"}","{\"db\":\"Orphanet\",\"id\":\"308442\"}","{\"db\":\"Orphanet\",\"id\":\"622\"}","{\"db\":\"Orphanet\",\"id\":\"79283\"}","{\"db\":\"OMIM\",\"id\":\"277410\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"METHYLMALONIC ACIDEMIA, cblH TYPE\"}","{\"db\":\"OMIM\",\"id\":\"277410\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE\"}","{\"db\":\"OMIM\",\"id\":\"611935.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE\"}","{\"db\":\"OMIM\",\"id\":\"611935.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE\"}","{\"db\":\"OMIM\",\"id\":\"611935.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Methylmalonicacidemia+with+homocystinuria+cbl+d/4719\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1328\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"277410\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["BBBG1","OGS1","OS","OSX"],"public_definition":"X-linked Opitz G/BBB syndrome (X-OS) is a multiple-congenital-anomaly disorder characterized by facial anomalies (hypertelorism, prominent forehead, widow's peak, broad nasal bridge, anteverted nares), genitourinary abnormalities (hypospadias, cryptorchidism, and hypoplastic/bifid scrotum), and laryngotracheoesophageal defects. Developmental delay and intellectual disability are observed in about 50% of affected males. Cleft lip and/or palate are present in approximately 50% of affected individuals. Other malformations (present in \u003c50% of individuals) include congenital heart defects, imperforate or ectopic anus, and midline brain defects (Dandy-Walker malformation and agenesis or hypoplasia of the corpus callosum and/or cerebellar vermis). Wide clinical variability occurs even among members of the same family. Female heterozygotes usually manifest hypertelorism only.","name":"Opitz-Frias syndrome","medgen_id":"C2936904","type":"Disease","id":"3313","attribute_content":[],"symbol":"GBBB1","keywords":[],"alternate_names":["HYPERTELORISM WITH ESOPHAGEAL ABNORMALITY AND HYPOSPADIAS","HYPERTELORISM-HYPOSPADIAS SYNDROME","OPITZ BBBG SYNDROME, TYPE I","OPITZ GBBB SYNDROME, TYPE I","OPITZ SYNDROME","OPITZ SYNDROME, X-LINKED","OPITZ-G SYNDROME, TYPE I","TELECANTHUS-HYPOSPADIAS SYNDROME"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301502\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1327\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301753\",\"@Source\":\"PubMed\"},{\"$\":\"NBK5192\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2745\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERTELORISM WITH ESOPHAGEAL ABNORMALITY AND HYPOSPADIAS\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERTELORISM-HYPOSPADIAS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ BBBG SYNDROME, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ GBBB SYNDROME, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300552.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ SYNDROME, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OPITZ-G SYNDROME, TYPE I\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TELECANTHUS-HYPOSPADIAS SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"BBBG1\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OGS1\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OS\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OSX\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypertelorism+with+esophageal+abnormality+and+hypospadias/3605\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"81771002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1327\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300000\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Nonsyndromic hearing loss and deafness, DFNA3 is characterized by pre- or postlingual, mild-to-profound progressive high-frequency sensorineural hearing impairment. Affected individuals have no other associated medical findings.","name":"Deafness, autosomal dominant 3a","medgen_id":"C2675750","type":"Disease","id":"4900","attribute_content":[],"symbol":"DFNA3A","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301708\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1536\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"601544\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"90635\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deafness%2C+autosomal+dominant+3a/8144\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1536\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601544\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"X-linked Charcot-Marie-Tooth neuropathy type 5 (CMTX5), part of the spectrum of PRPS1-related disorders, is characterized by peripheral neuropathy, early-onset (prelingual) bilateral profound sensorineural hearing loss, and optic neuropathy. The onset of peripheral neuropathy is between ages five and 12 years. The lower extremities are affected earlier and more severely than upper extremities. Initial manifestations often include foot drop or gait disturbance. Onset of visual impairment is between ages seven and 20 years. Intellect and life span are normal. Carrier females do not have findings of CMTX5.","name":"Charcot-Marie-Tooth disease, X-linked recessive, type 5","medgen_id":"C1839566","type":"Disease","id":"1422","attribute_content":[],"symbol":"CMTX5","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED RECESSIVE, 5","Charcot-Marie-Tooth Neuropathy X Type 5"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301731\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1876\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"311070\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"311070\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, X-LINKED RECESSIVE, 5\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1876\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth Neuropathy X Type 5\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+disease%2C+X-linked+recessive%2C+type+5/7964\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1876\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"311070\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CRX"],"name":"Leber congenital amaurosis 7","medgen_id":"C3151192","type":"Disease","id":"10323","attribute_content":[],"symbol":"LCA7","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301475\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1298\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"30285347\",\"@Source\":\"PubMed\"},{\"$\":\"NBK531510\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613829\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"65\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Leber+congenital+amaurosis+7/8722\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613829\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 2","medgen_id":"C3150943","type":"Disease","id":"6428","attribute_content":[],"symbol":"LQT2","keywords":[],"alternate_names":["LONG QT SYNDROME 2, ACQUIRED, REDUCED SUSCEPTIBILITY TO"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]},{\"@Abbrev\":\"HRS/EHRA, 2012\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"21810866\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613688\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"OMIM\",\"id\":\"603313.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LONG QT SYNDROME 2, ACQUIRED, REDUCED SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+2/4300\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3285\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613688\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3285\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 1","medgen_id":"C4551647","type":"Disease","id":"2703","attribute_content":[],"symbol":"LQT1","keywords":[],"alternate_names":["Romano-Ward syndrome"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]},{\"@Abbrev\":\"HRS/EHRA, 2012\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"21810866\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"192500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"SNOMED CT\",\"id\":\"20852007\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Romano-Ward syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+1/4297\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3284\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"192500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3284\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 3","medgen_id":"C1859062","type":"Disease","id":"2566","attribute_content":[],"symbol":"LQT3","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]},{\"@Abbrev\":\"HRS/EHRA, 2012\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"21810866\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"603830\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"603830\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3286\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"GDAP1-related hereditary motor and sensory neuropathy (GDAP1-HMSN) is a peripheral neuropathy (also known as a subtype of Charcot-Marie-Tooth disease) that typically affects the lower extremities earlier and more severely than the upper extremities. As the neuropathy progresses, the distal upper extremities also become severely affected. Proximal muscles can also become weak. Age at onset ranges from infancy to early childhood. In most cases, disease progression causes disabilities within the first or second decade of life. At the end of the second decade, most individuals are wheelchair bound. Disease progression varies considerably even within the same family. The neuropathy can be either of the demyelinating type with reduced nerve conduction velocities or the axonal type with normal nerve conduction velocities. Vocal cord paresis is common. Intelligence is normal. Life expectancy is usually normal, but on occasion may be reduced because of secondary complications.","name":"Charcot-Marie-Tooth disease, type 4A","medgen_id":"C1859198","type":"Disease","id":"785","attribute_content":[],"symbol":"CMT4A","keywords":[],"alternate_names":["Charcot-Marie-Tooth Neuropathy Type 4A","Charcot-Marie-Tooth disease, demyelinating, autosomal recessive, type 4a"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301641\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1468\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301711\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1539\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987431\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"214400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99948\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1539\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth Neuropathy Type 4A\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+4A/1303\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1539\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"214400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1252\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["HMSN IA","HMSN1A"],"name":"Charcot-Marie-Tooth disease, type IA","medgen_id":"C0270911","type":"Disease","id":"4780","attribute_content":[],"symbol":"CMT1A","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, WITH FOCALLY FOLDED MYELIN SHEATHS, TYPE 1A","CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1A","HEREDITARY MOTOR AND SENSORY NEUROPATHY IA"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301384\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1205\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987431\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"118220\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101081\"}","{\"db\":\"OMIM\",\"id\":\"118220\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, WITH FOCALLY FOLDED MYELIN SHEATHS, TYPE 1A\"}","{\"db\":\"OMIM\",\"id\":\"118220\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1A\"}","{\"db\":\"OMIM\",\"id\":\"118220\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEREDITARY MOTOR AND SENSORY NEUROPATHY IA\"}","{\"db\":\"OMIM\",\"id\":\"118220\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN IA\"}","{\"db\":\"OMIM\",\"id\":\"118220\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN1A\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+1A/1284\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"40632002\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"118220\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease involving both upper motor neurons (UMN) and lower motor neurons (LMN). UMN signs include hyperreflexia, extensor plantar response, increased muscle tone, and weakness in a topographic representation. LMN signs include weakness, muscle wasting, hyporeflexia, muscle cramps, and fasciculations. Initial presentation varies. Affected individuals typically present with either asymmetric focal weakness of the extremities (stumbling or poor handgrip) or bulbar findings (dysarthria, dysphagia). Other findings may include muscle fasciculations, muscle cramps, and labile affect, but not necessarily mood. Regardless of initial symptoms, atrophy and weakness eventually affect other muscles. The mean age of onset is 56 years in individuals with no known family history and 46 years in individuals with more than one affected family member (familial ALS or FALS). Average disease duration is about three years, but it can vary significantly. Death usually results from compromise of the respiratory muscles.","name":"Amyotrophic lateral sclerosis type 5","medgen_id":"C1865864","type":"Disease","id":"219","attribute_content":[],"symbol":"ALS5","keywords":[],"alternate_names":["AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301623\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1450\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Orphanet, 2007\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet, Amyotrophic lateral sclerosis, 2007\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_AmyotrophicLateralSclerosis.pdf\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"602099\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"300605\"}","{\"db\":\"OMIM\",\"id\":\"602099\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE\"}","{\"db\":\"OMIM\",\"id\":\"610844.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE\"}","{\"db\":\"OMIM\",\"id\":\"610844.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE\"}","{\"db\":\"OMIM\",\"id\":\"610844.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE\"}","{\"db\":\"OMIM\",\"id\":\"610844.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE\"}","{\"db\":\"OMIM\",\"id\":\"610844.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE\"}","{\"db\":\"OMIM\",\"id\":\"610844.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AMYOTROPHIC LATERAL SCLEROSIS 5, JUVENILE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Amyotrophic+Lateral+Sclerosis+Type+5/407\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10503\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1450\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"602099\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10503\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"1q21.1 microduplication is a chromosomal change in which a small amount of genetic material on chromosome 1 is abnormally copied (duplicated). The duplication occurs on the long (q) arm of the chromosome at a location designated q21.1.Some people with a 1q21.1 microduplication have developmental delay and intellectual disability that is typically mild to moderate. Individuals with this condition can also have features of autism spectrum disorder. These disorders are characterized by impaired communication and socialization skills, as well as delayed development of speech and language. Expressive language skills (vocabulary and the production of speech) tend to be more impaired than receptive language skills (the ability to understand speech) in affected individuals. In childhood, 1q21.1 microduplications may also be associated with an increased risk of attention-deficit/hyperactivity disorder (ADHD) and other behavioral problems. Psychiatric disorders such as schizophrenia or mood disorders such as anxiety or depression occur in some affected individuals, usually during adulthood. Rarely, recurrent seizures (epilepsy) occur in people with a 1q21.1 microduplication.Some individuals with a 1q21.1 microduplication are born with malformations of the heart, including a particular combination of heart defects known as tetralogy of Fallot. Less commonly, other physical malformations such as the urethra opening on the underside of the penis (hypospadias) in males, inward- and upward-turning feet (clubfeet), or misalignment of the hip joint (hip dysplasia) are present at birth. Individuals with a 1q21.1 microduplication may also have a larger than average head size or taller than average adult stature. Some have slightly unusual facial features such as wide-set eyes or low-set ears. As adults, individuals with a 1q21.1 microduplication may be prone to develop cysts, swollen and knotted (varicose) veins, or carpal tunnel syndrome, which is characterized by numbness, tingling, and weakness in the hands and fingers. However, there is no particular pattern of physical abnormalities that characterizes 1q21.1 microduplications. Signs and symptoms related to the chromosomal change vary even among affected members of the same family. Some people with the duplication have no identified physical, intellectual, or behavioral abnormalities.","name":"Chromosome 1q21.1 duplication syndrome","medgen_id":"C2675891","type":"Disease","id":"4799","attribute_content":[],"keywords":[],"alternate_names":["1q21.1 recurrent microduplication"],"content":"{\"Citation\":{\"@Abbrev\":\"Decipher\",\"@Type\":\"review\",\"URL\":{\"$\":\"https://decipher.sanger.ac.uk/syndrome/67\"}}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"612475\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"250994\"}","{\"db\":\"Decipher\",\"id\":\"67\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"1q21.1 recurrent microduplication\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Chromosome+1q21.1+Duplication+Syndrome/1497\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10591\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"1q211-microduplication\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":["MDRS1","RSS","SEPN1-RM"],"name":"Eichsfeld type congenital muscular dystrophy","medgen_id":"C0410180","type":"Disease","id":"4109","attribute_content":[],"symbol":"RSMD1","keywords":[],"ghr_links":"rigid spine muscular dystrophy","alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301467\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1290\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Int'l SCC for CMD, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21078917\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301468\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1291\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"602771\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"97244\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4723\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MDRS1\"}","{\"db\":\"OMIM\",\"id\":\"602771\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RSS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4723\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RSS\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"rigid-spine-muscular-dystrophy\",\"ref_field\":\"ghr_links\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Eichsfeld+type+congenital+muscular+dystrophy/8301\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"240063002\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602771\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4723\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Charcot-Marie-Tooth neuropathy type 2E/1F (CMT2E/1F) is characterized by a progressive peripheral motor and sensory neuropathy with variable clinical and electrophysiologic expression. Disease onset ranges from the first to the fifth decade of life; in some cases disease onset can be in infancy. Affected individuals have difficulty walking and running because of progressive distal weakness and wasting of the muscles of the lower limbs. Paresis in the distal part of the lower limbs varies from mild weakness to a complete paralysis of the distal muscle groups. Tendon reflexes are diminished or absent. Sensory signs are not prominent but are present in all affected individuals. Pes cavus, hammer toes, and claw hands are frequently observed. Ambulation is generally preserved.","name":"Charcot-Marie-Tooth disease type 2E","medgen_id":"C1843225","type":"Disease","id":"4779","attribute_content":[],"symbol":"CMT2E","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2E","Charcot-Marie-Tooth Neuropathy Type 2"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301366\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1187\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301462\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1285\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"607684\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99939\"}","{\"db\":\"OMIM\",\"id\":\"607684\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 2E\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+2E/1296\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9193\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1187\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607684\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CMT 2K"],"public_definition":"Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors). Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.","name":"Charcot-Marie-Tooth disease type 2K","medgen_id":"C1842983","type":"Disease","id":"782","attribute_content":[],"symbol":"CMT2K","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K","CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2K","CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2K"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301462\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1285\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"607831\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101097\"}","{\"db\":\"Orphanet\",\"id\":\"99944\"}","{\"db\":\"OMIM\",\"id\":\"606598.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"606598.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"606598.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"606598.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"606598.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"607831\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"606598.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"606598.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"606598.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2K\"}","{\"db\":\"OMIM\",\"id\":\"607831\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, TYPE 2K\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9199\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT 2K\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+2K/1302\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9199\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"charcot-marie-tooth-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607831\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["DI-CMTC"],"public_definition":"Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors). Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.","name":"Charcot-Marie-Tooth disease, dominant intermediate C","medgen_id":"C1842237","type":"Disease","id":"4782","attribute_content":[],"symbol":"CMTDIC","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE C"],"content":"{\"Citation\":{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987431\",\"@Source\":\"pmc\"}}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"608323\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"608323\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, DOMINANT INTERMEDIATE C\"}","{\"db\":\"OMIM\",\"id\":\"608323\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DI-CMTC\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+disease%2C+dominant+intermediate+c/7953\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"charcot-marie-tooth-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608323\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["DHMN5A","DSMAV","DSMAVA","HMN5A"],"public_definition":"GARS1-associated axonal neuropathy (Charcot-Marie-Tooth neuropathy type 2D / distal spinal muscular atrophy V [CMT2D/dSMA-V]) is characterized by adolescent or early-adult onset of weakness in the hands that may be preceded by transient cramping and pain in the hands on exposure to cold and cramping in calf muscles on exertion. This is followed by progressive weakness and atrophy of thenar and first dorsal interosseus muscles; hypothenar eminence is spared until later in the course of illness. The lower limbs are involved in about half of affected individuals, with severity varying from weakness and atrophy of the extensor digitorum brevis and weakness of toe dorsiflexors to classic peroneal muscular atrophy with foot drop. The phenotype is considered the CMT2D subtype when sensory deficits (reduction of pinprick, temperature, touch, and vibration perception in a stocking and [less often] glove pattern) are present and dSMA-V when sensory deficits are absent.","name":"Distal hereditary motor neuronopathy type 5","medgen_id":"C1833308","type":"Disease","id":"3091","attribute_content":[],"symbol":"HMN5","keywords":[],"alternate_names":["DHMN VA","Distal Spinal Muscular Atrophy V","HMN VA","NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V","NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA","NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VA","SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VA"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301420\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1242\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301484\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1307\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139536\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DHMN VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMN VA\"}","{\"db\":\"OMIM\",\"id\":\"600287.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V\"}","{\"db\":\"OMIM\",\"id\":\"600287.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V\"}","{\"db\":\"OMIM\",\"id\":\"600287.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V\"}","{\"db\":\"OMIM\",\"id\":\"600287.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE V\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEURONOPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, DISTAL HEREDITARY MOTOR, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"606158.0013\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, DISTAL, TYPE VA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DHMN5A\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSMAV\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSMAVA\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMN5A\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Distal+hereditary+motor+neuronopathy+type+5/8273\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1242\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600794\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CMT 2C","HMSN 2 C","HMSN IIC"],"public_definition":"The TRPV4-associated disorders (previously considered to be clinically distinct phenotypes before their molecular basis was discovered) are now grouped into neuromuscular disorders and skeletal dysplasias; however, the overlap within and between both groups is considerable. Bilateral progressive sensorineural hearing loss (SNHL) can occur in both. The three neuromuscular disorders (mildest to most severe): Charcot-Marie-Tooth disease type 2C (CMT2C). Scapuloperoneal spinal muscular atrophy (SPSMA). Congenital distal spinal muscular atrophy (CDSMA). The neuromuscular disorders are characterized by a progressive peripheral neuropathy with variable combinations of laryngeal dysfunction (i.e., vocal fold paresis), respiratory dysfunction, and joint contractures. The six skeletal dysplasias: Mildest: Familial digital arthropathy-brachydactyly. Intermediate: Autosomal dominant brachyolmia. Spondylometaphyseal dysplasia, Kozlowski type. Spondyloepiphyseal dysplasia, Maroteaux type. Most severe: Parastremmatic dysplasia. Metatropic dysplasia. The skeletal dysplasia is characterized by brachydactyly (in all 6); the five that are more severe have short stature that varies from mild to severe with progressive spinal deformity and involvement of the long bones and pelvis. In the mildest of the TRPV4-associated disorders life span is normal; in the most severe it is shortened.","name":"Charcot-Marie-Tooth disease type 2C","medgen_id":"C1853710","type":"Disease","id":"7141","attribute_content":[],"symbol":"HMSN2C","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2C","Charcot-Marie-Tooth Neuropathy Type 2C"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301462\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1285\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24830047\",\"@Source\":\"PubMed\"},{\"$\":\"NBK201366\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"606071\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"606071\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AXONAL, AUTOSOMAL DOMINANT, TYPE 2C\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1250\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT 2C\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1250\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN 2 C\"}","{\"db\":\"OMIM\",\"id\":\"606071\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN IIC\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1250\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK201366\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"606071\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Charcot-Marie-Tooth neuropathy type 4H (CMT4H) is a demyelinating form of CMT that is characterized by early onset (usually before age 3 years; range: birth to age 10 years) and slow progression. The degree of distal muscle weakness and amyotrophy varies between affected individuals as does the presence or absence and severity of foot deformities, scoliosis, and sensory involvement. Neuropathic pain has not been reported. To date, findings in18 individuals with molecularly confirmed CMT4H from 13 families have been reported.","name":"Charcot-Marie-Tooth disease, type 4H","medgen_id":"C1836336","type":"Disease","id":"786","attribute_content":[],"symbol":"CMT4H","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4H","CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4H","Charcot-Marie-Tooth Neuropathy Type 4H"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301641\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1468\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"23926620\",\"@Source\":\"PubMed\"},{\"$\":\"NBK153601\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"609311\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99954\"}","{\"db\":\"OMIM\",\"id\":\"609311\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4H\"}","{\"db\":\"OMIM\",\"id\":\"609311\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4H\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+disease%2C+type+4H/7962\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK153601\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609311\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["GEMSS"],"public_definition":"Weill-Marchesani syndrome (WMS) is a connective tissue disorder characterized by abnormalities of the lens of the eye, proportionate short stature, brachydactyly, and joint stiffness. The ocular problems, typically recognized in childhood, include microspherophakia (small spherical lens), myopia secondary to the abnormal shape of the lens, ectopia lentis (abnormal position of the lens), and glaucoma, which can lead to blindness. Height of adult males is 142-169 cm; height of adult females is 130-157 cm. Autosomal recessive and autosomal dominant WMS cannot be distinguished by clinical findings alone.","name":"Weill-Marchesani syndrome 2","medgen_id":"C1869115","type":"Disease","id":"5118","attribute_content":[],"symbol":"WMS2","keywords":[],"alternate_names":["MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL","SPHEROPHAKIA-BRACHYMORPHIA SYNDROME","Weill-Marchesani Syndrome, Autosomal Dominant"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301293\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1114\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MESODERMAL DYSMORPHODYSTROPHY, CONGENITAL\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPHEROPHAKIA-BRACHYMORPHIA SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GEMSS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2452\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"GEMSS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Weill-Marchesani+syndrome+2/9473\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1114\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608328\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 12","medgen_id":"C2675228","type":"Disease","id":"1452","attribute_content":[],"symbol":"CILD12","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 12, WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"612650\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"612648.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 12, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612648.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 12, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612648.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 12, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612650\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 12, WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+12/7982\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612650\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 19","medgen_id":"C3543826","type":"Disease","id":"17486","attribute_content":[],"symbol":"CILD19","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 19, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"614935\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"614935\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 19, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614935\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 11","medgen_id":"C2675229","type":"Disease","id":"4806","attribute_content":[],"symbol":"CILD11","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"612649\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"612647.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612647.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612647.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612647.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612647.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612647.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612649\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 11, WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+11/7981\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612649\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 6","medgen_id":"C1970506","type":"Disease","id":"815","attribute_content":[],"symbol":"CILD6","keywords":[],"alternate_names":["Primary Ciliary Dyskinesia 6: TXNDC3-Related Primary Ciliary Dyskinesia"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"610852\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+6/7989\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610852\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 13","medgen_id":"C2750790","type":"Disease","id":"6713","attribute_content":[],"symbol":"CILD13","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 13, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613193\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"613193\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 13, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+13/7983\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613193\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 2","medgen_id":"C1847554","type":"Disease","id":"4807","attribute_content":[],"symbol":"CILD2","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 2, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"606763\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"606763\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 2, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+2/7987\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"606763\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 7","medgen_id":"C2678473","type":"Disease","id":"816","attribute_content":[],"symbol":"CILD7","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 7, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"611884\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"603339.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 7, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"603339.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 7, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"611884\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 7, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+7/7990\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611884\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 9","medgen_id":"C2676235","type":"Disease","id":"1455","attribute_content":[],"symbol":"CILD9","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 9, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"612444\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"605483.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 9, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"605483.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 9, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612444\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 9, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+9/7991\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612444\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 18","medgen_id":"C3543825","type":"Disease","id":"17421","attribute_content":[],"symbol":"CILD18","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 18, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"614874\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"614864.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 18, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"614874\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 18, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614874\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 3","medgen_id":"C1837618","type":"Disease","id":"1453","attribute_content":[],"symbol":"CILD3","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"608644\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+3/7988\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608644\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 15","medgen_id":"C3151137","type":"Disease","id":"16054","attribute_content":[],"symbol":"CILD15","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 15, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613808\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"613808\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 15, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+15/7985\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613808\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 5","medgen_id":"C1837615","type":"Disease","id":"1454","attribute_content":[],"symbol":"CILD5","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 5, WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"608647\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"608647\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 5, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"610812.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 5, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"610812.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 5, WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"610812.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 5, WITHOUT SITUS INVERSUS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608647\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 10","medgen_id":"C2675867","type":"Disease","id":"972","attribute_content":[],"symbol":"CILD10","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 10, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"612518\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"612517.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 10, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"612518\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 10, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+10/7980\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612518\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 14","medgen_id":"C3151136","type":"Disease","id":"16027","attribute_content":[],"symbol":"CILD14","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 14, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613807\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"613807\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 14, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+14/7984\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613807\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Ciliary dyskinesia, primary, 16","medgen_id":"C3151460","type":"Disease","id":"16028","attribute_content":[],"symbol":"CILD16","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 16, WITH OR WITHOUT SITUS INVERSUS"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"614017\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"OMIM\",\"id\":\"614017\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 16, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ciliary+dyskinesia%2C+primary%2C+16/7986\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614017\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 11","medgen_id":"C2678483","type":"Disease","id":"5417","attribute_content":[],"symbol":"LQT11","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"611820\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+11/4299\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10437\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611820\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10437\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["WRS"],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Romano-Ward syndrome","medgen_id":"C0035828","type":"Disease","id":"16707","attribute_content":[],"symbol":"RWS","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"OMIM\",\"id\":\"192500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WRS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"6529\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Romano-Ward+syndrome/9638\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"romano-ward-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3284\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"20852007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501111\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"192500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 6","medgen_id":"C3150953","type":"Disease","id":"6362","attribute_content":[],"symbol":"LQT6","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613693\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+6/4304\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10434\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613693\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10434\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 13","medgen_id":"C3150733","type":"Disease","id":"6780","attribute_content":[],"symbol":"LQT13","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613485\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+13/8766\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613485\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 5","medgen_id":"C1867904","type":"Disease","id":"6230","attribute_content":[],"symbol":"LQT5","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613695\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+5/4303\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10433\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613695\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10433\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Such cardiac events typically occur during exercise and emotional stress, less frequently during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of untreated individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal events. While cardiac events may occur from infancy through middle age, they are most common from the preteen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7); hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8); and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.","name":"Long QT syndrome 10","medgen_id":"C2678484","type":"Disease","id":"5416","attribute_content":[],"symbol":"LQT10","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301308\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1129\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"611819\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101016\"}","{\"db\":\"Orphanet\",\"id\":\"768\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Long+QT+syndrome+10/4298\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10436\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1129\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611819\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10436\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["MPS1-H"],"public_definition":"Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap; thus, affected individuals are best described as having either severe or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory-tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal. By age three years, linear growth decreases. Intellectual disability is progressive and profound. Hearing loss is common. Death, typically caused by cardiorespiratory failure, usually occurs within the first ten years of life. Attenuated MPS I. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decades to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities can be present. Clinical onset is usually between ages three and ten years. Hearing loss and cardiac valvular disease are common.","name":"Dysostosis multiplex","medgen_id":"C0086795","type":"Disease","id":"5271","attribute_content":[],"keywords":[],"alternate_names":["Gargoylism, Hurler Syndrome","Hurler syndrome","MUCOPOLYSACCHARIDOSIS TYPE IH"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301341\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1162\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000943\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002760\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"607014\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93448\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mucopolysaccharidosis+type+I/4912\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hurler syndrome\"}","{\"db\":\"OMIM\",\"id\":\"607014\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUCOPOLYSACCHARIDOSIS TYPE IH\"}","{\"db\":\"OMIM\",\"id\":\"607014\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MPS1-H\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000943\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1162\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"public_definition":"Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Some form of neurologic and/or cognitive delay (ranging from mild to severe) is seen in all affected individuals. Neoplasia, mostly acute lymphoblastic leukemia, has been reported in some individuals.","name":"Cardiofaciocutaneous syndrome 3","medgen_id":"C3809006","type":"Disease","id":"17943","attribute_content":[],"symbol":"CFC3","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301365\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1186\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"615279\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1340\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1186\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615279\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Some form of neurologic and/or cognitive delay (ranging from mild to severe) is seen in all affected individuals. Neoplasia, mostly acute lymphoblastic leukemia, has been reported in some individuals.","name":"Cardiofaciocutaneous syndrome 4","medgen_id":"C3809007","type":"Disease","id":"17944","attribute_content":[],"symbol":"CFC4","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301365\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1186\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"615280\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1340\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1186\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615280\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Some form of neurologic and/or cognitive delay (ranging from mild to severe) is seen in all affected individuals. Neoplasia, mostly acute lymphoblastic leukemia, has been reported in some individuals.","name":"Cardiofaciocutaneous syndrome 2","medgen_id":"C3809005","type":"Disease","id":"17942","attribute_content":[],"symbol":"CFC2","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301365\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1186\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"615278\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1340\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1186\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615278\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["DCO"],"public_definition":"The phenotypic spectrum of SHOX deficiency disorders, caused by haploinsufficiency of the short stature homeobox-containing gene (SHOX), ranges from Leri-Weill dyschondrosteosis (LWD) at the severe end of the spectrum to nonspecific short stature at the mild end of the spectrum. In adults with SHOX deficiency, the proportion of LWD versus short stature without features of LWD is not well defined. In LWD the classic clinical triad is short stature, mesomelia, and Madelung deformity. Mesomelia, in which the middle portion of a limb is shortened in relation to the proximal portion, can be evident first in school-aged children and increases with age in frequency and severity. Madelung deformity (abnormal alignment of the radius, ulna, and carpal bones at the wrist) typically develops in mid-to-late childhood and is more common and severe in females. The phenotype of short stature caused by SHOX deficiency in the absence of mesomelia and Madelung deformity (called SHOX-deficient short stature in this GeneReview) is highly variable, even within the same family.","name":"Leri Weill dyschondrosteosis","medgen_id":"C0265309","type":"Disease","id":"2677","attribute_content":[],"symbol":"LWD","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301394\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1215\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"127300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"240\"}","{\"db\":\"OMIM\",\"id\":\"127300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DCO\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3224\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DCO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Leri+Weill+dyschondrosteosis/4180\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3224\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1215\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"127300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3224\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Parkinson disease 11","medgen_id":"C4083045","type":"Disease","id":"3272","attribute_content":[],"symbol":"PARK11","keywords":[],"alternate_names":["PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"607688\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"411602\"}","{\"db\":\"OMIM\",\"id\":\"607688\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"612003.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 11, AUTOSOMAL DOMINANT, SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+11/9080\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"607688\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CSNB2"],"public_definition":"X-linked congenital stationary night blindness (CSNB) is characterized by non-progressive retinal findings of reduced visual acuity ranging from 20/30 to 20/200; defective dark adaptation; refractive error, most typically myopia ranging from low (-0.25 diopters [D] to -4.75 D) to high (-10.00 D) but occasionally hyperopia; nystagmus; strabismus; normal color vision; and normal fundus examination. Characteristic ERG findings can help distinguish between complete X-linked CSNB and incomplete X-linked CSNB.","name":"Congenital stationary night blindness, type 2A","medgen_id":"C1848172","type":"Disease","id":"5652","attribute_content":[],"symbol":"CSNB2A","keywords":[],"alternate_names":["CACNA1F-Related X-Linked Congenital Stationary Night Blindness","CSNB, INCOMPLETE, X-LINKED","NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301423\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1245\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"300071\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"215\"}","{\"db\":\"OMIM\",\"id\":\"300071\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CSNB, INCOMPLETE, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300071\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2\"}","{\"db\":\"OMIM\",\"id\":\"300071\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CSNB2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+stationary+night+blindness%2C+type+2A/8082\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1245\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300071\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["OAK"],"public_definition":"Optic atrophy type 1 (OPA1, or Kjer type optic atrophy) is characterized by bilateral and symmetric optic nerve pallor associated with insidious decrease in visual acuity (usually between ages 4 and 6 years), visual field defects, and color vision defects. Visual impairment is usually moderate (6/10 to 2/10), but ranges from mild or even insignificant to severe (legal blindness with acuity \u003c1/20). The visual field defect is typically centrocecal, central, or paracentral; it is often large in those with severe disease. The color vision defect is often described as acquired blue-yellow loss (tritanopia). Other findings can include auditory neuropathy resulting in sensorineural hearing loss that ranges from severe and congenital to subclinical (i.e., identified by specific audiologic testing only). Visual evoked potentials are typically absent or delayed; pattern electroretinogram shows an abnormal N95:P50 ratio. Tritanopia is the classic feature of color vision defect, but more diffuse nonspecific dyschromatopsia is not uncommon. Ophthalmoscopic examination discloses temporal or diffuse pallor of the optic discs, sometimes associated with optic disc excavation. The neuroretinal rim shows some pallor in most cases, sometimes associated with a temporal pigmentary gray crescent.","name":"Dominant hereditary optic atrophy","medgen_id":"C0338508","type":"Disease","id":"5679","attribute_content":[],"symbol":"OPA1","keywords":[],"alternate_names":["Optic Atrophy Type 1","Optic Atrophy, Autosomal Dominant"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301426\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1248\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"165500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98673\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1248\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Optic Atrophy Type 1\"}","{\"db\":\"OMIM\",\"id\":\"165500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OAK\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9890\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OAK\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Dominant+hereditary+optic+atrophy/8280\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"2065009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1248\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"165500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9890\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CACH","CLE"],"public_definition":"Childhood ataxia with central nervous system hypomyelination / vanishing white matter (CACH/VWM) is characterized by ataxia, spasticity, and variable optic atrophy. The phenotypic range includes a prenatal/congenital form, a subacute infantile form (onset age \u003c1 year), an early childhood-onset form (onset age 1 to \u003c4 years), a late childhood-/juvenile-onset form (onset age 4 to \u003c18 years), and an adult-onset form (onset 18 years). The prenatal/congenital form is characterized by severe encephalopathy. In the later-onset forms initial motor and intellectual development is normal or mildly delayed, followed by neurologic deterioration with a chronic progressive or subacute course. While in childhood-onset forms motor deterioration dominates, in adult-onset forms cognitive decline and personality changes dominate. Chronic progressive decline can be exacerbated by rapid deterioration during febrile illnesses or following head trauma or major surgical procedures, or by acute and extreme fright.","name":"Leukoencephalopathy with vanishing white matter","medgen_id":"C1858991","type":"Disease","id":"2596","attribute_content":[],"symbol":"VWM","keywords":[],"alternate_names":["CHILDHOOD ATAXIA WITH CENTRAL NERVOUS SYSTEM HYPOMYELINIZATION","LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301435\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1258\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"603896\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"135\"}","{\"db\":\"Orphanet\",\"id\":\"157713\"}","{\"db\":\"Orphanet\",\"id\":\"157716\"}","{\"db\":\"Orphanet\",\"id\":\"157719\"}","{\"db\":\"Orphanet\",\"id\":\"99853\"}","{\"db\":\"Orphanet\",\"id\":\"99854\"}","{\"db\":\"OMIM\",\"id\":\"603896\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHILDHOOD ATAXIA WITH CENTRAL NERVOUS SYSTEM HYPOMYELINIZATION\"}","{\"db\":\"OMIM\",\"id\":\"603945.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"603945.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"603945.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"606273.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"606454.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"603896\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CACH\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"231\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CLE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"CACH+Syndrome/1012\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"231\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1258\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"603896\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["HIBM","IBM2","QSM"],"public_definition":"GNE-related myopathy, also known as inclusion body myopathy 2, is characterized by slowly progressive distal muscle weakness that begins in the late teens to early adult years with gait disturbance and foot drop secondary to anterior tibialis muscle weakness. Weakness eventually includes the hand and thigh muscles but commonly spares the quadriceps muscles, even in advanced disease. Affected individuals are usually wheelchair bound about 20 years after onset. If quadriceps sparing is incomplete, loss of ambulation tends to occur earlier.","name":"GNE myopathy","medgen_id":"C1853926","type":"Disease","id":"3097","attribute_content":[],"symbol":"NM","keywords":[],"alternate_names":["GNE-Related Myopathies","INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE","INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE","Inclusion body myopathy 2","MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES","Nonaka myopathy"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301439\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1262\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"600737\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"605820\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"602\"}","{\"db\":\"OMIM\",\"id\":\"600737\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"605820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"605820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Inclusion+body+myopathy+2/3793\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Inclusion body myopathy 2\"}","{\"db\":\"OMIM\",\"id\":\"605820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nonaka+myopathy/5252\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Nonaka myopathy\"}","{\"db\":\"OMIM\",\"id\":\"605820\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HIBM\"}","{\"db\":\"OMIM\",\"id\":\"600737\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IBM2\"}","{\"db\":\"OMIM\",\"id\":\"605820\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IBM2\"}","{\"db\":\"OMIM\",\"id\":\"600737\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"QSM\"}","{\"db\":\"OMIM\",\"id\":\"605820\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"QSM\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9493\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"QSM\"}","{\"db\":\"Orphanet\",\"id\":\"602\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1262\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"605820\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1888\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["AHD","AWS"],"public_definition":"Alagille syndrome (ALGS) is a complex multisystem disorder involving primarily the liver, heart, eyes, face, and skeleton. The clinical features are highly variable, even within families. The major clinical manifestations of ALGS are cholestasis, characterized by bile duct paucity on liver biopsy; congenital cardiac defects, primarily involving the pulmonary arteries; posterior embryotoxon in the eye; typical facial features; and butterfly vertebrae. Renal and central nervous abnormalities also occur. Mortality is approximately 10%, with vascular accidents, cardiac disease, and liver disease accounting for most of the deaths.","name":"Alagille syndrome 1","medgen_id":"C1956125","type":"Disease","id":"142","attribute_content":[],"symbol":"ALGS1","keywords":[],"alternate_names":["JAG1-Related Alagille Syndrome"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301450\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1273\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"118450\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"261600\"}","{\"db\":\"Orphanet\",\"id\":\"261619\"}","{\"db\":\"Orphanet\",\"id\":\"52\"}","{\"db\":\"OMIM\",\"id\":\"118450\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AHD\"}","{\"db\":\"OMIM\",\"id\":\"118450\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AWS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Alagille+syndrome+1/7661\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1273\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"118450\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"ATP8B1 deficiency encompasses a phenotypic spectrum ranging from severe to intermediate to mild, based on an individual's clinical findings and laboratory test results, including liver biopsy. Severe ATP8B1 deficiency is characterized by onset of symptoms of cholestasis (pruritus and attacks of jaundice) within the first few months of life. Secondary manifestations such as coagulopathy (due to vitamin K deficiency), malabsorption, and poor weight gain may present earlier than age three months. Without surgical intervention, cirrhosis and evolution to end-stage hepatic failure and death usually ensue before the third decade. Mild ATP8B1 deficiency is characterized by intermittent episodes of cholestasis manifest as severe pruritus and jaundice; chronic liver damage does not typically develop. In contrast to patients in whom bouts of cholestasis are induced only by particular triggers known to increase risk of cholestasis (drug exposure, shifts in hormonal milieu [including those resulting from ingestion of contraceptive drugs or from pregnancy], coexistent malignancy), some or all bouts of cholestasis in individuals with mild ATP8B1 deficiency have different or unknown triggers.","name":"Cholestasis, benign recurrent intrahepatic 1","medgen_id":"C1855731","type":"Disease","id":"1428","attribute_content":[],"symbol":"BRIC1","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301474\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1297\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"243300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"65682\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10028\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1297\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"243300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10028\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Dystrophic epidermolysis bullosa (DEB) is a genetic skin disorder affecting skin and nails that usually presents at birth. DEB is divided into two major types depending on inheritance pattern: recessive dystrophic epidermolysis bullosa (RDEB) and dominant dystrophic epidermolysis bullosa (DDEB). Each type is further divided into multiple clinical subtypes. Absence of a known family history of DEB does not preclude the diagnosis. Clinical findings in severe generalized RDEB include skin fragility manifest by blistering with minimal trauma that heals with milia and scarring. Blistering and erosions affecting the whole body may be present in the neonatal period. Oral involvement may lead to mouth blistering, fusion of the tongue to the floor of the mouth, and progressive diminution of the size of the oral cavity. Esophageal erosions can lead to webs and strictures that can cause severe dysphagia. Consequently, malnutrition and vitamin and mineral deficiency may lead to growth restriction in young children. Corneal erosions can lead to scarring and loss of vision. Blistering of the hands and feet followed by scarring fuses the digits into \"mitten\" hands and feet, with contractures and pseudosyndactyly. The lifetime risk of aggressive squamous cell carcinoma is higher than 90%. In contrast, the blistering in the less severe forms of RDEB may be localized to hands, feet, knees, and elbows with or without involvement of flexural areas and the trunk, and without the mutilating scarring seen in severe generalized RDEB. In DDEB, blistering is often mild and limited to hands, feet, knees, and elbows, but nonetheless heals with scarring. Dystrophic nails, especially toenails, are common and may be the only manifestation of DDEB.","name":"Dystrophic epidermolysis bullosa","medgen_id":"C0079294","type":"Disease","id":"9485","attribute_content":[],"keywords":[],"alternate_names":["Epidermolysis Bullosa Dystrophica"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301481\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1304\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"Genetic Alliance\",\"id\":\"Dystrophic+Epidermolysis+Bullosa/2423\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"254185007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1304\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":["EBDD"],"public_definition":"Dystrophic epidermolysis bullosa (DEB) is a genetic skin disorder affecting skin and nails that usually presents at birth. DEB is divided into two major types depending on inheritance pattern: recessive dystrophic epidermolysis bullosa (RDEB) and dominant dystrophic epidermolysis bullosa (DDEB). Each type is further divided into multiple clinical subtypes. Absence of a known family history of DEB does not preclude the diagnosis. Clinical findings in severe generalized RDEB include skin fragility manifest by blistering with minimal trauma that heals with milia and scarring. Blistering and erosions affecting the whole body may be present in the neonatal period. Oral involvement may lead to mouth blistering, fusion of the tongue to the floor of the mouth, and progressive diminution of the size of the oral cavity. Esophageal erosions can lead to webs and strictures that can cause severe dysphagia. Consequently, malnutrition and vitamin and mineral deficiency may lead to growth restriction in young children. Corneal erosions can lead to scarring and loss of vision. Blistering of the hands and feet followed by scarring fuses the digits into \"mitten\" hands and feet, with contractures and pseudosyndactyly. The lifetime risk of aggressive squamous cell carcinoma is higher than 90%. In contrast, the blistering in the less severe forms of RDEB may be localized to hands, feet, knees, and elbows with or without involvement of flexural areas and the trunk, and without the mutilating scarring seen in severe generalized RDEB. In DDEB, blistering is often mild and limited to hands, feet, knees, and elbows, but nonetheless heals with scarring. Dystrophic nails, especially toenails, are common and may be the only manifestation of DDEB.","name":"Generalized dominant dystrophic epidermolysis bullosa","medgen_id":"C0432322","type":"Disease","id":"14025","attribute_content":[],"symbol":"DDEB","keywords":[],"alternate_names":["DYSTROPHIC EPIDERMOLYSIS BULLOSA, AUTOSOMAL DOMINANT","Epidermolysis bullosa dystrophica, autosomal dominant"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301481\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1304\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"131750\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"216989\"}","{\"db\":\"Orphanet\",\"id\":\"231568\"}","{\"db\":\"OMIM\",\"id\":\"131750\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTROPHIC EPIDERMOLYSIS BULLOSA, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"131750\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EBDD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Generalized+dominant+dystrophic+epidermolysis+bullosa/8457\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2139\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1304\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"131750\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Polymicrogyria is a condition characterized by abnormal development of the brain before birth. The surface of the brain normally has many ridges or folds, called gyri. In people with polymicrogyria, the brain develops too many folds, and the folds are unusually small. The name of this condition literally means too many (poly-) small (micro-) folds (-gyria) in the surface of the brain.Polymicrogyria can affect part of the brain or the whole brain. When the condition affects one side of the brain, researchers describe it as unilateral. When it affects both sides of the brain, it is described as bilateral. The signs and symptoms associated with polymicrogyria depend on how much of the brain, and which particular brain regions, are affected.Researchers have identified multiple forms of polymicrogyria. The mildest form is known as unilateral focal polymicrogyria. This form of the condition affects a relatively small area on one side of the brain. It may cause minor neurological problems, such as mild seizures that can be easily controlled with medication. Some people with unilateral focal polymicrogyria do not have any problems associated with the condition.Bilateral forms of polymicrogyria tend to cause more severe neurological problems. Signs and symptoms of these conditions can include recurrent seizures (epilepsy), delayed development, crossed eyes, problems with speech and swallowing, and muscle weakness or paralysis. The most severe form of the disorder, bilateral generalized polymicrogyria, affects the entire brain. This condition causes severe intellectual disability, problems with movement, and seizures that are difficult or impossible to control with medication.Polymicrogyria most often occurs as an isolated feature, although it can occur with other brain abnormalities. It is also a feature of several genetic syndromes characterized by intellectual disability and multiple birth defects. These include 22q11.2 deletion syndrome, Adams-Oliver syndrome, Aicardi syndrome, Galloway-Mowat syndrome, Joubert syndrome, and Zellweger spectrum disorder.","name":"Polymicrogyria, bilateral temporooccipital","medgen_id":"C4013648","type":"Disease","id":"3994","attribute_content":[],"symbol":"BTOP","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301504\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1329\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"612691\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"208441\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"polymicrogyria\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"612691\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["FIGD"],"public_definition":"Isolated gonadotropin-releasing hormone (GnRH) deficiency (IGD) is characterized by inappropriately low serum concentrations of the gonadotropins LH (luteinizing hormone) and FSH (follicle-stimulating hormone) in the presence of low circulating concentrations of sex steroids. IGD is associated with a normal sense of smell (normosmic IGD) in approximately 40% of affected individuals and an impaired sense of smell (Kallmann syndrome) in approximately 60%. IGD can first become apparent in infancy, adolescence, or adulthood. Infant boys with congenital IGD often have micropenis and cryptorchidism. Adolescents and adults with IGD have clinical evidence of hypogonadism and incomplete sexual maturation on physical examination. Adult males with IGD tend to have prepubertal testicular volume (i.e., \u003c4 mL), absence of secondary sexual features (e.g., facial and axillary hair growth, deepening of the voice), decreased muscle mass, diminished libido, erectile dysfunction, and infertility. Adult females have little or no breast development and primary amenorrhea. Although skeletal maturation is delayed, the rate of linear growth is usually normal except for the absence of a distinct pubertal growth spurt.","name":"Hypogonadotropic hypogonadism 12 with or without anosmia","medgen_id":"C1856897","type":"Disease","id":"17382","attribute_content":[],"symbol":"HH12","keywords":[],"alternate_names":["Eunuchoidism familial hypogonadotropic"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301509\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1334\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"614841\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"432\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Eunuchoidism+Familial+Hypogonadotropic/2663\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Eunuchoidism familial hypogonadotropic\"}","{\"db\":\"OMIM\",\"id\":\"614841\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FIGD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"276\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FIGD\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1334\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614841\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors). Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.","name":"Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, autosomal recessive","medgen_id":"C1843183","type":"Disease","id":"1418","attribute_content":[],"keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE","CMT2 WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE","Charcot-Marie-Tooth disease type 4A"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"607706\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101097\"}","{\"db\":\"OMIM\",\"id\":\"607706\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, AXONAL, WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"607706\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CMT2 WITH VOCAL CORD PARESIS, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+disease%2C+axonal%2C+with+vocal+cord+paresis%2C+autosomal+recessive/7952\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9195\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"charcot-marie-tooth-disease\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"name":"Charcot-Marie-Tooth disease, demyelinating, type 4F","medgen_id":"C3540453","type":"Disease","id":"10098","attribute_content":[],"symbol":"CMT4F","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, TYPE 4F, LATE-ONSET","Charcot-Marie-Tooth disease, type 4F"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"614895\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99952\"}","{\"db\":\"OMIM\",\"id\":\"605725.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, TYPE 4F, LATE-ONSET\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9204\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"614895\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["PHHI"],"name":"Persistent hyperinsulinemic hypoglycemia of infancy","medgen_id":"C2931832","type":"Disease","id":"2181","attribute_content":[],"symbol":"HHF1","keywords":[],"alternate_names":["HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA","HYPERINSULINISM, CONGENITAL","HYPERINSULINISM, FAMILIAL, WITH PANCREATIC NESIDIOBLASTOSIS","HYPOGLYCEMIA, HYPERINSULINEMIC, OF INFANCY","Hyperinsulinemic hypoglycemia, familial, 1","NESIDIOBLASTOSIS OF PANCREAS","Persistent Hyperinsulinemia Hypoglycemia of Infancy"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301549\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1375\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"256450\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"276575\"}","{\"db\":\"Orphanet\",\"id\":\"276598\"}","{\"db\":\"Orphanet\",\"id\":\"79643\"}","{\"db\":\"OMIM\",\"id\":\"256450\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA\"}","{\"db\":\"OMIM\",\"id\":\"256450\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERINSULINISM, CONGENITAL\"}","{\"db\":\"OMIM\",\"id\":\"256450\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERINSULINISM, FAMILIAL, WITH PANCREATIC NESIDIOBLASTOSIS\"}","{\"db\":\"OMIM\",\"id\":\"256450\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPOGLYCEMIA, HYPERINSULINEMIC, OF INFANCY\"}","{\"db\":\"OMIM\",\"id\":\"256450\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NESIDIOBLASTOSIS OF PANCREAS\"}","{\"db\":\"OMIM\",\"id\":\"256450\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PHHI\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Persistent+hyperinsulinemic+hypoglycemia+of+infancy/5686\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"360339005\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"256450\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"mode_of_inheritance":"Autosomal Recessive and Autosomal Dominant"}
{"alternate_symbols":[],"public_definition":"Chorea-acanthocytosis (ChAc) is characterized by a progressive movement disorder, cognitive and behavior changes, a myopathy that can be subclinical, and chronic hyperCKemia in serum. Although the disorder is named for acanthocytosis of the red blood cells, this feature is variable. The movement disorder is mostly limb chorea, but some individuals present with parkinsonism. Dystonia is common and affects the oral region and especially the tongue, causing dysarthria and serious dysphagia with resultant weight loss. Habitual tongue and lip biting are characteristic, as well as tongue protrusion dystonia. Progressive cognitive and behavioral changes resemble those in a frontal lobe syndrome. Seizures are observed in almost half of affected individuals and can be the initial manifestation. Myopathy results in progressive distal muscle wasting and weakness. Mean age of onset in ChAc is about 30 years, although ChAc can develop as early as the first decade or as late as the seventh decade. It runs a chronic progressive course and may lead to major disability within a few years. Life expectancy is reduced, with age of death ranging from 28 to 61 years.","name":"Choreoacanthocytosis","medgen_id":"C0393576","type":"Disease","id":"805","attribute_content":[],"symbol":"CHAC","keywords":[],"alternate_names":["Chorea-acanthocytosis"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301561\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1387\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"200150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2388\"}","{\"db\":\"Orphanet\",\"id\":\"263440\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3956\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Chorea-acanthocytosis\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Choreoacanthocytosis/1384\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3956\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1387\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501217\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"200150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"X-linked lymphoproliferative disease (XLP) has two recognizable subtypes, XLP1 and XLP2. XLP1 is characterized predominantly by one of three commonly recognized phenotypes: Inappropriate immune response to Epstein-Barr virus (EBV) infection leading to hemophagocytic lymphohistiocytosis (HLH) or severe mononucleosis. Dysgammaglobulinemia. Lymphoproliferative disease (malignant lymphoma). XLP2 is most often characterized by HLH (often associated with EBV), dysgammaglobulinemia, and inflammatory bowel disease. HLH resulting from EBV infection is associated with an unregulated and exaggerated immune response with widespread proliferation of cytotoxic T cells, EBV-infected B cells, and macrophages. Dysgammaglobulinemia is typically hypogammaglobulinemia of one or more immunoglobulin subclasses. The malignant lymphomas are typically B-cell lymphomas, non-Hodgkin type, often extranodal, and in particular involving the intestine.","name":"Lymphoproliferative syndrome 2, X-linked","medgen_id":"C1845076","type":"Disease","id":"2711","attribute_content":[],"symbol":"XLP2","keywords":[],"alternate_names":["XIAP DEFICIENCY"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301580\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1406\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"300635\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2442\"}","{\"db\":\"Orphanet\",\"id\":\"538934\"}","{\"db\":\"OMIM\",\"id\":\"300635\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"XIAP DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"X-linked+lymphoproliferative+syndrome+2/9494\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1406\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300635\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Medium-chain acyl-coenzyme A dehydrogenase (MCAD) is one of the enzymes involved in mitochondrial fatty acid -oxidation. Fatty acid -oxidation fuels hepatic ketogenesis, which provides a major source of energy once hepatic glycogen stores become depleted during prolonged fasting and periods of higher energy demands. MCAD deficiency is the most common disorder of fatty acid -oxidation and one of the most common inborn errors of metabolism. Most children are now diagnosed through newborn screening. Clinical symptoms in a previously apparently healthy child with MCAD deficiency include hypoketotic hypoglycemia and vomiting that may progress to lethargy, seizures, and coma triggered by a common illness. Hepatomegaly and liver disease are often present during an acute episode. Children appear normal at birth and  if not identified through newborn screening  typically present between age three and 24 months, although presentation even as late as adulthood is possible. The prognosis is excellent once the diagnosis is established and frequent feedings are instituted to avoid any prolonged periods of fasting.","name":"Medium-chain acyl-coenzyme A dehydrogenase deficiency","medgen_id":"C0220710","type":"Disease","id":"81","attribute_content":[],"symbol":"ACADMD","keywords":[],"alternate_names":["CARNITINE DEFICIENCY SECONDARY TO MEDIUM-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301597\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1424\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"201450\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"42\"}","{\"db\":\"OMIM\",\"id\":\"201450\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CARNITINE DEFICIENCY SECONDARY TO MEDIUM-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Medium-chain+acyl-coenzyme+A+dehydrogenase+deficiency/4547\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"540\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"128596003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1424\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"201450\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CTSD"],"name":"Ceroid lipofuscinosis neuronal 10","medgen_id":"C1864669","type":"Disease","id":"1352","attribute_content":[],"symbol":"CLN10","keywords":[],"alternate_names":["CTSD-Related Neuronal Ceroid-Lipofuscinosis"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301601\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1428\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"610127\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"168486\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Ceroid+Lipofuscinosis+Neuronal+10/1251\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1218\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610127\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1218\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CHN","CMT4E"],"name":"Congenital hypomyelinating neuropathy 1, autosomal recessive","medgen_id":"C4721436","type":"Disease","id":"5635","attribute_content":[],"symbol":"CHN1","keywords":[],"alternate_names":["Charcot-Marie-Tooth disease, type 4E","Congenital Hypomyelination","Congenital hypomyelinating neuropathy","NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMAL RECESSIVE"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301641\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1468\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"605253\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99951\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+4E/1308\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital hypomyelinating neuropathy\"}","{\"db\":\"SNOMED CT\",\"id\":\"230562000\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Congenital hypomyelinating neuropathy\"}","{\"db\":\"OMIM\",\"id\":\"605253\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, CONGENITAL HYPOMYELINATING OR AMYELINATING, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9203\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CHN\"}","{\"db\":\"OMIM\",\"id\":\"605253\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT4E\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9203\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT4E\"}","{\"db\":\"OMIM\",\"id\":\"605253\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CMT4B"],"public_definition":"Charcot-Marie-Tooth disease encompasses a group of disorders called hereditary sensory and motor neuropathies that damage the peripheral nerves. Peripheral nerves connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, heat, and sound. Damage to the peripheral nerves that worsens over time can result in alteration or loss of sensation and wasting (atrophy) of muscles in the feet, legs, and hands.Charcot-Marie-Tooth disease usually becomes apparent in adolescence or early adulthood, but onset may occur anytime from early childhood through late adulthood. Symptoms of Charcot-Marie-Tooth disease vary in severity and age of onset even among members of the same family. Some people never realize they have the disorder because their symptoms are so mild, but most have a moderate amount of physical disability. A small percentage of people experience severe weakness or other problems which, in very rare cases, can be life-threatening. In most affected individuals, however, Charcot-Marie-Tooth disease does not affect life expectancy.Typically, the earliest symptoms of Charcot-Marie-Tooth disease result from muscle atrophy in the feet. Affected individuals may have foot abnormalities such as high arches (pes cavus), flat feet (pes planus), or curled toes (hammer toes). They often have difficulty flexing the foot or walking on the heel of the foot. These difficulties may cause a higher than normal step (steppage gait) and increase the risk of ankle injuries and tripping. As the disease worsens, muscles in the lower legs usually weaken, but leg and foot problems rarely require the use of a wheelchair.Affected individuals may also develop weakness in the hands, causing difficulty with daily activities such as writing, fastening buttons, and turning doorknobs. People with Charcot-Marie-Tooth disease typically experience a decreased sensitivity to touch, heat, and cold in the feet and lower legs, but occasionally feel aching or burning sensations. In rare cases, affected individuals have loss of vision or gradual hearing loss that sometimes leads to deafness.There are several types of Charcot-Marie-Tooth disease, which are differentiated by their effects on nerve cells and patterns of inheritance. Type 1 (CMT1) is characterized by abnormalities in myelin, the fatty substance that covers nerve cells, protecting them and helping to transmit nerve impulses. These abnormalities slow the transmission of nerve impulses and can affect the health of the nerve fiber. Type 2 (CMT2) is characterized by abnormalities in the fiber, or axon, that extends from a nerve cell body to muscles or to sense organs. These abnormalities reduce the strength of the nerve impulse. In forms of Charcot-Marie-Tooth disease classified as intermediate type, the nerve impulses are both slowed and reduced in strength, probably due to abnormalities in both myelin and axons. Type 4 (CMT4) is distinguished from the other types by its pattern of inheritance; it can affect either the axons or the myelin. Type X Charcot-Marie-Tooth disease (CMTX) is caused by mutations in genes on the X chromosome, one of the two sex chromosomes. Within the various types of Charcot-Marie-Tooth disease, subtypes (such as CMT1A, CMT1B, CMT2A, CMT4A, and CMTX1) indicate different genetic causes.Sometimes other, historical names are used to refer to particular forms of Charcot-Marie-Tooth disease. For example, Roussy-Levy syndrome is a form of CMT11 with the additional feature of rhythmic shaking (tremors). Dejerine-Sottas syndrome is a term sometimes used to describe a severe, early childhood form of Charcot-Marie-Tooth disease; it is also sometimes called type 3 (CMT3). Depending on the specific gene that is altered, this severe, early-onset form of the disorder may also be classified as CMT1 or CMT4. CMTX5 is also known as Rosenberg-Chutorian syndrome.","name":"Charcot-Marie-Tooth disease, type 4B1","medgen_id":"C1832399","type":"Disease","id":"883","attribute_content":[],"symbol":"CMT4B1","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, WITH FOCALLY FOLDED MYELIN SHEATHS, AUTOSOMAL RECESSIVE, TYPE 4B1","Charcot-Marie-Tooth Neuropathy Type 4B1"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301641\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1468\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"601382\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99955\"}","{\"db\":\"OMIM\",\"id\":\"601382\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, WITH FOCALLY FOLDED MYELIN SHEATHS, AUTOSOMAL RECESSIVE, TYPE 4B1\"}","{\"db\":\"OMIM\",\"id\":\"601382\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT4B\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+4B1/1304\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"charcot-marie-tooth-disease\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601382\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["HARP"],"public_definition":"Pantothenate kinase-associated neurodegeneration (PKAN) is a type of neurodegeneration with brain iron accumulation (NBIA). The phenotypic spectrum of PKAN includes classic PKAN and atypical PKAN. Classic PKAN is characterized by early childhood onset of progressive dystonia, dysarthria, rigidity, and choreoathetosis. Pigmentary retinal degeneration is common. Atypical PKAN is characterized by later onset (age \u003e10 years), prominent speech defects, psychiatric disturbances, and more gradual progression of disease.","name":"Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration","medgen_id":"C1846582","type":"Disease","id":"2393","attribute_content":[],"keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301663\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1490\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"607236\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"157855\"}","{\"db\":\"Genetic Alliance\",\"id\":\"HARP+Syndrome/3244\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1490\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"public_definition":"Myofibrillar myopathy is part of a group of disorders called muscular dystrophies that affect muscle function and cause weakness. Myofibrillar myopathy primarily affects skeletal muscles, which are muscles that the body uses for movement. In some cases, the heart (cardiac) muscle is also affected.The signs and symptoms of myofibrillar myopathy vary widely among affected individuals, typically depending on the condition's genetic cause. Most people with this disorder begin to develop muscle weakness (myopathy) in mid-adulthood. However, features of this condition can appear anytime between infancy and late adulthood. Muscle weakness most often begins in the hands and feet (distal muscles), but some people first experience weakness in the muscles near the center of the body (proximal muscles). Other affected individuals develop muscle weakness throughout their body. Facial muscle weakness can cause swallowing and speech difficulties. Muscle weakness worsens over time.Other signs and symptoms of myofibrillar myopathy can include a weakened heart muscle (cardiomyopathy), muscle pain (myalgia), loss of sensation and weakness in the limbs (peripheral neuropathy), and respiratory failure. Individuals with this condition may have skeletal problems including joint stiffness (contractures) and abnormal side-to-side curvature of the spine (scoliosis). Rarely, people with this condition develop clouding of the lens of the eyes (cataracts).","name":"Myofibrillar myopathy, filamin C-related","medgen_id":"C1836050","type":"Disease","id":"1288","attribute_content":[],"symbol":"MFM5","keywords":[],"alternate_names":["FILAMINOPATHY, AUTOSOMAL DOMINANT","MYOPATHY, MYOFIBRILLAR, 5"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301672\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1499\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"609524\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"609524\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FILAMINOPATHY, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"102565.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MYOPATHY, MYOFIBRILLAR, 5\"}","{\"db\":\"OMIM\",\"id\":\"102565.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MYOPATHY, MYOFIBRILLAR, 5\"}","{\"db\":\"OMIM\",\"id\":\"609524\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MYOPATHY, MYOFIBRILLAR, 5\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Myofibrillar+myopathy%2C+filamin+C-related/8942\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"myofibrillar-myopathy\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609524\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Huntington disease-like 2 (HDL2) typically presents in midlife with a relentless progressive triad of movement, emotional, and cognitive abnormalities which lead to death within ten to 20 years. HDL2 cannot be differentiated from Huntington disease clinically. Neurologic abnormalities include chorea, hypokinesia (rigidity, bradykinesia), dysarthria, and hyperreflexia in the later stages of the disease. There is a strong correlation between the duration of the disease and the progression of the motor and cognitive disorder.","name":"Huntington disease-like 2","medgen_id":"C1847987","type":"Disease","id":"5270","attribute_content":[],"symbol":"HDL2","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301701\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1529\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"606438\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"98934\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Huntington+disease-like+2/8568\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1529\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"606438\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"The FLNB-related disorders include a spectrum of phenotypes ranging from mild (spondylocarpotarsal synostosis [SCT] syndrome and Larsen syndrome) to severe (atelosteogenesis types I [AOI] and III [AOIII], boomerang dysplasia). SCT syndrome is characterized by disproportionate short stature, block vertebrae, scoliosis and lordosis, carpal and tarsal fusion, club feet, hearing loss, dental enamel hypoplasia, and mild facial dysmorphisms. Larsen syndrome is characterized by congenital dislocations of the hip, knee, and elbow; club feet (equinovarus or equinovalgus foot deformities); scoliosis and cervical kyphosis, which can be associated with a cervical myelopathy; short, broad, spatulate distal phalanges; and distinctive craniofacies (prominent forehead, depressed nasal bridge, malar flattening, and widely spaced eyes). Both can have midline cleft palate and conductive hearing loss. AOIII and AOI are characterized by severe short-limbed dwarfism; dislocated hips, knees, and elbows; and club feet. AOI is lethal in the perinatal period.","name":"Boomerang dysplasia","medgen_id":"C0432201","type":"Disease","id":"514","attribute_content":[],"symbol":"BOOMD","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301736\",\"@Source\":\"PubMed\"},{\"$\":\"NBK2534\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"112310\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1263\"}","{\"db\":\"Orphanet\",\"id\":\"156723\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Boomerang+Dysplasia/895\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"933\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"254054000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK2534\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"112310\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["ILS"],"public_definition":"PAFAH1B1-associated lissencephaly includes Miller-Dieker syndrome (MDS), isolated lissencephaly sequence (ILS), and (rarely) subcortical band heterotopia (SBH). Lissencephaly and SBH are cortical malformations caused by deficient neuronal migration during embryogenesis. Lissencephaly refers to a \"smooth brain\" with absent gyri (agyria) or abnormally wide gyri (pachygyria). SBH refers to a band of heterotopic gray matter located just beneath the cortex and separated from it by a thin zone of normal white matter. MDS is characterized by lissencephaly, typical facial features, and severe neurologic abnormalities. ILS is characterized by lissencephaly and its direct sequelae: developmental delay, intellectual disability, and seizures.","name":"Lissencephaly 1","medgen_id":"C0431375","type":"Disease","id":"2563","attribute_content":[],"symbol":"LIS1","keywords":[],"alternate_names":["Isolated Lissencephaly Sequence","LIS1-Associated Lissencephaly/Subcortical Band Heterotopia"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301752\",\"@Source\":\"PubMed\"},{\"$\":\"NBK5189\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"607432\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"102009\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK5189\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"LIS1-Associated Lissencephaly/Subcortical Band Heterotopia\"}","{\"db\":\"OMIM\",\"id\":\"607432\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ILS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5049\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ILS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Lissencephaly+1/4269\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5049\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK5189\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"607432\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5049\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Spondylocostal dysostosis (SCDO), defined radiographically as multiple segmentation defects of the vertebrae (M-SDV) in combination with abnormalities of the ribs, is characterized clinically by: a short trunk in proportion to height; short neck; non-progressive mild scoliosis in most affected individuals, and occasionally, more significant scoliosis. Respiratory function in neonates may be compromised by reduced size of the thorax. By age two years lung growth may improve sufficiently to support relatively normal growth and development; however, even then life-threatening complications can occur, especially pulmonary hypertension in children with severely restricted lung capacity from birth. Males with SCDO appear to be at increased risk for inguinal hernia.","name":"Spondylocostal dysostosis 4, autosomal recessive","medgen_id":"C3150942","type":"Disease","id":"15796","attribute_content":[],"symbol":"SCDO4","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301771\",\"@Source\":\"PubMed\"},{\"$\":\"NBK8828\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613686\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2311\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spondylocostal+dysostosis+4%2C+autosomal+recessive/9348\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK8828\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613686\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Spondylocostal dysostosis (SCDO), defined radiographically as multiple segmentation defects of the vertebrae (M-SDV) in combination with abnormalities of the ribs, is characterized clinically by: a short trunk in proportion to height; short neck; non-progressive mild scoliosis in most affected individuals, and occasionally, more significant scoliosis. Respiratory function in neonates may be compromised by reduced size of the thorax. By age two years lung growth may improve sufficiently to support relatively normal growth and development; however, even then life-threatening complications can occur, especially pulmonary hypertension in children with severely restricted lung capacity from birth. Males with SCDO appear to be at increased risk for inguinal hernia.","name":"Spondylocostal dysostosis 3","medgen_id":"C1853296","type":"Disease","id":"5978","attribute_content":[],"symbol":"SCDO3","keywords":[],"alternate_names":["SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301771\",\"@Source\":\"PubMed\"},{\"$\":\"NBK8828\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"609813\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2311\"}","{\"db\":\"OMIM\",\"id\":\"602576.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"602576.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"609813\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPONDYLOCOSTAL DYSOSTOSIS 3, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spondylocostal+dysostosis+3/6804\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4973\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK8828\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"609813\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Spondylocostal dysostosis (SCDO), defined radiographically as multiple segmentation defects of the vertebrae (M-SDV) in combination with abnormalities of the ribs, is characterized clinically by: a short trunk in proportion to height; short neck; non-progressive mild scoliosis in most affected individuals, and occasionally, more significant scoliosis. Respiratory function in neonates may be compromised by reduced size of the thorax. By age two years lung growth may improve sufficiently to support relatively normal growth and development; however, even then life-threatening complications can occur, especially pulmonary hypertension in children with severely restricted lung capacity from birth. Males with SCDO appear to be at increased risk for inguinal hernia.","name":"Spondylocostal dysostosis 2","medgen_id":"C1837549","type":"Disease","id":"5977","attribute_content":[],"symbol":"SCDO2","keywords":[],"alternate_names":["Spondylothoracic Dysostosis"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301771\",\"@Source\":\"PubMed\"},{\"$\":\"NBK8828\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"608681\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2311\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spondylocostal+dysostosis+2/6803\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9703\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK8828\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608681\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9703\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Koolen-de Vries syndrome (KdVS) is characterized by developmental delay/intellectual disability, neonatal/childhood hypotonia, dysmorphisms, congenital malformations, and behavioral features. Psychomotor developmental delay is noted in all individuals from an early age. The majority of individuals with KdVS function in the mild-to-moderate range of intellectual disability. Other findings include speech and language delay (100%), epilepsy (~33%), congenital heart defects (25%-50%), renal and urologic anomalies (25%-50%), and cryptorchidism (71% of males). Behavior in most is described as friendly, amiable, and cooperative.","name":"Koolen-de Vries syndrome","medgen_id":"C1864871","type":"Disease","id":"904","attribute_content":[],"symbol":"KDVS","keywords":[],"alternate_names":["17q21.31 microdeletion syndrome","CHROMOSOME 17q21.31 DELETION SYNDROME","KANSL1-Related Intellectual Disability Syndrome"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301783\",\"@Source\":\"PubMed\"},{\"$\":\"NBK24676\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"610443\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"363958\"}","{\"db\":\"Orphanet\",\"id\":\"96169\"}","{\"db\":\"Genetic Alliance\",\"id\":\"17q21.31+Microdeletion+Syndrome/9\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"17q21.31 microdeletion syndrome\"}","{\"db\":\"OMIM\",\"id\":\"610443\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHROMOSOME 17q21.31 DELETION SYNDROME\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK24676\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"KANSL1-Related Intellectual Disability Syndrome\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK24676\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"610443\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"KCNQ2-related disorders represent a continuum of overlapping neonatal epileptic phenotypes caused by a heterozygous pathogenic variant in KCNQ2. The clinical features of KCNQ2-related disorders range from KCNQ2-related benign familial neonatal epilepsy (KCNQ2-BFNE) at the mild end to KCNQ2-related neonatal epileptic encephalopathy (KCNQ2-NEE) at the severe end. KCNQ2-BFNE is characterized by a wide spectrum of seizure types (tonic or apneic episodes, focal clonic activity, or autonomic changes) that start in otherwise healthy infants between the second and eighth day of life and spontaneously disappear between the first and the sixth to 12th month of life. Motor activity may be confined to one body part, migrate to other body regions, or generalize. Seizures are generally brief, lasting one to two minutes. Rarely, KCNQ2-BFNE may evolve into status epilepticus. About 10%-15% of individuals with BFNE develop epileptic seizures later in life. KCNQ2-NEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features. Seizures generally cease between ages nine months and four years. At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia and thalamic hyperintensities that later resolve. Moderate to severe developmental impairment is present.","name":"Early infantile epileptic encephalopathy 7","medgen_id":"C3150986","type":"Disease","id":"15768","attribute_content":[],"symbol":"EIEE7","keywords":[],"alternate_names":["KCNQ2-Related Neonatal Epileptic Encephalopathy"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20437616\",\"@Source\":\"PubMed\"},{\"$\":\"NBK32534\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613720\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"439218\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Epileptic+encephalopathy%2C+early+infantile%2C+7/8345\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK32534\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613720\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["KMS","NKS"],"public_definition":"Kabuki syndrome (KS) is characterized by typical facial features (long palpebral fissures with eversion of the lateral third of the lower eyelid; arched and broad eyebrows; short columella with depressed nasal tip; large, prominent, or cupped ears), minor skeletal anomalies, persistence of fetal fingertip pads, mild-to-moderate intellectual disability, and postnatal growth deficiency. Other findings may include: congenital heart defects; genitourinary anomalies; cleft lip and/or palate; gastrointestinal anomalies including anal atresia, ptosis, and strabismus; and widely spaced teeth and hypodontia. Functional differences can include: increased susceptibility to infections and autoimmune disorders, seizures, endocrinologic abnormalities (including isolated premature thelarche in females), feeding problems, and hearing loss.","name":"Kabuki syndrome","medgen_id":"C0796004","type":"Disease","id":"33104","attribute_content":[],"keywords":[],"alternate_names":["Kabuki make-up syndrome"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21882399\",\"@Source\":\"PubMed\"},{\"$\":\"NBK62111\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS147920\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"2322\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Kabuki+syndrome/3945\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Kabuki make-up syndrome\"}","{\"db\":\"SNOMED CT\",\"id\":\"313426007\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Kabuki make-up syndrome\"}","{\"db\":\"OMIM\",\"id\":\"147920\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"KMS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6810\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"KMS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6810\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NKS\"}","{\"db\":\"OMIM\",\"id\":\"PS147920 \",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6810\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK62111\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"public_definition":"Kindler syndrome (KS), a rare subtype of inherited epidermolysis bullosa, is characterized by skin fragility and acral blister formation beginning at birth, diffuse cutaneous atrophy, photosensitivity (which is most prominent during childhood and usually decreases after adolescence), poikiloderma, diffuse palmoplantar hyperkeratosis, and pseudosyndactyly. Mucosal manifestations are also common and include hemorrhagic mucositis and gingivitis, periodontal disease, premature loss of teeth, and labial leukokeratosis. Other mucosal findings can include ectropion, esophageal strictures/stenosis, anal stenosis, colitis, urethral stenosis/strictures, and severe phimosis. Severe long-term complications of KS include periodontitis, mucosal strictures, and aggressive squamous cell carcinomas. Manifestations can range from mild to severe.","name":"Kindler's syndrome","medgen_id":"C0406557","type":"Disease","id":"2519","attribute_content":[],"symbol":"KNDLRS","keywords":[],"alternate_names":["Hereditary acrokeratotic poikiloderma of Weary"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"26937547\",\"@Source\":\"PubMed\"},{\"$\":\"NBK349072\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"173650\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2908\"}","{\"db\":\"Orphanet\",\"id\":\"306539\"}","{\"db\":\"SNOMED CT\",\"id\":\"238835001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hereditary acrokeratotic poikiloderma of Weary\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Poikiloderma+of+Kindler/5812\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"238836000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK349072\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"173650\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","name":"Nephronophthisis 15","medgen_id":"C3541853","type":"Disease","id":"17403","attribute_content":[],"symbol":"NPHP15","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"614845\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3156\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614845\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["NPH1"],"public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","name":"Nephronophthisis 1","medgen_id":"C4551979","type":"Disease","id":"3445","attribute_content":[],"symbol":"NPHP1","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"256100\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"OMIM\",\"id\":\"256100\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NPH1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"206\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NPH1\"}","{\"db\":\"GeneTests\",\"id\":\"21201\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephronophthisis+1/5141\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"206\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"256100\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"206\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","name":"Nephronophthisis 13","medgen_id":"C3280612","type":"Disease","id":"16690","attribute_content":[],"symbol":"NPHP13","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"614377\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Nephronophthisis+13/8981\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"614377\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","name":"Nephronophthisis","medgen_id":"C0687120","type":"Disease","id":"16739","attribute_content":[],"keywords":[],"alternate_names":["juvenile nephronophthisis"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000090\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004748\",\"type\":\"secondary\"}","{\"db\":\"OMIM\",\"id\":\"PS256100\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000090\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"juvenile nephronophthisis\"}","{\"db\":\"GeneTests\",\"id\":\"72016\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000090\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"204958008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":["NPH3"],"public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","name":"Adolescent nephronophthisis","medgen_id":"C1858392","type":"Disease","id":"5620","attribute_content":[],"symbol":"NPHP3","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"604387\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"OMIM\",\"id\":\"604387\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NPH3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Adolescent+nephronophthisis/7636\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"444749006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"604387\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["NPH2"],"public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","name":"Infantile nephronophthisis","medgen_id":"C1865872","type":"Disease","id":"3446","attribute_content":[],"symbol":"NPHP2","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"602088\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"655\"}","{\"db\":\"Orphanet\",\"id\":\"93591\"}","{\"db\":\"OMIM\",\"id\":\"602088\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NPH2\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Infantile+nephronophthisis/8661\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"444558002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"602088\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult. Infantile NPH can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years. Juvenile NPH, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size. Adolescent/adult NPH is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype, inter- and intrafamilial variability in rate of progression to ESRD is considerable. Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that constitute a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Lken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).","name":"Nephronophthisis 19","medgen_id":"C4015542","type":"Disease","id":"32718","attribute_content":[],"symbol":"NPHP19","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27336129\",\"@Source\":\"PubMed\"},{\"$\":\"NBK368475\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"616217\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"84081\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK368475\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616217\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"The spectrum of isolated sulfite oxidase deficiency ranges from classic early-onset (severe) disease to late-onset (mild) disease. Classic ISOD is characterized in the first few hours to days of life by intractable seizures, feeding difficulties, and rapidly progressive encephalopathy manifest as abnormal tone (especially opisthotonus, spastic quadriplegia, and pyramidal signs) followed by progressive microcephaly and profound intellectual disability. Lens subluxation or dislocation, another characteristic finding, may be evident after the newborn period. Children usually die during the first few months of life. Late-onset ISOD manifests between ages six and 18 months and is characterized by ectopia lentis (variably present), developmental delay/regression, movement disorder characterized by dystonia and choreoathetosis, ataxia, and (rarely) acute hemiplegia due to metabolic stroke. The clinical course may be progressive or episodic. In the episodic form encephalopathy, dystonia, choreoathetosis, and/or ataxia are intermittent.","name":"Sulfite oxidase deficiency","medgen_id":"C2931746","type":"Disease","id":"3860","attribute_content":[],"symbol":"ISOD","keywords":[],"alternate_names":["Sulfocysteinuria"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"28933809\",\"@Source\":\"PubMed\"},{\"$\":\"NBK453433\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003643\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"272300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"833\"}","{\"db\":\"Orphanet\",\"id\":\"99731\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5062\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Sulfocysteinuria\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Sulfite+oxidase+deficiency/6924\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003643\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5062\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"367368009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK453433\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"272300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"WAC-related intellectual disability (ID) is typically characterized by variable degrees of developmental delay and/or intellectual disability. Behavioral abnormalities including anxiety, attention deficit/hyperactivity disorder, and/or autism spectrum disorder are observed in the majority of older children and adults. Most affected infants have significant but nonspecific features at birth such as neonatal hypotonia and feeding problems. Some affected individuals come to medical attention with respiratory or vision problems. Facial features may be mildly dysmorphic, but are nonspecific. To date, 18 individuals have been identified with WAC-related ID.","name":"Desanto-shinawi syndrome","medgen_id":"C4225239","type":"Disease","id":"34538","attribute_content":[],"symbol":"DESSH","keywords":[],"alternate_names":["DEVELOPMENTAL DELAY, BEHAVIORAL ABNORMALITIES, FACIAL DYSMORPHISM, AND OCULAR ABNORMALITIES"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29190062\",\"@Source\":\"PubMed\"},{\"$\":\"NBK465012\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"616708\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"284169\"}","{\"db\":\"Orphanet\",\"id\":\"466943\"}","{\"db\":\"Orphanet\",\"id\":\"466950\"}","{\"db\":\"OMIM\",\"id\":\"616708\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DEVELOPMENTAL DELAY, BEHAVIORAL ABNORMALITIES, FACIAL DYSMORPHISM, AND OCULAR ABNORMALITIES\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK465012\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"616708\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"NKX6-2-related disorder is characterized by a spectrum of progressive neurologic manifestations resulting from diffuse central nervous system hypomyelination. At the severe end of the spectrum is neonatal-onset nystagmus, severe spastic tetraplegia with joint contractures and scoliosis, and visual and hearing impairment, all of which rapidly progress resulting in death in early childhood. At the milder end of the spectrum is normal achievement of early motor milestones in the first year of life followed by slowly progressive complex spastic ataxia with pyramidal findings (spasticity with increased muscle tone and difficulty with gait and fine motor coordination) and cerebellar findings (nystagmus, extraocular movement disorder, dysarthria, titubation, and ataxia) with loss of developmental milestones. To date NKX6-2-related disorder has been reported in 25 individuals from 13 families.","name":"SPASTIC ATAXIA 8, AUTOSOMAL RECESSIVE, WITH HYPOMYELINATING LEUKODYSTROPHY","medgen_id":"C4479653","type":"Disease","id":"37906","attribute_content":[],"symbol":"SPAX8","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"30285346\",\"@Source\":\"PubMed\"},{\"$\":\"NBK531509\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"617560\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"527497\"}","{\"db\":\"OMIM\",\"id\":\"605955.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"605955.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617560\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK531509\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617560\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["SEMDC","SMD"],"name":"Spondylometaphyseal dysplasia","medgen_id":"C0700635","type":"Disease","id":"4453","attribute_content":[],"symbol":"SEMDSTWK","keywords":[],"alternate_names":["Spondyloepimetaphyseal dysplasia Strudwick type"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31021589\",\"@Source\":\"PubMed\"},{\"$\":\"NBK540447\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002657\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"184250\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"254\"}","{\"db\":\"Orphanet\",\"id\":\"93346\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Spondyloepimetaphyseal+dysplasia+Strudwick+type/6814\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spondyloepimetaphyseal dysplasia Strudwick type\"}","{\"db\":\"OMIM\",\"id\":\"184250\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SEMDC\"}","{\"db\":\"OMIM\",\"id\":\"184250\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SMD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"134\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"SMD\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002657\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"184250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"name":"Aortic valve disorder","medgen_id":"C3887892","type":"Disease","id":"421","attribute_content":[],"symbol":"AOVD1","keywords":[],"alternate_names":["AORTIC STENOSIS, CALCIFIC","AORTIC VALVE DISEASE","AORTIC VALVE DISEASE 1","AORTIC VALVE, CALCIFICATION OF"],"content":"{\"Citation\":[{\"@Abbrev\":\"ACMG, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22237449\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173340\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"109730\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"109730\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AORTIC STENOSIS, CALCIFIC\"}","{\"db\":\"OMIM\",\"id\":\"109730\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AORTIC VALVE DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"109730\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AORTIC VALVE DISEASE 1\"}","{\"db\":\"OMIM\",\"id\":\"190198.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AORTIC VALVE DISEASE 1\"}","{\"db\":\"OMIM\",\"id\":\"190198.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AORTIC VALVE DISEASE 1\"}","{\"db\":\"OMIM\",\"id\":\"190198.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AORTIC VALVE DISEASE 1\"}","{\"db\":\"OMIM\",\"id\":\"190198.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AORTIC VALVE DISEASE 1\"}","{\"db\":\"OMIM\",\"id\":\"109730\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AORTIC VALVE, CALCIFICATION OF\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Aortic+valve+disorder/7701\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"8722008\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"109730\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["PARK"],"name":"Parkinson disease, late-onset","medgen_id":"C3160718","type":"Disease","id":"3762","attribute_content":[],"symbol":"PD","keywords":[],"alternate_names":["PARKINSON DISEASE, AGE OF ONSET, MODIFIER","PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO","Parkinson's disease"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2011\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"20482602\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"168600\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"300144.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, AGE OF ONSET, MODIFIER\"}","{\"db\":\"OMIM\",\"id\":\"157140.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"601517.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"603680.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"606463.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"606463.0048\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"OMIM\",\"id\":\"607047.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE, LATE-ONSET, SUSCEPTIBILITY TO\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+Disease/5603\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Parkinson's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"49049000\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Parkinson's disease\"}","{\"db\":\"OMIM\",\"id\":\"168600\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PARK\"}","{\"db\":\"OMIM\",\"id\":\"168600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["EVRX","FEVRX","NDP"],"public_definition":"NDP-related retinopathies are characterized by a spectrum of fibrous and vascular changes of the retina at birth that progress through childhood or adolescence to cause varying degrees of visual impairment. The most severe phenotype is described as Norrie disease (ND), characterized by grayish-yellow fibrovascular masses (pseudogliomas) secondary to retinal vascular dysgenesis and detachment. Congenital blindness is almost always present. Approximately 30%-50% of males with ND have developmental delay / intellectual disability, behavioral abnormalities, or psychotic-like features. The majority of males with ND develop sensorineural hearing loss. Less severe phenotypes include: persistent hyperplastic primary vitreous (PHPV), characterized by a fibrotic white stalk from the optic disk to the lens; X-linked familial exudative vitreoretinopathy (XL-FEVR), characterized by peripheral retinal vascular anomalies with or without fibrotic changes and retinal detachment; retinopathy of prematurity (ROP); and Coats disease, an exudative proliferative vasculopathy. Phenotypes can vary within families.","name":"Familial exudative vitreoretinopathy, X-linked","medgen_id":"C1844579","type":"Disease","id":"1259","attribute_content":[],"symbol":"EVR2","keywords":[],"alternate_names":["EXUDATIVE VITREORETINOPATHY 2, X-LINKED","EXUDATIVE VITREORETINOPATHY, FAMILIAL, 2","FEVR, X-LINKED"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301506\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1331\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"305390\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"891\"}","{\"db\":\"OMIM\",\"id\":\"300658.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXUDATIVE VITREORETINOPATHY 2, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300658.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXUDATIVE VITREORETINOPATHY 2, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300658.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXUDATIVE VITREORETINOPATHY 2, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"300658.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXUDATIVE VITREORETINOPATHY 2, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"305390\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXUDATIVE VITREORETINOPATHY 2, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"305390\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EXUDATIVE VITREORETINOPATHY, FAMILIAL, 2\"}","{\"db\":\"OMIM\",\"id\":\"305390\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FEVR, X-LINKED\"}","{\"db\":\"OMIM\",\"id\":\"305390\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EVRX\"}","{\"db\":\"OMIM\",\"id\":\"305390\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FEVRX\"}","{\"db\":\"Genetic Alliance\",\"id\":\"X-linked+familial+exudative+vitreoretinopathy/9487\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1331\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"305390\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["NDP"],"public_definition":"NDP-related retinopathies are characterized by a spectrum of fibrous and vascular changes of the retina at birth that progress through childhood or adolescence to cause varying degrees of visual impairment. The most severe phenotype is described as Norrie disease (ND), characterized by grayish-yellow fibrovascular masses (pseudogliomas) secondary to retinal vascular dysgenesis and detachment. Congenital blindness is almost always present. Approximately 30%-50% of males with ND have developmental delay / intellectual disability, behavioral abnormalities, or psychotic-like features. The majority of males with ND develop sensorineural hearing loss. Less severe phenotypes include: persistent hyperplastic primary vitreous (PHPV), characterized by a fibrotic white stalk from the optic disk to the lens; X-linked familial exudative vitreoretinopathy (XL-FEVR), characterized by peripheral retinal vascular anomalies with or without fibrotic changes and retinal detachment; retinopathy of prematurity (ROP); and Coats disease, an exudative proliferative vasculopathy. Phenotypes can vary within families.","name":"Atrophia bulborum hereditaria","medgen_id":"C0266526","type":"Disease","id":"5658","attribute_content":[],"symbol":"ND","keywords":[],"alternate_names":["Norrie Disease"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301506\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1331\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"310600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"649\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7224\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NDP\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Norrie+disease/5270\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7224\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"15228007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1331\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"310600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"NDP-related retinopathies are characterized by a spectrum of fibrous and vascular changes of the retina at birth that progress through childhood or adolescence to cause varying degrees of visual impairment. The most severe phenotype is described as Norrie disease (ND), characterized by grayish-yellow fibrovascular masses (pseudogliomas) secondary to retinal vascular dysgenesis and detachment. Congenital blindness is almost always present. Approximately 30%-50% of males with ND have developmental delay / intellectual disability, behavioral abnormalities, or psychotic-like features. The majority of males with ND develop sensorineural hearing loss. Less severe phenotypes include: persistent hyperplastic primary vitreous (PHPV), characterized by a fibrotic white stalk from the optic disk to the lens; X-linked familial exudative vitreoretinopathy (XL-FEVR), characterized by peripheral retinal vascular anomalies with or without fibrotic changes and retinal detachment; retinopathy of prematurity (ROP); and Coats disease, an exudative proliferative vasculopathy. Phenotypes can vary within families.","name":"Exudative retinopathy","medgen_id":"C0154832","type":"Disease","id":"1522","attribute_content":[],"keywords":[],"alternate_names":["Coats disease"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301506\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1331\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110944\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"Gene\",\"id\":\"1283\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007898\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"300216\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"190\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6121\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Coats disease\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007898\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"25506007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1331\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":["CFD1"],"public_definition":"The eight disorders comprising the FGFR-related craniosynostosis spectrum are Pfeiffer syndrome, Apert syndrome, Crouzon syndrome, Beare-Stevenson syndrome, FGFR2-related isolated coronal synostosis, Jackson-Weiss syndrome, Crouzon syndrome with acanthosis nigricans (AN), and Muenke syndrome (isolated coronal synostosis caused by the p.Pro250Arg pathogenic variant in FGFR3). Muenke syndrome and FGFR2-related isolated coronal synostosis are characterized only by uni- or bicoronal craniosynostosis; the remainder are characterized by bicoronal craniosynostosis or cloverleaf skull, distinctive facial features, and variable hand and foot findings.","name":"Crouzon syndrome","medgen_id":"C0010273","type":"Disease","id":"4878","attribute_content":[],"keywords":[],"alternate_names":["CRANIOFACIAL DYSOSTOSIS, TYPE I","Craniofacial dysostosis","Craniofacial dysostosis type 1"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301628\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1455\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111019\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004439\",\"type\":\"primary\"}","{\"db\":\"MeSH\",\"id\":\"D003394\"}","{\"db\":\"OMIM\",\"id\":\"123500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"207\"}","{\"db\":\"OMIM\",\"id\":\"123500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CRANIOFACIAL DYSOSTOSIS, TYPE I\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004439\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Craniofacial dysostosis\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6206\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Craniofacial dysostosis type 1\"}","{\"db\":\"OMIM\",\"id\":\"123500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CFD1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6206\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CFD1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Crouzon+Syndrome/2018\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004439\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6206\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"28861008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1455\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"public_definition":"Noonan syndrome (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population.","name":"Noonan syndrome 6","medgen_id":"C2750732","type":"Disease","id":"6940","attribute_content":[],"symbol":"NS6","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301303\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1124\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"AAP, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20876176\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613224\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"648\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Noonan+syndrome+6/5265\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10701\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1124\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613224\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10701\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Noonan syndrome (NS) is characterized by characteristic facies, short stature, congenital heart defect, and developmental delay of variable degree. Other findings can include broad or webbed neck, unusual chest shape with superior pectus carinatum and inferior pectus excavatum, cryptorchidism, varied coagulation defects, lymphatic dysplasias, and ocular abnormalities. Although birth length is usually normal, final adult height approaches the lower limit of normal. Congenital heart disease occurs in 50%-80% of individuals. Pulmonary valve stenosis, often with dysplasia, is the most common heart defect and is found in 20%-50% of individuals. Hypertrophic cardiomyopathy, found in 20%-30% of individuals, may be present at birth or develop in infancy or childhood. Other structural defects include atrial and ventricular septal defects, branch pulmonary artery stenosis, and tetralogy of Fallot. Up to one fourth of affected individuals have mild intellectual disability, and language impairments in general are more common in NS than in the general population.","name":"Noonan syndrome 7","medgen_id":"C3150970","type":"Disease","id":"15790","attribute_content":[],"symbol":"NS7","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301303\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1124\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"AAP, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20876176\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"613706\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"648\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Noonan+syndrome+7/9019\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1124\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"613706\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["DFN3"],"name":"Deafness, X-linked 2","medgen_id":"C1844678","type":"Disease","id":"4932","attribute_content":[],"symbol":"DFNX2","keywords":[],"alternate_names":["DFNB 1 Nonsyndromic Hearing Loss and Deafness"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301607\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1434\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24651602\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"304400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"383\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1272\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DFNB 1 Nonsyndromic Hearing Loss and Deafness\"}","{\"db\":\"OMIM\",\"id\":\"304400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DFN3\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4504\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DFN3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Deafness%2C+X-Linked+2/2161\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4504\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"304400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4504\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Glycogen storage disease type III (GSD III) is characterized by variable liver, cardiac muscle, and skeletal muscle involvement. GSD IIIa is the most common subtype, present in about 85% of affected individuals; it manifests with liver and muscle involvement. GSD IIIb, with liver involvement only, comprises about 15% of all GSD III. In infancy and early childhood, liver involvement presents as ketotic hypoglycemia, hepatomegaly, hyperlipidemia, and elevated hepatic transaminases. In adolescence and adulthood, liver disease becomes less prominent. Hypertrophic cardiomyopathy develops in the majority of those with GSD IIIa, usually during childhood. Its clinical significance ranges from asymptomatic in the majority to severe cardiac dysfunction, congestive heart failure, and (rarely) sudden death. Skeletal myopathy manifesting as weakness is not usually evident in childhood, but slowly progresses, typically becoming prominent in the third to fourth decade.","name":"Glycogen storage disease type III","medgen_id":"C0017922","type":"Disease","id":"2236","attribute_content":[],"symbol":"GSD3","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301788\",\"@Source\":\"PubMed\"},{\"$\":\"NBK26372\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20631546\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"232400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"366\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Glycogen+Storage+Disease+Type+3/3123\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"66937008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK26372\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"232400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"KCNQ2-related disorders represent a continuum of overlapping neonatal epileptic phenotypes caused by a heterozygous pathogenic variant in KCNQ2. The clinical features of KCNQ2-related disorders range from KCNQ2-related benign familial neonatal epilepsy (KCNQ2-BFNE) at the mild end to KCNQ2-related neonatal epileptic encephalopathy (KCNQ2-NEE) at the severe end. KCNQ2-BFNE is characterized by a wide spectrum of seizure types (tonic or apneic episodes, focal clonic activity, or autonomic changes) that start in otherwise healthy infants between the second and eighth day of life and spontaneously disappear between the first and the sixth to 12th month of life. Motor activity may be confined to one body part, migrate to other body regions, or generalize. Seizures are generally brief, lasting one to two minutes. Rarely, KCNQ2-BFNE may evolve into status epilepticus. About 10%-15% of individuals with BFNE develop epileptic seizures later in life. KCNQ2-NEE is characterized by multiple daily seizures beginning in the first week of life that are mostly tonic, with associated focal motor and autonomic features. Seizures generally cease between ages nine months and four years. At onset, EEG shows a burst-suppression pattern or multifocal epileptiform activity; early brain MRI can show basal ganglia and thalamic hyperintensities that later resolve. Moderate to severe developmental impairment is present.","name":"Benign familial neonatal seizures 1","medgen_id":"C3149074","type":"Disease","id":"5025","attribute_content":[],"symbol":"BFNS1","keywords":[],"alternate_names":["Benign Neonatal Epilepsy 1","KCNQ2-Related Benign Familial Neonatal Epilepsy"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20437616\",\"@Source\":\"PubMed\"},{\"$\":\"NBK32534\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20298421\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"121200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1949\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Convulsions%2C+Benign+Familial+Infantile%2C+1/1892\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK32534\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"121200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CMT3","DSN","DSS","HMSN3"],"name":"Dejerine-Sottas disease","medgen_id":"C0011195","type":"Disease","id":"5298","attribute_content":[],"keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, TYPE 3","HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE III","HMSN Type III"],"content":"{\"Citation\":[{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987431\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"145900\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"64748\"}","{\"db\":\"OMIM\",\"id\":\"145900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, TYPE 3\"}","{\"db\":\"OMIM\",\"id\":\"145900\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEREDITARY MOTOR AND SENSORY NEUROPATHY TYPE III\"}","{\"db\":\"OMIM\",\"id\":\"145900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT3\"}","{\"db\":\"OMIM\",\"id\":\"145900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSN\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9204\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSN\"}","{\"db\":\"OMIM\",\"id\":\"145900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9204\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSS\"}","{\"db\":\"OMIM\",\"id\":\"145900\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN3\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9204\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN3\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypertrophic+neuropathy+of+Dejerine-Sottas/3622\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"111499002\",\"ref_field\":\"name\"}"]}
{"alternate_symbols":[],"name":"Parkinson disease 14","medgen_id":"C2751842","type":"Disease","id":"6750","attribute_content":[],"symbol":"PARK14","keywords":[],"alternate_names":["DYSTONIA-PARKINSONISM, ADULT-ONSET","PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/MDS-ES, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23279440\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"612953\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"199351\"}","{\"db\":\"OMIM\",\"id\":\"612953\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"DYSTONIA-PARKINSONISM, ADULT-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"612953\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+14/9082\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612953\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["PKPS"],"name":"Parkinson disease 15","medgen_id":"C1850100","type":"Disease","id":"3273","attribute_content":[],"symbol":"PARK15","keywords":[],"alternate_names":["PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE","PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET","PARKINSONIAN-PYRAMIDAL SYNDROME"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/MDS-ES, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23279440\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"171695\"}","{\"db\":\"OMIM\",\"id\":\"605648.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"605648.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"605648.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"605648.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 15, AUTOSOMAL RECESSIVE EARLY-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSONIAN-PYRAMIDAL SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PKPS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+15/9083\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"260300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["KRPPD","PARK9"],"name":"Parkinson disease 9","medgen_id":"C1847640","type":"Disease","id":"2530","attribute_content":[],"symbol":"KRS","keywords":[],"alternate_names":["PARKINSON DISEASE 9, AUTOSOMAL RECESSIVE, JUVENILE-ONSET"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301402\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1223\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EFNS/MDS-ES, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23279440\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"306674\"}","{\"db\":\"Orphanet\",\"id\":\"314632\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PARKINSON DISEASE 9, AUTOSOMAL RECESSIVE, JUVENILE-ONSET\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"KRPPD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9174\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"KRPPD\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PARK9\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parkinson+disease+9/5605\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9174\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606693\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["ICS","PCD"],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Kartagener syndrome","medgen_id":"C4551906","type":"Disease","id":"4805","attribute_content":[],"symbol":"CILD1","keywords":[],"alternate_names":["CILIARY DYSKINESIA, PRIMARY, 1","CILIARY DYSKINESIA, PRIMARY, 1, WITH OR WITHOUT SITUS INVERSUS","IMMOTILE CILIA SYNDROME","POLYNESIAN BRONCHIECTASIS"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"PCD Foundation, 2016\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"4912005\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"244400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"Orphanet\",\"id\":\"98861\"}","{\"db\":\"OMIM\",\"id\":\"244400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 1\"}","{\"db\":\"OMIM\",\"id\":\"604366.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 1\"}","{\"db\":\"OMIM\",\"id\":\"604366.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 1\"}","{\"db\":\"OMIM\",\"id\":\"604366.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 1\"}","{\"db\":\"OMIM\",\"id\":\"604366.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 1\"}","{\"db\":\"OMIM\",\"id\":\"244400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CILIARY DYSKINESIA, PRIMARY, 1, WITH OR WITHOUT SITUS INVERSUS\"}","{\"db\":\"OMIM\",\"id\":\"244400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMOTILE CILIA SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"244400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"POLYNESIAN BRONCHIECTASIS\"}","{\"db\":\"OMIM\",\"id\":\"244400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ICS\"}","{\"db\":\"OMIM\",\"id\":\"244400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PCD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Kartagener+syndrome/3958\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6815\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"42402006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"244400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CILD","ICS"],"public_definition":"Primary ciliary dyskinesia (PCD) is associated with situs abnormalities, abnormal sperm motility, and abnormal ciliary structure and function that result in retention of mucus and bacteria in the respiratory tract leading to chronic otosinopulmonary disease. More than 75% of full-term neonates with PCD have \"neonatal respiratory distress\" requiring supplemental oxygen for days to weeks. Chronic airway infection, apparent in early childhood, results in bronchiectasis that is almost uniformly present in adulthood. Nasal congestion and sinus infections, apparent in early childhood, persist through adulthood. Chronic/recurrent ear infection, apparent in most young children, can be associated with transient or later irreversible hearing loss. Situs inversus totalis (mirror-image reversal of all visceral organs with no apparent physiologic consequences) is present in 40%-50% of individuals with PCD; heterotaxy (discordance of right and left patterns of ordinarily asymmetric structures that can be associated with significant malformations) is present in approximately 12%. Virtually all males with PCD are infertile as a result of abnormal sperm motility.","name":"Primary ciliary dyskinesia","medgen_id":"C0008780","type":"Disease","id":"15219","attribute_content":[],"symbol":"PCD","keywords":[],"alternate_names":["Ciliary dyskinesia"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301301\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1122\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"PCD Foundation, 2016\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"4912005\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012265\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"PS244400\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"244\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012265\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Ciliary dyskinesia\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4484\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ICS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Primary+ciliary+dyskinesia/5941\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4484\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1122\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":[],"public_definition":"GARS1-associated axonal neuropathy (Charcot-Marie-Tooth neuropathy type 2D / distal spinal muscular atrophy V [CMT2D/dSMA-V]) is characterized by adolescent or early-adult onset of weakness in the hands that may be preceded by transient cramping and pain in the hands on exposure to cold and cramping in calf muscles on exertion. This is followed by progressive weakness and atrophy of thenar and first dorsal interosseus muscles; hypothenar eminence is spared until later in the course of illness. The lower limbs are involved in about half of affected individuals, with severity varying from weakness and atrophy of the extensor digitorum brevis and weakness of toe dorsiflexors to classic peroneal muscular atrophy with foot drop. The phenotype is considered the CMT2D subtype when sensory deficits (reduction of pinprick, temperature, touch, and vibration perception in a stocking and [less often] glove pattern) are present and dSMA-V when sensory deficits are absent.","name":"Charcot-Marie-Tooth disease type 2D","medgen_id":"C1832274","type":"Disease","id":"1415","attribute_content":[],"symbol":"CMT2D","keywords":[],"alternate_names":["Charcot-Marie-Tooth Neuropathy Type 2D"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301420\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1242\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301462\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1285\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"601472\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99938\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+2D/1295\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1251\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1242\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601472\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["CMT4C1"],"public_definition":"Charcot-Marie-Tooth neuropathy type 4C (CMT4C) is a demyelinating neuropathy characterized by early-onset severe spine deformities. The majority of affected children present with scoliosis or kyphoscoliosis between ages two and ten years, although earlier and later onset are observed. Slowly progressive neuropathy usually manifests in the first decade or adolescence, and occasionally earlier or later. Foot deformities (pes cavus, pes planus, or pes valgus) are common.","name":"Charcot-Marie-Tooth disease, type 4C","medgen_id":"C1866636","type":"Disease","id":"1420","attribute_content":[],"symbol":"CMT4C","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4C","Charcot-Marie-Tooth Neuropathy Type 4C","Charcot-Marie-Tooth Neuropathy Type 4C (CMT4C)"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301514\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1340\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301641\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1468\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"601596\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99949\"}","{\"db\":\"OMIM\",\"id\":\"601596\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4C\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1340\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth Neuropathy Type 4C\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000503093\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CMT4C1\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+4C/1307\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1340\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601596\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":[],"public_definition":"Charcot-Marie-Tooth neuropathy type 4J (CMT4J) is a peripheral neuropathy characterized by childhood onset (manifest as clumsy gait) with accelerated limb weakness and muscle atrophy during the teen or adult years that is typically asymmetric and can involve both distal and proximal limb muscles. Although sensory symptoms are minimal, examination may reveal decreased response to touch, pin prick, or vibration distally. Bulbar and cranial nerve functions are often spared; intellect is normal.","name":"Charcot-Marie-Tooth disease, type 4J","medgen_id":"C1970011","type":"Disease","id":"4785","attribute_content":[],"symbol":"CMT4J","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4J","Charcot-Marie-Tooth Neuropathy Type 4J"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301641\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1468\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301532\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1358\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"24228289\",\"@Source\":\"PubMed\"},{\"$\":\"NBK169431\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"611228\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139515\"}","{\"db\":\"OMIM\",\"id\":\"611228\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, AUTOSOMAL RECESSIVE, TYPE 4J\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+disease%2C+type+4J/7963\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK169431\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"611228\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["FCMD"],"public_definition":"Fukuyama congenital muscular dystrophy (FCMD) is characterized by hypotonia, symmetric generalized muscle weakness, and CNS migration disturbances that result in changes consistent with cobblestone lissencephaly with cerebral and cerebellar cortical dysplasia. Mild, typical, and severe phenotypes are recognized. Onset typically occurs in early infancy with poor suck, weak cry, and floppiness. Affected individuals have contractures of the hips, knees, and interphalangeal joints. Later features include myopathic facial appearance, pseudohypertrophy of the calves and forearms, motor and speech delays, intellectual disability, seizures, ophthalmologic abnormalities including visual impairment and retinal dysplasia, and progressive cardiac involvement after age ten years. Swallowing disturbance occurs in individuals with severe FCMD and in individuals older than age ten years, leading to recurrent aspiration pneumonia and death.","name":"Fukuyama congenital muscular dystrophy","medgen_id":"C0410174","type":"Disease","id":"1903","attribute_content":[],"symbol":"MDDGA4","keywords":[],"alternate_names":["WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301385\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1206\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"Int'l SCC for CMD, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21078917\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"253800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"272\"}","{\"db\":\"Orphanet\",\"id\":\"588\"}","{\"db\":\"Orphanet\",\"id\":\"899\"}","{\"db\":\"OMIM\",\"id\":\"253800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"253800\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FCMD\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6475\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FCMD\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fukuyama+Type+Muscular+Dystrophy/2962\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fukuyama-congenital-muscular-dystrophy\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"111502003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1206\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"253800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["MDC1C"],"name":"Congenital muscular dystrophy-dystroglycanopathy (with or without mental retardation) type B5","medgen_id":"C1847759","type":"Disease","id":"5568","attribute_content":[],"symbol":"MDDGB5","keywords":[],"alternate_names":["MUSCULAR DYSTROPHY, CONGENITAL, 1C","MUSCULAR DYSTROPHY, CONGENITAL, FKRP-RELATED","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUT MENTAL RETARDATION), TYPE B, 5"],"content":"{\"Citation\":[{\"@Abbrev\":\"Int'l SCC for CMD, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21078917\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301468\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1291\",\"@Source\":\"BookShelf\"}]}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"52428\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, 1C\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY, CONGENITAL, FKRP-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH OR WITHOUT MENTAL RETARDATION), TYPE B, 5\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MDC1C\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+muscular+dystrophy-dystroglycanopathy+%28with+or+with\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"606612\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["HHRH"],"public_definition":"Hypophosphatasia is characterized by defective mineralization of bone and/or teeth in the presence of low activity of serum and bone alkaline phosphatase. Clinical features range from stillbirth without mineralized bone at the severe end to pathologic fractures of the lower extremities in later adulthood at the mild end. Although the disease spectrum is a continuum, six clinical forms are usually recognized based on age at diagnosis and severity of features: Perinatal (severe) hypophosphatasia characterized by respiratory insufficiency and hypercalcemia. Perinatal (benign) hypophosphatasia with prenatal skeletal manifestations that slowly resolve into one of the milder forms. Infantile hypophosphatasia with onset between birth and age six months of rickets without elevated serum alkaline phosphatase activity. Childhood (juvenile) hypophosphatasia that ranges from low bone mineral density for age with unexplained fractures to rickets, and premature loss of primary teeth with intact roots. Adult hypophosphatasia characterized by stress fractures and pseudofractures of the lower extremities in middle age, sometimes associated with early loss of adult dentition. Odontohypophosphatasia characterized by premature exfoliation of primary teeth and/or severe dental caries without skeletal manifestations.","name":"Childhood hypophosphatasia","medgen_id":"C0220743","type":"Disease","id":"2389","attribute_content":[],"keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301329\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1150\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061990\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"241510\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"247667\"}","{\"db\":\"Orphanet\",\"id\":\"436\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8735\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HHRH\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hypophosphatasia+childhood/3678\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8735\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"30174008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1150\",\"ref_field\":\"public_definition\"}"]}
{"alternate_symbols":["HMSN4D","HMSNL","NMSL"],"name":"Charcot-Marie-Tooth disease, type 4D","medgen_id":"C1832334","type":"Disease","id":"4784","attribute_content":[],"symbol":"CMT4D","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4D","Charcot-Marie-Tooth Neuropathy Type 4D"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301641\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1468\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987431\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"601455\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99950\"}","{\"db\":\"OMIM\",\"id\":\"601455\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, AUTOSOMAL RECESSIVE, TYPE 4D\"}","{\"db\":\"OMIM\",\"id\":\"601455\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN4D\"}","{\"db\":\"OMIM\",\"id\":\"601455\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSNL\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3973\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSNL\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3973\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"NMSL\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neuropathy%2C+hereditary+motor+and+sensory%2C+LOM+type/5204\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601455\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"3973\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["HMSN1D"],"name":"Charcot-Marie-Tooth disease, demyelinating, type 1d","medgen_id":"C1843247","type":"Disease","id":"880","attribute_content":[],"symbol":"CMT1D","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1D","Charcot-Marie-Tooth disease, type 1D","HMSN ID"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301384\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1205\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"607678\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101084\"}","{\"db\":\"OMIM\",\"id\":\"607678\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1D\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+1D/1287\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth disease, type 1D\"}","{\"db\":\"OMIM\",\"id\":\"607678\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN ID\"}","{\"db\":\"OMIM\",\"id\":\"607678\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN1D\"}","{\"db\":\"OMIM\",\"id\":\"607678\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["HMSN1C"],"name":"Charcot-Marie-Tooth disease, type 1C","medgen_id":"C0270913","type":"Disease","id":"783","attribute_content":[],"symbol":"CMT1C","keywords":[],"alternate_names":["CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1C","CMT, SLOW NERVE CONDUCTION TYPE C","Charcot-Marie-Tooth disease, type IC","HMSN IC","NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE IC"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301384\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1205\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"MDA Consensus document - CMT testing, 2011\",\"@Type\":\"general\",\"ID\":{\"$\":\"3058597\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"601098\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"101083\"}","{\"db\":\"OMIM\",\"id\":\"601098\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHARCOT-MARIE-TOOTH NEUROPATHY, TYPE 1C\"}","{\"db\":\"OMIM\",\"id\":\"601098\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CMT, SLOW NERVE CONDUCTION TYPE C\"}","{\"db\":\"SNOMED CT\",\"id\":\"4183003\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Charcot-Marie-Tooth disease, type IC\"}","{\"db\":\"OMIM\",\"id\":\"601098\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN IC\"}","{\"db\":\"OMIM\",\"id\":\"601098\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NEUROPATHY, HEREDITARY MOTOR AND SENSORY, TYPE IC\"}","{\"db\":\"OMIM\",\"id\":\"601098\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN1C\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Charcot-Marie-Tooth+Disease+Type+1C/1286\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"601098\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["ZEB2"],"public_definition":"Mowat-Wilson syndrome (MWS) is characterized by distinctive facial features (widely spaced eyes, broad eyebrows with a medial flare, low-hanging columella, prominent or pointed chin, open-mouth expression, and uplifted earlobes with a central depression), congenital heart defects with predilection for abnormalities of the pulmonary arteries and/or valves, Hirschsprung disease or chronic constipation, genitourinary anomalies (particularly hypospadias in males), and hypogenesis or agenesis of the corpal callosum. Most affected individuals have moderate-to-severe intellectual disability. Speech is typically limited to a few words or is absent, with relative preservation of receptive language skills. Growth restriction with microcephaly and seizure disorder are also common. Most affected people have a happy demeanor and a wide-based gait that can sometimes be confused with Angelman syndrome.","name":"Mowat-Wilson syndrome","medgen_id":"C1856113","type":"Disease","id":"2968","attribute_content":[],"symbol":"MOWS","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301585\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1412\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21343952\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"235730\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2152\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Mowat-Wilson+syndrome/4895\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"mowat-wilson-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9673\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1412\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"235730\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"]}
{"alternate_symbols":["EKV","EKVP","PSEK"],"disease_mechanism_id":"273","name":"Erythrokeratodermia variabilis","medgen_id":"C4551486","type":"Disease","id":"5043","attribute_content":[],"symbol":"EKVP1","keywords":[],"alternate_names":["ERYTHROKERATODERMIA FIGURATA, CONGENITAL FAMILIAL, IN PLAQUES","ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1","ERYTHROKERATODERMIA VARIABILIS WITH ERYTHEMA GYRATUM REPENS","ERYTHROKERATODERMIA, PROGRESSIVE SYMMETRIC","Erythrokeratodermia variabilis et progressiva"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"317\"}","{\"db\":\"Orphanet\",\"id\":\"495\"}","{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA FIGURATA, CONGENITAL FAMILIAL, IN PLAQUES\"}","{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1\"}","{\"db\":\"OMIM\",\"id\":\"603324.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1\"}","{\"db\":\"OMIM\",\"id\":\"603324.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1\"}","{\"db\":\"OMIM\",\"id\":\"603324.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1\"}","{\"db\":\"OMIM\",\"id\":\"603324.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1\"}","{\"db\":\"OMIM\",\"id\":\"603324.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA VARIABILIS ET PROGRESSIVA 1\"}","{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA VARIABILIS WITH ERYTHEMA GYRATUM REPENS\"}","{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ERYTHROKERATODERMIA, PROGRESSIVE SYMMETRIC\"}","{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EKV\"}","{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EKVP\"}","{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PSEK\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Erythrokeratodermia+variabilis+et+progressiva/8359\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"70041004\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"133200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["IS","ISSX1"],"disease_mechanism_id":"273","name":"Epileptic encephalopathy, early infantile, 1","medgen_id":"C3463992","type":"Disease","id":"1617","attribute_content":[],"symbol":"EIEE1","keywords":[],"alternate_names":["INFANTILE SPASM SYNDROME, X-LINKED 1","OHTAHARA SYNDROME, X-LINKED","X-Linked Infantile Spasm Syndrome"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"3175\"}","{\"db\":\"Orphanet\",\"id\":\"364063\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INFANTILE SPASM SYNDROME, X-LINKED 1\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OHTAHARA SYNDROME, X-LINKED\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7887\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"IS\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ISSX1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000331025\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332436\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519156\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520051\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520980\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520995\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520998\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530238\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551668\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557944\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558371\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"OMIM\",\"id\":\"308350\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":[],"disease_mechanism_id":"273","public_definition":"Early infantile epileptic encephalopathy 1 (EIEE1) is a seizure disorder characterized by a type of seizure known as infantile spasms. The spasms usually appear before the age of 1. Several types of spasms have been described, but the most commonly reported type involves bending at the waist and neck and extending the arms and legs (sometimes called a jackknife spasm). Each spasm lasts only seconds, but they occur in clusters several minutes long. Although individuals do not usually have spasms while they are sleeping, the spasms commonly occur just after awakening. Infantile spasms usually stop by age 5, but many children then develop other types of seizures that recur throughout their lives.Most babies with EIEE1 have characteristic results on an electroencephalogram (EEG), a test used to measure the electrical activity of the brain. The EEG of these individuals typically shows an irregular pattern known as hypsarrhythmia, and this finding can help differentiate infantile spasms from other types of seizures.Because of the recurrent seizures, babies with EIEE1 stop developing normally and begin to lose skills they have acquired (developmental regression), such as sitting, rolling over, and babbling. Most affected individuals also have intellectual disability throughout their lives.","name":"West syndrome","medgen_id":"C0037769","type":"Disease","id":"18336","attribute_content":[],"symbol":"EIEE1","keywords":[],"alternate_names":["Spasms, Infantile"],"xrefs":["{\"db\":\"Orphanet\",\"id\":\"3451\"}","{\"db\":\"MeSH\",\"id\":\"D013036\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Spasms, Infantile\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530022\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530238\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552301\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558073\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"West+syndrome/7475\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7887\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"28055006\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"early-infantile-epileptic-encephalopathy-1\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500883\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["CAMR","MRXS10"],"disease_mechanism_id":"273","name":"2-methyl-3-hydroxybutyric aciduria","medgen_id":"C3266731","type":"Disease","id":"53","attribute_content":[],"symbol":"HSD10MD","keywords":[],"alternate_names":["17-beta-hydroxysteroid dehydrogenase X deficiency","CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR","HSD10 MITOCHONDRIAL DISEASE","HSD17B10 DEFICIENCY","MENTAL RETARDATION, X-LINKED, SYNDROMIC 10"],"xrefs":["{\"db\":\"OMIM\",\"id\":\"300438\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"391417\"}","{\"db\":\"OMIM\",\"id\":\"300438\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR\"}","{\"db\":\"OMIM\",\"id\":\"300256.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300256.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300256.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300256.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300256.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300256.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300256.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300256.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300438\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD10 MITOCHONDRIAL DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"300438\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HSD17B10 DEFICIENCY\"}","{\"db\":\"OMIM\",\"id\":\"300438\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED, SYNDROMIC 10\"}","{\"db\":\"OMIM\",\"id\":\"300438\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CAMR\"}","{\"db\":\"OMIM\",\"id\":\"300438\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRXS10\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Beta+Ketothiolase+Deficiency/812\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10716\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"300438\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":[],"disease_mechanism_id":"273","name":"Global developmental delay","medgen_id":"C0557874","type":"Disease","id":"17050","attribute_content":[],"symbol":"DD","keywords":[],"alternate_names":["Cognitive delay","Delayed cognitive development","Delayed development","Delayed developmental milestones","Delayed intellectual development","Delayed milestones","Delayed psychomotor development","Developmental delay","Developmental delay in early childhood","Developmental retardation","Lack of psychomotor development","Mental and motor retardation","Motor and developmental delay","Psychomotor delay","Psychomotor development deficiency","Psychomotor development failure","Psychomotor developmental delay","Psychomotor retardation","Retarded development","Retarded mental development","Retarded psychomotor development"],"content":"{\"Citation\":{\"@Abbrev\":\"AAN/CNS, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21956720\",\"@Source\":\"PubMed\"}}}","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000754\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001255\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001277\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001292\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002433\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002473\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002532\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006793\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006867\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006885\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006935\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007005\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007094\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007106\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007174\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007224\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007228\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007342\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cognitive delay\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Delayed cognitive development\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Delayed development\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Delayed developmental milestones\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Delayed intellectual development\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Delayed milestones\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Delayed psychomotor development\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Developmental delay\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Developmental delay in early childhood\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Developmental retardation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lack of psychomotor development\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Mental and motor retardation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Motor and developmental delay\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Psychomotor delay\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Psychomotor development deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Psychomotor development failure\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Psychomotor developmental delay\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Psychomotor retardation\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Retarded development\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Retarded mental development\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001263\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Retarded psychomotor development\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509471\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520936\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521543\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522222\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553938\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558520\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568239\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501388\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":[],"disease_mechanism_id":"273","public_definition":"Phenylalanine hydroxylase (PAH) deficiency results in intolerance to the dietary intake of the essential amino acid phenylalanine and produces a spectrum of disorders. The risk of adverse outcome varies based on the degree of PAH deficiency. Without effective therapy, most individuals with severe PAH deficiency, known as classic PKU, develop profound and irreversible intellectual disability. Affected individuals on an unrestricted diet who have phenylalanine levels above normal but below 1,200 mol/L (20 mg/dL) are at much lower risk for impaired cognitive development in the absence of treatment.","name":"Phenylketonuria","medgen_id":"C0751434","type":"Disease","id":"3795","attribute_content":[],"symbol":"PKU","keywords":[],"alternate_names":["Classic phenylketonuria","Phenylketonurias"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301677\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1504\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"USPSTF, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2267416\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21915151\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24385074\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"3918542\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Camp et al., 2014\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"24667081\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"261600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"716\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260641\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000330994\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505064\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505124\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506557\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507953\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509046\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000560957\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Phenylketonuria/5714\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"154735006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1504\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"261600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7383\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["HMSN4"],"disease_mechanism_id":"273","public_definition":"Refsum disease is characterized by anosmia and early-onset retinitis pigmentosa, which are both universal findings with variable combinations of neuropathy, deafness, ataxia, and ichthyosis. Onset of symptoms ranges from age seven months to older than age 50 years. Cardiac arrhythmia and heart failure caused by cardiomyopathy are potentially severe health problems that develop later in life.","name":"Phytanic acid storage disease","medgen_id":"C0034960","type":"Disease","id":"5851","attribute_content":[],"symbol":"RDPA","keywords":[],"alternate_names":["HMSN IV","REFSUM DISEASE, ADULT, 1","REFSUM DISEASE, CLASSIC"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301527\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1353\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"Gene\",\"id\":\"8024\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"773\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HMSN IV\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"REFSUM DISEASE, ADULT, 1\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"REFSUM DISEASE, CLASSIC\"}","{\"db\":\"OMIM\",\"id\":\"266500\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HMSN4\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004880\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318975\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506571\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506572\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515436\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515763\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515765\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525961\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553865\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561876\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Phytanic+acid+storage+disease/9107\",\"ref_field\":\"name\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Refsum+disease+with+increased+pipecolic+acidemia/6182\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"25362006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1353\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"600964\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4371\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["PHHI"],"disease_mechanism_id":"273","public_definition":"Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia). In infants and young children, these episodes are characterized by a lack of energy (lethargy), irritability, or difficulty feeding. Repeated episodes of low blood sugar increase the risk for serious complications such as breathing difficulties, seizures, intellectual disability, vision loss, brain damage, and coma.The severity of congenital hyperinsulinism varies widely among affected individuals, even among members of the same family. About 60 percent of infants with this condition experience a hypoglycemic episode within the first month of life. Other affected children develop hypoglycemia by early childhood. Unlike typical episodes of hypoglycemia, which occur most often after periods without food (fasting) or after exercising, episodes of hypoglycemia in people with congenital hyperinsulinism can also occur after eating.","name":"Islet cell hyperplasia","medgen_id":"C2931833","type":"Disease","id":"2358","attribute_content":[],"symbol":"HHF2","keywords":[],"alternate_names":["HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA","HYPERINSULINEMIC HYPOGLYCEMIA, PERSISTENT","HYPERINSULINISM, CONGENITAL","HYPERINSULINISM, FAMILIAL","HYPERINSULINISM, NEONATAL","Hyperinsulinemic hypoglycemia familial 2","Nesidioblastosis","PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301549\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1375\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"276580\"}","{\"db\":\"Orphanet\",\"id\":\"276603\"}","{\"db\":\"Orphanet\",\"id\":\"79644\"}","{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERINSULINEMIC HYPOGLYCEMIA DUE TO FOCAL ADENOMATOUS HYPERPLASIA\"}","{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERINSULINEMIC HYPOGLYCEMIA, PERSISTENT\"}","{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERINSULINISM, CONGENITAL\"}","{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERINSULINISM, FAMILIAL\"}","{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HYPERINSULINISM, NEONATAL\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9927\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hyperinsulinemic hypoglycemia familial 2\"}","{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY\"}","{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PHHI\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000241589\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260573\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000284792\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000284796\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500516\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506422\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507676\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530438\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530439\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552549\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556820\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559250\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Islet+cell+hyperplasia/8684\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"42681006\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"congenital-hyperinsulinism\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"601820\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9927\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["AHCH","X-AHC"],"disease_mechanism_id":"273","public_definition":"NR0B1-related adrenal hypoplasia congenita includes both X-linked adrenal hypoplasia congenita (X-linked AHC) and Xp21 deletion (previously called complex glycerol kinase deficiency). X-linked AHC is characterized by primary adrenal insufficiency and/or hypogonadotropic hypogonadism (HH). Adrenal insufficiency is acute infantile onset (average age 3 weeks) in approximately 60% of affected males and childhood onset (ages 1-9 years) in approximately 40%. HH typically manifests in a male with adrenal insufficiency as delayed puberty (i.e., onset age \u003e14 years) and less commonly as arrested puberty at about Tanner Stage 3. Rarely, X-linked AHC manifests initially in early adulthood as delayed-onset adrenal insufficiency, partial HH, and/or infertility. Heterozygous females very occasionally have manifestations of adrenal insufficiency or hypogonadotropic hypogonadism. Xp21 deletion includes deletion of NR0B1 (causing X-linked AHC) and GK (causing glycerol kinase deficiency), and in some cases deletion of DMD (causing Duchenne muscular dystrophy). Developmental delay has been reported in males with Xp21 deletion when the deletion extends proximally to include DMD or when larger deletions extend distally to include IL1RAPL1 and DMD.","name":"Congenital adrenal hypoplasia, X-linked","medgen_id":"C0342482","type":"Disease","id":"87","attribute_content":[],"symbol":"AHC","keywords":[],"alternate_names":["ADRENAL HYPOPLASIA, CONGENITAL, WITH HYPOGONADOTROPIC HYPOGONADISM","Isolated X-Linked Adrenal Hypoplasia Congenita"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301604\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1431\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"300200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"95702\"}","{\"db\":\"OMIM\",\"id\":\"300200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENAL HYPOPLASIA, CONGENITAL, WITH HYPOGONADOTROPIC HYPOGONADISM\"}","{\"db\":\"OMIM\",\"id\":\"300200\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"AHCH\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Congenital+adrenal+hypoplasia%2C+X-linked/7542\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"237764004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1431\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["PBDS","ZS"],"disease_mechanism_id":"273","public_definition":"Zellweger spectrum disorder (ZSD) is a phenotypic continuum ranging from severe to mild. While individual phenotypes (e.g., Zellweger syndrome [ZS], neonatal adrenoleukodystrophy [NALD], and infantile Refsum disease [IRD]) were described in the past before the biochemical and molecular bases of this spectrum were fully determined, the term \"ZSD\" is now used to refer to all individuals with a PEX gene defect regardless of phenotype. Individuals with ZSD usually come to clinical attention in the newborn period or later in childhood. Affected newborns are hypotonic and feed poorly. They have distinctive facies, congenital malformations (neuronal migration defects associated with neonatal-onset seizures, renal cysts, and bony stippling [chondrodysplasia punctata] of the patella[e] and other long bones), and liver disease that can be severe. Infants with severe ZSD are significantly impaired and typically die during the first year of life, usually having made no developmental progress. Individuals with intermediate/milder ZSD do not have congenital malformations, but rather progressive peroxisome dysfunction variably manifest as sensory loss (secondary to retinal dystrophy and sensorineural hearing loss); neurologic involvement (ataxia, polyneuropathy, and leukodystrophy); liver dysfunction; adrenal insufficiency; and renal oxalate stones. While hypotonia and developmental delays are typical, intellect can be normal. Some have osteopenia; almost all have ameleogenesis imperfecta in the secondary teeth.","name":"Peroxisome biogenesis disorders, Zellweger syndrome spectrum","medgen_id":"C1832200","type":"Disease","id":"5752","attribute_content":[],"symbol":"PBD, ZSS","keywords":[],"alternate_names":["ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL","INFANTILE PHYTANIC ACID STORAGE DISEASE","PEROXISOME BIOGENESIS DISORDER (NALD/IRD)","PEROXISOME BIOGENESIS DISORDER (NEONATAL ADRENOLEUKODYSTROPHY/INFANTILE REFSUM DISEASE)","Peroxisome biogenesis disorders","Zellweger spectrum disorders","Zellweger syndrome spectrum"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1448\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"Orphanet\",\"id\":\"79189\"}","{\"db\":\"OMIM\",\"id\":\"601539\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"ADRENOLEUKODYSTROPHY, AUTOSOMAL NEONATAL\"}","{\"db\":\"OMIM\",\"id\":\"601539\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"INFANTILE PHYTANIC ACID STORAGE DISEASE\"}","{\"db\":\"OMIM\",\"id\":\"601539\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PEROXISOME BIOGENESIS DISORDER (NALD/IRD)\"}","{\"db\":\"OMIM\",\"id\":\"601539\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"PEROXISOME BIOGENESIS DISORDER (NEONATAL ADRENOLEUKODYSTROPHY/INFANTILE REFSUM DISEASE)\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9473\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Peroxisome biogenesis disorders\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500811\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"PBDS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500811\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"ZS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004880\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000028499\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000028503\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000070507\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000070509\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318883\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318886\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000318975\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500811\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501466\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501472\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501473\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501474\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501625\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501626\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501628\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501629\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501630\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501631\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501632\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501633\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501634\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501635\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501644\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501647\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525961\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Peroxisome+biogenesis+disorders/5684\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1448\",\"ref_field\":\"public_definition\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1448\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["FSP","HSP"],"disease_mechanism_id":"273","name":"Hereditary spastic paraplegia","medgen_id":"C0037773","type":"Disease","id":"14327","attribute_content":[],"keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301682\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1509\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS303350\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"685\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6637\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FSP\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6637\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"HSP\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500041\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500218\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500428\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508756\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525862\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525863\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528277\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+spastic+paraplegia/3383\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6637\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"39912006\",\"ref_field\":\"name\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["MRD28"],"disease_mechanism_id":"273","public_definition":"ADNP-related intellectual disability and autism spectrum disorders (ADNP-related ID/ASD) are characterized by mild to severe intellectual disability and autism spectrum disorder (ASD). Of the 24 individuals reported to date, 23 were ascertained in cohorts with autism spectrum disorder (ASD) / intellectual disability (ID); one was identified in a clinical setting. The clinical information available on 12 of the 24 revealed: delayed developmental milestones (walking independently between 19 months and 4.5 years) and speech ranging from no words to sentences. ASD was characterized by stereotypic behavior and impaired social interaction. Other common findings include behavioral problems, sleep disturbance, hypotonia, seizures, feeding difficulties, visual problems (hypermetropia, strabismus, cortical visual impairment), and cardiac defects.","name":"Helsmoortel-Van der Aa Syndrome","medgen_id":"C4014538","type":"Disease","id":"21244","attribute_content":[],"symbol":"HVDAS","keywords":[],"alternate_names":["ADNP-Related Disorders"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"27054228\",\"@Source\":\"PubMed\"},{\"$\":\"NBK355518\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"615873\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"404448\"}","{\"db\":\"OMIM\",\"id\":\"615873\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRD28\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Illumina Clinical Services Laboratory,Illumina\",\"id\":\"725236\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK355518\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"615873\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":[],"disease_mechanism_id":"273","name":"Maturity-onset diabetes of the young,  type 2","medgen_id":"C1841962","type":"Disease","id":"5458","attribute_content":[],"symbol":"MODY2","keywords":[],"alternate_names":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"29792621\",\"@Source\":\"PubMed\"},{\"$\":\"NBK500456\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"125851\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"552\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512295\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512817\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552325\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552544\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556820\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556824\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000557910\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558434\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559250\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568234\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Maturity-onset+diabetes+of+the+young%2C+type+2/4507\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10657\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"125851\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10657\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["HFE-HH"],"disease_mechanism_id":"273","public_definition":"HFE hemochromatosis is characterized by inappropriately high absorption of iron by the small intestinal mucosa. The phenotypic spectrum of HFE hemochromatosis includes: Persons with clinical HFE hemochromatosis, in whom manifestations of end-organ damage secondary to iron overload are present; Individuals with biochemical HFE hemochromatosis, in whom transferrin-iron saturation is increased and the only evidence of iron overload is increased serum ferritin concentration; and Non-expressing p.Cys282Tyr homozygotes, in whom neither clinical manifestations of HFE hemochromatosis nor iron overload are present. Clinical HFE hemochromatosis is characterized by excessive storage of iron in the liver, skin, pancreas, heart, joints, and anterior pituitary gland. In untreated individuals, early symptoms include: abdominal pain, weakness, lethargy, weight loss, arthralgias, diabetes mellitus; and increased risk of cirrhosis when the serum ferritin is higher than 1,000 ng/mL. Other findings may include progressive increase in skin pigmentation, congestive heart failure, and/or arrhythmias, arthritis, and hypogonadism. Clinical HFE hemochromatosis is more common in men than women.","name":"Hemochromatosis type 1","medgen_id":"C3469186","type":"Disease","id":"9582","attribute_content":[],"symbol":"HFE1","keywords":[],"alternate_names":["HFE-Associated Hereditary Hemochromatosis"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301613\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1440\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987432\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"USPSTF, 2006\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"16880462\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AASLD, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3149125\",\"@Source\":\"pmc\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"235200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"465508\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000028914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000246764\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260619\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000264968\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000271417\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000322758\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332464\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500300\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500638\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501267\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501371\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507663\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508786\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508970\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509340\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519366\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519384\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521586\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528695\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551894\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558915\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000560323\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000560567\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1440\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"235200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":[],"disease_mechanism_id":"273","public_definition":"Cystic fibrosis (CF) is a multisystem disease affecting epithelia of the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. Pulmonary disease is the major cause of morbidity and mortality in CF. Meconium ileus occurs at birth in 15%-20% of newborns with CF. More than 95% of males with CF are infertile. Congenital absence of the vas deferens (CAVD) is generally identified during evaluation of infertility or as an incidental finding at the time of a surgical procedure. Hypoplasia or aplasia of the vas deferens and seminal vesicles may occur either bilaterally or unilaterally. Testicular development and function and spermatogenesis are usually normal.","name":"Cystic fibrosis","medgen_id":"C0010674","type":"Disease","id":"1695","attribute_content":["{\"Attribute\":{\"$\":\"More than 1,000 CFTR variants have been reported.  Most common pathogenic variant is p.Phe508del.\",\"@Type\":\"disease mechanism\"}}"],"symbol":"CF","keywords":[],"alternate_names":[],"content":"{\"Citation\":[{\"@Abbrev\":\"ACMG/ACOG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11280952\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110945\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301428\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1250\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACOG, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19888064\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2005\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15789152\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110977\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"CPGPT/CF FPT Committees, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20675678\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ECFS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20605539\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19914445\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19914443\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG ACT Sheets, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21938795\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG Lab QA, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12394352\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CDC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22475884\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Accurso et al., 2010\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"3148255\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACOG, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21422883\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CPIC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"4026598\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"NSGC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24014130\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"HGS Australasia, 2014\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"25431289\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Wainwright et al., 2015\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"25981758\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"17761616\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"DailyMed Drug Label, 2012\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"DailyMed Drug Label, KALYDECO, 2012\"},\"URL\":{\"$\":\"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"586\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004176\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000005248\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000025280\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000028916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000074114\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000194834\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000209428\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226639\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000277984\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000288561\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320929\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000324499\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000328569\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000330969\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332363\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501211\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501918\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501920\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501921\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502992\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505699\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506511\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507003\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507006\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507010\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507864\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507950\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508782\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508810\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508811\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508812\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508889\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508890\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508893\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508894\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514611\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515757\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515758\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520059\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521501\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521905\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528606\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529460\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553017\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556535\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556536\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558875\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558928\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568279\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cystic+Fibrosis/2071\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6233\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"190905008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1250\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6233\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["COL1A1"],"disease_mechanism_id":"273","public_definition":"COL1A1/2-related osteogenesis imperfecta (OI) is characterized by fractures with minimal or absent trauma, variable dentinogenesis imperfecta (DI), and, in adult years, hearing loss. The clinical features of COL1A1/2-related OI represent a continuum ranging from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal dentition, normal stature, and normal life span. Fractures can occur in any bone, but are most common in the extremities. DI is characterized by gray or brown teeth that may appear translucent and wear down and break easily. COL1A1/2-related OI has been classified into four types (I, II, III, and IV) based on clinical presentation and radiographic findings. This classification system can be helpful in providing information about prognosis and management for a given individual. The four OI types are now referred to as follows: OI type I: classic non-deforming OI with blue sclerae. OI type II: perinatally lethal OI. OI type III: progressively deforming OI. OI type IV: common variable OI with normal sclerae.","name":"Osteogenesis imperfecta type I","medgen_id":"C0023931","type":"Disease","id":"5697","attribute_content":[],"symbol":"OI1","keywords":[],"alternate_names":["Lobstein's Disease","OI TYPE IA","OI, TYPE I"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301472\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1295\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EMQN, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3234509\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Orphanet, 2008\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"Orphanet Emergency Guidelines: Osteogenesis imperfecta (OI)\"},\"URL\":{\"$\":\"https://www.orpha.net/data/patho/Pro/en/Emergency_OsteogenesisImperfecta.pdf\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"166200\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"216796\"}","{\"db\":\"Orphanet\",\"id\":\"666\"}","{\"db\":\"OMIM\",\"id\":\"166240\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OI TYPE IA\"}","{\"db\":\"OMIM\",\"id\":\"166200\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OI, TYPE I\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260571\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332445\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511197\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521190\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525779\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552541\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561718\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562498\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Osteogenesis+imperfecta+type+1/5454\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"385482004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1295\",\"ref_field\":\"public_definition\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000323271\",\"ref_field\":\"symbol\"}","{\"db\":\"OMIM\",\"id\":\"166200\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["WMS","WS"],"disease_mechanism_id":"273","public_definition":"Williams syndrome (WS) is characterized by cardiovascular disease (elastin arteriopathy, peripheral pulmonary stenosis, supravalvar aortic stenosis, hypertension), distinctive facies, connective tissue abnormalities, intellectual disability (usually mild), a specific cognitive profile, unique personality characteristics, growth abnormalities, and endocrine abnormalities (hypercalcemia, hypercalciuria, hypothyroidism, and early puberty). Feeding difficulties often lead to poor weight gain in infancy. Hypotonia and hyperextensible joints can result in delayed attainment of motor milestones.","name":"Williams syndrome","medgen_id":"C0175702","type":"Disease","id":"5123","attribute_content":[],"symbol":"WBS","keywords":[],"alternate_names":["CHROMOSOME 7q11.23 DELETION SYNDROME, 1.5- TO 1.8-MB"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301427\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1249\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACC/AHA, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19038677\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"904\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CHROMOSOME 7q11.23 DELETION SYNDROME, 1.5- TO 1.8-MB\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WMS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7891\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WMS\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7891\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"WS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508950\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509084\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519140\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520014\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521643\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000525881\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528276\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529011\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000531722\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Williams+syndrome/7501\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"williams-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7891\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"63247009\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1249\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"194050\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7891\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":[],"disease_mechanism_id":"273","public_definition":"Primary trimethylaminuria is characterized by a fishy odor resembling that of rotten or decaying fish that results from excess excretion of trimethylamine in the urine, breath, sweat, and reproductive fluids. No physical symptoms are associated with trimethylaminuria. Affected individuals appear normal and healthy; however, the unpleasant odor often results in social and psychological problems. Symptoms are usually present from birth and may worsen during puberty. In females, symptoms are more severe just before and during menstruation, after taking oral contraceptives, and around the time of menopause.","name":"Trimethylaminuria","medgen_id":"C0342739","type":"Disease","id":"3918","attribute_content":[],"symbol":"TMAU","keywords":[],"alternate_names":["FISH-ODOR SYNDROME","High urine trimethylamine levels"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301282\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1103\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"22126753\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003614\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"602079\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"602079\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FISH-ODOR SYNDROME\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003614\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"High urine trimethylamine levels\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505067\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000518973\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Trimethylaminuria/7223\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003614\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6447\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"237959005\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1103\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"602079\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6447\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"loss of function"}
{"alternate_symbols":["CFC"],"disease_mechanism_id":"274","public_definition":"Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Some form of neurologic and/or cognitive delay (ranging from mild to severe) is seen in all affected individuals. Neoplasia, mostly acute lymphoblastic leukemia, has been reported in some individuals.","name":"Cardio-facio-cutaneous syndrome","medgen_id":"C1275081","type":"Disease","id":"34556","attribute_content":[],"symbol":"CFC1","keywords":[],"alternate_names":["Cardiofaciocutaneous syndrome"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301365\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1186\",\"@Source\":\"BookShelf\"}]}}","xrefs":["{\"db\":\"OMIM\",\"id\":\"PS115150\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"1340\"}","{\"db\":\"Orphanet\",\"id\":\"1340\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cardiofaciocutaneous syndrome\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000523331\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000523332\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000523334\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528361\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cardiofaciocutaneous+Syndrome/1087\",\"ref_field\":\"name\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"9146\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"403770008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1186\",\"ref_field\":\"public_definition\"}"],"disease_mechanism":"gain of function"}
{"alternate_symbols":[],"disease_mechanism_id":"274","public_definition":"Cardiofaciocutaneous (CFC) syndrome is characterized by cardiac abnormalities (pulmonic stenosis and other valve dysplasias, septal defects, hypertrophic cardiomyopathy, rhythm disturbances), distinctive craniofacial appearance, and cutaneous abnormalities (including xerosis, hyperkeratosis, ichthyosis, keratosis pilaris, ulerythema ophryogenes, eczema, pigmented moles, hemangiomas, and palmoplantar hyperkeratosis). The hair is typically sparse, curly, fine or thick, woolly or brittle; eyelashes and eyebrows may be absent or sparse. Nails may be dystrophic or fast growing. Some form of neurologic and/or cognitive delay (ranging from mild to severe) is seen in all affected individuals. Neoplasia, mostly acute lymphoblastic leukemia, has been reported in some individuals.","name":"Cardiofaciocutaneous syndrome 1","medgen_id":"CN029449","type":"Disease","id":"667","attribute_content":[],"symbol":"CFC1","keywords":[],"alternate_names":["Cardio-facio-cutaneous syndrome"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301365\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1186\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"115150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1340\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cardiofaciocutaneous+Syndrome/1087\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cardio-facio-cutaneous syndrome\"}","{\"db\":\"SNOMED CT\",\"id\":\"403770008\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Cardio-facio-cutaneous syndrome\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000273063\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000326240\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327662\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000327664\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501359\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501601\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501607\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501611\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501614\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501615\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501680\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501683\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501982\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502541\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502573\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000502575\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505949\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505951\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508882\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511170\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511407\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511408\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511409\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511410\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514883\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514885\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515559\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515566\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519366\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519383\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519384\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520039\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520040\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520875\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521399\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521418\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000523331\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000523332\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000523334\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528361\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528362\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528536\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528542\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551628\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551630\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561717\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000562242\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1186\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"115150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"gain of function"}
{"alternate_symbols":["D-HUS","aHUS"],"disease_mechanism_id":"283","public_definition":"Hemolytic-uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney and other organs. The onset of atypical HUS (aHUS) ranges from the neonatal period to adulthood. Genetic aHUS accounts for an estimated 60% of all aHUS. Individuals with genetic aHUS frequently experience relapse even after complete recovery following the presenting episode; 60% of genetic aHUS progresses to end-stage renal disease (ESRD).","name":"Atypical hemolytic-uremic syndrome 1","medgen_id":"C2749604","type":"Disease","id":"2026","attribute_content":[],"symbol":"AHUS1","keywords":[],"alternate_names":["AHUS, SUSCEPTIBILITY TO, 1","HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1"],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301541\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1367\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"NEJM, 2009\",\"@Type\":\"review\",\"ID\":{\"$\":\"19846853\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Brit Cmt Stand Hematol/BTS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19821824\",\"@Source\":\"PubMed\"}}]}","xrefs":["{\"db\":\"OMIM\",\"id\":\"235400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2134\"}","{\"db\":\"Orphanet\",\"id\":\"90038\"}","{\"db\":\"Orphanet\",\"id\":\"93581\"}","{\"db\":\"OMIM\",\"id\":\"235400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"AHUS, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"134370.0022\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"OMIM\",\"id\":\"235400\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"8702\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"D-HUS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000287551\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"aHUS\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000287551\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000335917\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500217\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000509831\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511429\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000511746\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512537\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512782\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515531\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000519406\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Atypical+hemolytic-uremic+syndrome+1/7753\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1367\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"235400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"disease_mechanism":"Other"}
